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Uncertainty and variability in environmental risk assessment of human pharmaceuticals
1.1 PHARMACEUTICALS IN THE ENVIRONMENT
Since ancient times humans have used natural resources for the treatment of disease. 
Indeed, archaeological evidence suggests that natural antibiotics and laxatives were 
already used in prehistorical times [1], and the first structural documentations of 
traditional Chinese medicine date back more than 3000 years [2]. However, it took until 
halfway through the nineteenth century for modern day medicine to arise. Facilitated 
by the emergence of the sciences of pharmacology and synthetic organic chemistry, 
the already present apothecaries began their transition into pharmaceutical companies 
[3, 4]. Since then, pharmaceutical companies have grown into the global enterprises 
with yearly billion-dollar revenues that they are today [5], contributing significantly to 
the worldwide increase in life expectancy and quality [6]. Along the way, the originally 
empirical chemistry-driven search for new pharmaceuticals shifted towards a target-
based biology-driven approach in which new pharmaceuticals are designed rather than 
discovered [4]. Consequently, newly developed pharmaceuticals have become increasingly 
effective through designing for increased potency, bioavailability and degradation 
resistance [8]. Due to these characteristics and their large consumption volumes [9], human 
pharmaceuticals can be transported into the environment via the effluent of sewage 
treatment plants or bound to sewage sludge dispersed on agricultural soils (Fig. 1.1).
Indeed, several decades ago the first observations of pharmaceuticals detected in the 
aquatic environment arose in scientific literature [10-12]. However, only after the publication 
of influential reviews from Halling-Sørensen et al. [7], Ternes [13] and Daughton and 
Ternes [14] did the topic catch broader interest, resulting in a considerable increase in 
the amount of peer-reviewed publications related to pharmaceuticals in the environment 
[15, 16]. The majority of these studies focused on the documentation of the presence of 
pharmaceuticals in media such as wastewaters, surface waters and ground waters [17-19]. 
As a result of improvements in analytical sensitivity and selectivity, pharmaceuticals were 
even detected in drinking waters [e.g., 20, 21], proving that they can eventually make their 
way back to humans. Additionally, human exposure routes other than drinking water 
have been identified in the form of the consumption of fish [22-24] and agricultural crops, 
as pharmaceuticals bound to agriculturally dispersed sewage sludge can be taken up from 
soils into plants [25].
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FIGURE 1.1 
Pathways of human pharmaceuticals into the aquatic environment (modified from Halling-
Sørensen et al. [7]).
Although concentrations reported are generally low, i.e. in the ng/L to µg/L range [18,19,26], 
adverse effects caused by pharmaceuticals are not unlikely considering their specific 
modes of action and high potency. This has become apparent in the feminising effect of 
(semi-)synthetic steroidal hormones on fish downstream of sewage treatment plants [27], 
and the catastrophic decline of vulture populations in the Indian subcontinent due to 
diclofenac poisoning [28]. Contrary to ecological risks, human health risks resulting from 
environmental exposure to pharmaceuticals have been considered negligible in a number 
of risk assessment studies [29-32]. However, since these studies tend to lack differentiation 
(e.g., spatially or interindividually), completeness (e.g., only exposure via drinking water), 
and/or specificity (e.g., the use of general dilution factors or general intake rates), a more 
sophisticated analysis is required before solid conclusions can be drawn. 
Human pharmaceuticals
Excretion parent
compound
Disposal of leftover
pharmaceuticals to sewerage
Sewage treatment plant
Sludge dispersed on
agricultural soils Sewage effluent
Runoff Aquatic environment
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1.2 REGULATION AND PRIORITISATION OF  
PHARMACEUTICALS
In the wake of the increasing scientific and public awareness on the issue of human 
pharmaceuticals in the environment, a formal European guideline has been installed for 
the registration of new pharmaceuticals [33]. This guideline requires new pharmaceuticals 
to be subjected to an environmental risk assessment (ERA) for their registration (see Box 
1.1 for a description of chemical risk assessment in general and Box 1.2 for a description of 
the ERA required for pharmaceuticals). However, any potential risks to the environment 
identified through this procedure are not grounds to block their marketing approval. 
Furthermore, existing pharmaceuticals are not part of the guideline and are thus not 
explicitly addressed in current legislation. Exceptions to this are three pharmaceutical 
compounds that have been proposed for inclusion on the list of priority substances as 
formulated in the Water Framework Directive, i.e. the abovementioned diclofenac and 
the two steroidal hormones 17α-ethinylestradiol and 17β-estradiol [34]. However, there are 
currently thousands of different pharmaceuticals in use, a far too large number to assess 
experimentally within a reasonable timeframe. Therefore, their prioritisation for further 
study has been identified as one of the key outstanding issues concerning pharmaceuticals 
in the environment [35].
A logical first step is to focus on the group, or groups, of pharmaceuticals considered 
most likely to be a threat to the environment and/or human health. Cunningham et al. [29] 
identified anticancer agents and antibiotics as two such groups (see Box 1.3). Subsequently, 
several methods can be used for further prioritisation of the individual pharmaceuticals, 
a number of which have been discussed and compared by Roos et al. [36]. More recently, 
Caldwell et al. [37] have proposed a combined prioritisation approach integrating multiple 
earlier developed methods. Many of these methods are either based on simple chemical-
specific characteristics and hazard estimations [38, 39], basic exposure and toxicological 
predictions [40], or information on pharmaceutical potency [41]. While such relatively 
simple and straightforward approaches enable the assessment of a large number of 
pharmaceuticals, their lack of spatial differentiation limits their application potential [35]. 
Indeed, prioritisations are likely to vary between geographical regions due to differences 
in for example pharmaceutical consumption, demographics, sewage treatment plant 
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design, environmental characteristics, et cetera. This favours a prioritisation approach 
based on exposure scenarios, i.e. combinations of location, pharmaceutical and exposure 
group, rather than on pharmaceuticals alone. 
1.3 UNCERTAINTY AND VARIABILITY IN RISK  
ASSESSMENT
Environmental exposure to pharmaceuticals can possibly cause adverse effects. The aim 
of chemical risk assessment is to estimate the probability and extent of these effects. This 
is done by combining assessments of exposure and dose-response relationships (see Box 
1.1). However, to pinpoint the true level of exposure and the exact relationship between 
dose and response is often impossible due to the influence of uncertainty. Uncertainty is 
intrinsic to chemical risk assessment, as it originates from the complexity of the assessment 
and our limited knowledge of the underlying physical, chemical and biological processes. 
To adequately support decision making in risk management, uncertainty should be 
explored as part of the risk assessment process. A quantification of uncertainty reflects 
the level of ignorance about the true risk, and as such can aid in the application of the 
precautionary principle in risk management [43]. 
Walker et al. [44] define any uncertainty that can be described adequately in statistical 
terms as statistical uncertainty. The most obvious type of statistical uncertainty is 
parameter uncertainty, i.e. the uncertainty in the estimation of a model parameter of 
interest due to limited knowledge of its true value. An established way to account for 
parameter uncertainty is via Monte Carlo simulations [e.g., 45]. In a Monte Carlo simulation, 
the model is run repeatedly, each time using different values drawn from uncertainty 
distributions for each of the uncertain input parameters. This iterative process results 
in a large number of possible model outcomes. The variation in these possible model 
outcomes represents the uncertainty in the outcome as a result of parameter uncertainty. 
Next to parameter uncertainty, other types of uncertainty that are less easily quantified 
might be of importance, such as context uncertainty (related to the boundaries of the 
system to be modelled) or model uncertainty (related to the variables and relationships 
included in the model) [44]. Although a quantitative approach of these types of uncertainty 
is often unfeasible, a qualitative description can still benefit risk management. 
16
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BOX 1.1 
Chemical risk assessment
Chemical risk assessment involves four steps: hazard identification, exposure 
assessment, effect assessment, and finally risk characterisation (Fig. 1.2) [42]. During 
hazard identification, the intrinsic toxicity of the chemical of concern is assessed. The 
fate and exposure assessment step involves either the estimation of the concentration in 
the medium of contact (e.g., aquatic risk assessment), or of the intake dose (e.g., human 
risk assessment). During effect assessment the relationship between exposure and effect, 
i.e., the dose-response relationship, is established. Finally, the estimated or measured 
exposure is compared with this dose-response relationship in order to characterise the 
risk. Alternatively, the dose-response derived during the effect assessment step can be 
used as a starting point for the comparison, e.g., if the aim is to derive a safe level of 
exposure for regulatory purposes (e.g., the surface water concentration at which 5% of 
the species in an aquatic ecosystem are protected).
Parameters that intrinsically have one true value that is unknown due to limited 
knowledge can be distinguished from parameters that are intrinsically variable, e.g., over 
time, space, between individuals or between species, but are represented in the model by 
a single value. While the first type of variation can be classified as parameter uncertainty, 
the second type of variation is often classified as ontic uncertainty [e.g., 48], heterogeneity 
[e.g., 49], or variability [45, 50]. In this thesis, the latter term is used. From the perspective of 
Hazard 
identification
Risk 
characterisation
Effect 
assessment
Fate & Exposure
assessment
FIGURE 1.2 
Steps in the risk assessment process [42]
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risk management, it is important to distinguish between these two phenomena because 
variability determines the population fraction at risk, while uncertainty determines the 
reliability of the assessment. Uncertainty and variability can be separately propagated 
into the model outcome via the use of nested Monte Carlo simulations [50, 58, 59], a two-step 
iterative process in which first all uncertain parameters are sampled and fixed, followed 
by a Monte Carlo simulation on the variable parameters. This process is then repeated a 
large number of times, each time with a new set of uncertain parameters. This way, the 
influence of both uncertainty and variability on the model outcome can be assessed. 
BOX 1.2 
Environmental Risk Assessment (ERA) for pharmaceuticals in Europe
The “Guideline on the environmental risk assessment of medicinal products for human 
use”, released in 2006 by the European Medicines Agency [33], outlines when an ERA 
is required before marketing approval for a human pharmaceutical. It follows a tiered 
approach of three steps:
1. As a pre-screening, a conservative simplified exposure assessment is performed 
using worst-case assumptions on the absence of degradation or metabolism 
processes. If the predicted environmental concentration (PEC) in surface water 
does not exceed a threshold value of 10 ng/L, no further ERA has to be performed 
[46]. Exceptions are made for highly lipophilic or potential endocrine-disrupting 
pharmaceuticals that may affect organisms below this threshold value [47].
2. Any pharmaceuticals that do not pass the first step are subjected to an assessment 
in which risks are characterised in various environmental compartments, based 
on a prescribed set of experimental environmental fate and effects data. Potential 
risks identified in this step should be investigated in the next step.
3. In this final step of the EMA guideline, a more elaborate risk assessment is 
performed. This may include refined modelling of removal during sewage 
treatment, a chronic sediment ERA, a refined assessment of risks for 
microorganisms in sewage treatment plants, and a terrestrial assessment in 
which sewage sludge disposal is taken into account. 
18
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BOX 1.3 
Focus groups of pharmaceuticals
Anticancer agents
Anticancer agents, also known as antineoplastics, form a heterogeneous group of 
pharmaceuticals with a high potency, many of which disrupt DNA synthesis. Hence 
they possess fetotoxic, genotoxic and teratogenic properties, potentially already at very 
low concentrations. Considering that all animals and plants rely on the synthesis of 
DNA for their existence, anticancer agents that disrupt DNA synthesis are likely to do 
so in all living organisms. This has already been shown for fish [51] and invertebrates [52,53]. 
Antibiotics
Similar to antineoplastics, antibiotics are also pharmaceuticals designed to kill, but 
their intended targets are bacteria that cause illness and disease. Therefore, human 
health concerns about environmental exposure to antibiotics are less than in the 
case of antineoplastics. However, since all major nutrient cycles in the environment 
depend on the activity of bacterial communities, they might be considered highly 
problematic from an ecological perspective. Additionally, antibiotics entering sewage 
treatment plants can affect bacterial communities used for biological degradation and 
consequently decrease the efficiency of these sewage treatment plants to remove other 
pollutants from the water [e.g., 54] Finally, antibiotics might induce indirect human health 
effects through the emergence of antibiotic resistant bacteria [e.g., 55-57].
1.4 AIM AND OUTLINE OF THE THESIS
This thesis deals with uncertainty and variability, i.e. spatial, interindividual, and 
interspecies variability, in the risk assessment of human pharmaceuticals, specifically 
antibiotics and antineoplastics. It aims to perform a complete probabilistic risk 
assessment, including all components of the chemical risk assessment framework (Fig. 
1.2), and including both human health and aquatic risks. 
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Chapters 2-4 focus on the presentation of a methodology for the spatially explicit 
prioritisation of human pharmaceuticals in Europe, based on an integrated assessment of 
risk quotients for the aquatic environment and human health. It follows the consecutive 
stages of emission, environmental fate, exposure, and effect, along the way using chemical- 
and location-specific information on among others demographics, sewage treatment, 
environmental characteristics, drinking water purification, and consumption patterns. 
Its application results in a ranking of exposure scenarios throughout Europe which can 
then provide direction towards either monitoring activities or additional research. In 
Chapter 2, its application in a regulatory setting is illustrated, thus based on country-
specific consumption data of pharmaceuticals. In Chapter 3, its use as a decision-support 
tool for physicians is presented, i.e. the location-specific assessment and comparison of 
the environmental impact of two alternative pharmaceutical prescriptions. In Chapter 
4, the value of using a spatially explicit approach for local prioritisation under uncertain 
conditions is analysed via a probabilistic assessment of all of its compartments.
In Chapter 5, the concentrations in European surface waters and sewage effluents 
of a set of antineoplastic agents are estimated with a sophisticated geographic-based 
hydrological model. Similar to Chapters 2-4, the spatial variability in predicted 
concentrations is assessed.
Chapter 6 and 7 present two methodologies for probabilistic effect assessment of 
human health (Chapter 6) and the aquatic environment (Chapter 7). The probabilistic 
human effect assessment methodology in Chapter 6 presents a framework in which 
uncertainty and interindividual variability are separately addressed, enabling a more 
informed setting of human exposure limits. The probabilistic aquatic effect assessment 
methodology in Chapter 7 is based on a hierarchical Bayesian approach to using species 
sensitivity distributions in the risk assessment of chemical mixtures. As such, it provides 
an alternative for traditional uncertainty analysis methods when dealing with mixtures 
consisting of data-poor chemicals. 
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ABSTRACT
This paper presents a screening tool for the location-specific prioritisation of 
human pharmaceutical emissions in Europe, based on risk quotients for the 
aquatic environment and human health. The tool provides direction towards 
either monitoring activities or additional research. Its application is illustrated for 
a set of 11 human antibiotics and 7 antineoplastics. Risk quotients for the aquatic 
environment were highest for levofloxacin, doxycycline and ciprofloxacin, located in 
Northern Italy (Milan region; particularly levofloxacin) and other densely populated 
areas in Europe (e.g., London, Krakow and the Ruhr area). Risk quotients for human 
health not only depend on pharmaceutical and location, but also on behavioral 
characteristics, such as consumption patterns. Infants in eastern Spain that consume 
locally produced food and conventionally treated drinking water were predicted to 
run the highest risks. A limited comparison with measured concentrations in surface 
water showed that predicted and measured concentrations are approximately within 
one order of magnitude.
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2.1 INTRODUCTION
Human pharmaceuticals are produced in significant amounts with high production 
volume [7, 14, 60]. As a result of increasing life expectancies and advancing health care 
technology, the levels of pharmaceutical production are predicted to continue to increase. 
Not surprisingly, pharmaceuticals have been detected around the world in a wide range 
of environmental media, such as urban and hospital wastewater effluents, surface waters, 
ground waters and drinking waters (extensively reviewed by [18, 61-64]). Although reported 
concentrations are generally low, their specific modes of action make pharmaceuticals a 
group of substances of potential concern, even when present at low concentrations. This 
has become apparent in for example the feminising effect that ethinyl estradiol (EE2) has 
on fish in surface waters [65].
Contrary to ecological risks, risks for human health due to environmental exposure 
to pharmaceuticals have been considered unlikely in a number of risk assessment studies 
[29, 31, 66-68]. However, these risk assessment studies often lack differentiation (e.g., spatially 
or interindividually), completeness (e.g., only exposure via drinking water), and/or 
specificity (e.g., the use of general dilution factors or general intake rates).
Over the past decades, the public and policy makers have become more aware of 
the possible adverse consequences of the emission of human pharmaceuticals to the 
environment [69], and they have been incorporated into European legislation [33, 70], in 
which an environmental risk assessment is required for their registration (European 
Council Directive 2001/83/EC) [71]. European and national policy makers are struggling 
with the so-called ‘who-what-where?’ question: what substances can cause significant 
risks for what exposure groups at what locations?
In this paper, we present a screening tool that can be used to identify combinations 
of human pharmaceuticals, locations and exposure groups in Europe for prioritisation, 
either because the risk quotients for the aquatic environment or human health are 
relatively high, or because a relatively high risk quotient cannot be excluded on the basis of 
currently available data. The results can thus be used to identify high risk pharmaceuticals 
and exposure situations, as well as to support decisions on whether future focus should be 
on monitoring activities or additional research. The tool is illustrated in a case study for 
the prioritisation of human pharmaceuticals, thus excluding veterinary pharmaceuticals.
24
2
Uncertainty and variability in environmental risk assessment of human pharmaceuticals
2.2 METHODOLOGY
2.2.1 Model framework
The screening tool presented here was designed to estimate aquatic and human health 
risk quotients for specific combinations of substances, locations and exposure groups 
in Europe, based on consumption data that represent dispensed amounts at the level of 
individual EU Member States. The consumption data were propagated into regional risk 
quotients, following the consecutive stages of emission, fate, exposure and effect. These 
steps are further explained below.
2.2.1.1 Consumption
Data on the consumption of antibiotics (Section 2.2.2.2) were obtained per Member State 
via the former European Surveillance of Antimicrobial Consumption project (ESAC; years 
1997 to 2009) [72-75], which finished in 2011 and is continued as ESAC-Net at ECDC [76]. 
Data on the consumption of antineoplastics (Section 2.2.2.2) were obtained via publicly 
available sources and literature (Table A2.1). The use of antibiotics was divided into 
inpatient use, i.e. hospital use, and outpatient (ambulatory) use, i.e. outside hospitals. This 
distinction was made because ambulatory dispensed pharmaceuticals can be subjected to 
non-compliance (Section 2.2.1.2). Antibiotic volumes of use were expressed in defined 
daily dose (DDD) per 1000 inhabitants and per day in accordance with the WHO 
Anatomical Therapeutic Chemical (ATC) classification and the DDD measurement unit 
(version 2011) [77]. If the most recent consumption data were from before 2010, they were 
extrapolated to 2010 with population sizes from Eurostat [78]. When consumption data 
were not available for a combination of pharmaceutical and Member State, they were 
estimated with the average per capita use from all neighboring States. A more detailed 
description of the consumption calculations can be found in Appendix A2.1.
2.2.1.2 Emission
Emission pathways taken into account were surface water and agricultural soil. 
Pharmaceuticals end up in wastewater either as a result of non-compliance and disposal 
via flushing or as a result of actual consumption and excretion as parent compounds or 
re-convertible metabolites via urine. State-specific non-compliance rates were derived 
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from the European Social Survey, round 2 [79, 80]; State-specific disposal via the sewerage 
was estimated with values from literature [e.g., 81] and information on the presence and 
efficiency of national take-back schemes for leftover medications [82]. Wastewater is 
subsequently discharged into the surface water either directly or via passage through 
a sewage treatment plant (STP). Direct and indirect emissions were calculated at the 
level of individual agglomerations and STPs, respectively, based on agglomeration/STP 
size, STP-connectivity and removal capacity (Waterbase-UWWTD database) [83]. Next, 
the emissions were aggregated on a 100 ∗ 100 km2 grid, making them suitable for fate 
calculations. Emissions per km2 agricultural soil were calculated for each member state, 
based on predicted concentrations in secondary sewage sludge and state-specific sludge 
disposal practices [84, 85]. They were then combined with the agricultural surface area per 
grid to obtain grid-specific emissions to agricultural soil. The Appendix contains a more 
detailed description of the derivation of non-compliance rates (Appendix A2.2), disposal 
data (Appendix A2.3), removal efficiencies during sewage treatment (Appendix A2.4) 
and agricultural sludge disposal (Appendix A2.5).
2.2.1.3 Fate
Fate calculations were performed with the (generic) multimedia fate model SimpleBox[86], 
spatially parameterised with data from Pistocchi and Pennington [87] on a 100 ∗ 100 km2 
scale, and adapted for fate calculations with ionising compounds [88]. Environmental 
degradation was taken into account for three processes: biodegradation, hydrolysis (in 
water, sediment and soil) and photolysis (in water only). The derivation of data on these 
removal processes is described in Appendix A2.6. Surface water concentrations derived 
from these calculations were used for the estimation of the aquatic risk quotients (Section 
2.2.1.6).
2.2.1.4 Human exposure
Human contact media that were taken into account were drinking water, fruits and 
vegetables, meat products, milk products, fish, surface water and soil. The degree of 
exposure is determined by the concentrations in these contact media as well as the 
intensity of the contact with them. Concentrations in food were estimated from those 
in surface water and agricultural pore water using bioconcentration factors (BCFs) for 
26
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fish [89], root concentration factors (RCFs) for fruits and vegetables [90], and biotransfer 
factors (BTFs) for meat and milk products [91]. Concentrations in drinking water depend 
on the source of the water and the purification techniques applied. While data on the 
first were available at the level of the individual Member States [92], spatially explicit data 
on drinking water purification levels were not. We therefore formulated three possible 
purification scenarios: conventional, advanced and no purification. The conventional 
purification scenario was regarded as the minimum scenario in order for the EU Member 
States to meet the European quality standards (Council Directive 98/83/EC) [93]. The 
scenario of no purification represents small scale supplies, such as private/individual 
wells or community-managed supplies, for which abstraction was assumed to be from 
groundwater sources only. To capture the variation in potential exposure, a range of 
human exposure groups was formulated per spatial grid. These groups were characterised 
by the spatial component and four parameters: age (0–1 years, 1–10 years, 18–65 years 
and > 65 years), drinking water purification scenario (none, conventional and advanced), 
diving behavior (none, recreational and professional; 18–65 years only), and food origin 
(local and Europe-wide). For Europe-wide food, the average concentration from all grids 
was used to represent the concentrations in these food items. The approach resulted in 36 
different exposure groups per grid. A more detailed description of their parameterisation 
can be found in Appendix A2.7.
2.2.1.5 Effect
For the characterisation of human and aquatic toxicities of the pharmaceuticals, toxicity 
values were used that represent the hazardous dose and the hazardous concentration at 
which 50% of the species is affected (HD50 and HC50, respectively) [94]. HD50 and HC50 
values were based on acute toxicity data because chronic toxicity data were largely lacking 
and under the assumption that relative acute and chronic toxicities of the substances 
are similar. HD50 values were derived from all oral mammalian LD50 values available 
in publicly accessible databases [95-97]; HC50 values were derived from LC50 values, EC50 
values (half maximal effective concentration) and IC50 values (half maximal inhibitory 
concentration) available from literature and in publicly accessible databases [98-101]. The 
derivation of the HC50 values was done separately for four taxonomic groups (i.e. bacteria, 
phototrophs [water plants and algae], invertebrates, vertebrates). When no toxicity data 
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were available for phototrophs, invertebrates or vertebrates, the ECOSAR module from 
the EPI Suite predictive tool [102] was used to predict LC50s (daphnia, fish) and EC50s 
(algae).
Subsequently, the HC50 value for the most sensitive group was used, based on the 
observation that the pharmaceuticals’ relative toxicities for the different taxonomic 
groups were hardly correlated (ρ ≤ 0.50), except for phototrophs and bacteria (ρ = 0.73 at 
n = 10). The data also showed that bacteria were the most sensitive taxonomic group for 
exposure to antibiotics. Therefore, when bacterial HC50 values were lacking for a specific 
antibiotic (i.e. doxycycline), they were derived by dividing the HC50 for phototrophs 
by a safety factor of 10. Table A2.12 contains the toxicity values derived for the aquatic 
environment and human health. The toxicity values from which the HD50 and HC50 values 
were calculated can be found in Appendix A2.9.
2.2.1.6 Risk quotients
The risk quotients for all combinations of substance, location and exposure group were 
calculated by division of concentrations (for the aquatic environment) or daily intakes 
(for human health) by the toxicity values. Because HD50 and HC50 values do not represent 
an acceptable or no-effect level, a risk quotient of one (RQ = 1.0) cannot be interpreted 
as the verge between safe and unsafe. The risk quotients are therefore only used to 
compare the risks of different exposure scenarios, and not to assess the acceptability of 
these risks. Finally, summed risk quotients for all antibiotics and for all antineoplastics 
were calculated per grid and exposure group (for human health) on the basis of the 
concentration addition principle [103].
2.2.2 Chemicals selection and properties
2.2.2.1 Substance parameterisation
The tool was designed to identify both pharmaceuticals with relatively high risk 
quotients as well as pharmaceuticals for which currently insufficient data are available 
to exclude such risk quotients. To this end, substance-specific variables were consistently 
parameterised according to a four-step preference approach:
28
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1. Experimental or measurement data;
2. Extrapolation from related data (e.g., from degradation rates in other 
environmental media);
3. Structure or property based predictions (e.g., the use of QSARs);
4. Worst-case assumptions.
Interpretation of the results can be done by analysing the background of the input 
data in order to identify pharmaceuticals of interest for monitoring (substances with high 
data availability and low data uncertainty) or further research (substances with low data 
availability and high data uncertainty).
2.2.2.2 Substance selection
The screening tool presented here was applied to a number of substances which 
were selected within the framework of the EU FP7 project PHARMAS (http://www.
pharmas-eu.org). Based on recommendations from Cunningham et al. [29], PHARMAS 
focuses on two groups of pharmaceuticals: antineoplastics and antibiotics. PHARMAS 
ultimately selected eleven antibiotics and seven antineoplastics, representing both 
substances with low and higher data availabilities. The group of antibiotics represented 
two cephalosporins (ceftriaxone and cefuroxime), four tetracyclines (chlortetracycline, 
doxycycline, oxytetracycline, tetracycline), three fluoroquinolones (ciprofloxacin, 
levofloxacin, ofloxacin), the macrolide erythromycin, and trimethoprim; the group of 
antineoplastics consisted of two alkylating agents (cyclophosphamide and ifosfamide), 
three antimetabolites (capecitabine, 5-fluorouracil, methotrexate), the anti-estrogen 
tamoxifen, and hydroxycarbamide. Table 2.1 contains information on the data level of 
the relevant properties of the pharmaceuticals, according to the four-step preference 
approach described in Section 2.2.2.1.
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TABLE 2.1
Data level of the relevant properties of the pharmaceuticals.
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Emissions
Sewage treatment
Primary sorption 3 3 3 1 3 1 3 2 2 2 1 3 1 3 3 1 3 3
Secondary sorption 3 3 3 1 3 1 3 2 1 1 1 3 1 3 3 1 3 1
Biodegradation 1 2 2 1 4 1 4 1 4 1 1 4 1 1 4 1 1 4
N-removal 4 4 4 1 4 4 4 4 4 1 1 4 4 4 4 4 4 4
P-removal 4 4 4 1 4 4 4 1 4 4 4 4 4 4 4 4 4 4
UV-treatment 4 4 4 1 4 4 4 4 4 1 1 4 4 4 4 4 4 4
Chlorination 4 4 4 1 4 4 4 4 4 1 1 4 4 4 4 4 4 4
Ozonation 1 4 4 1 4 1 4 1 1 4 1 4 4 4 4 4 4 4
Sand filtration 4 4 4 1 4 1 4 4 4 1 1 4 4 4 4 4 4 4
Microfiltration 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Other
Excretion 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Fate
Environmental degradation
Biodegr. water 1 1 2 2 3 2 1 2 1 2 1 3 2 1 3 2 3 3
Biodegr. soil 2 2 1 2 3 1 2 2 1 1 1 3 2 2 3 2 3 3
Biodegr. sediment 1 1 2 2 3 2 2 2 1 2 1 3 2 2 3 2 3 3
Hydrolysis water 1 1 1 4 4 1 1 4 1 1 1 1 1 4 4 1 1 4
Hydrolysis soil 4 4 4 4 4 1 4 4 1 4 1 4 4 4 4 4 4 4
Hydrolysis sediment 1 1 4 4 4 4 4 4 1 4 1 4 4 4 4 4 4 4
Photolysis 1 1 4 1 4 4 1 4 1 1 1 4 1 4 4 1 1 4
Partitioning
Soil-water 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Water-air 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 >>
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Exposure
Accumulation
BCFs 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
RCFs 3 3 3 3 3 3 3 3 3 3 1 3 3 3 3 3 3 3
BTFs 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Drinking water  
treatment
Coagulation 4 4 4 1 4 1 4 4 4 4 1 4 4 4 4 4 4 4
Powder act. carbon 4 4 4 4 4 1 4 4 4 4 1 4 4 4 4 4 4 4
Sand filtration 4 4 4 2 4 2 4 2 4 2 2 4 4 4 4 4 4 4
Chlorination 4 4 1 1 1 1 4 4 1 1 1 4 4 4 4 4 4 4
Nanofiltration 4 4 4 4 4 1 4 4 4 4 1 4 4 4 4 4 4 4
Reverse osmosis 4 4 4 4 4 1 4 4 4 4 1 4 4 4 4 4 4 4
Membr. bioreactor 4 4 4 4 4 1 4 1 4 4 4 4 4 4 4 4 4 4
Ozonation 2 4 4 1 4 1 4 4 2 4 1 4 4 4 4 4 4 4
UV-treatment 4 4 4 1 4 4 4 4 4 1 1 4 4 4 4 4 4 4
Effect
Aquatic toxicity 1 1 1 1 2 1 1 1 1 1 1 1 3 1 3 3 1 1
Human toxicity 2 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1
1: experimental or measurement data; 2: extrapolation from related data; 3: structure or property based  
predictions; 4: worst-case assumptions.
2.2.2.3 Zwitterions
All pharmaceuticals in our study were anionic, cationic or zwitterionic compounds 
(Table A2.5). The parameterisation of the latter group of substances (i.e. fluoroquinolones 
and tetracyclines) requires some elaboration, because QSARs (Quantitative Structure–
Activity Relationships) on their partitioning behavior and accumulative properties are 
currently unavailable. The QSAR developed by Franco and Trapp [104] that describes 
the relationship between KOW and KOC for cations was used to estimate the water–soil 
partitioning of zwitterions in the environment. This choice was based on the general 
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observation that sorption of zwitterions is mainly determined by the presence of a 
positively charged cation [105, 106]. The same QSAR was used for the estimation of the 
water-sludge partitioning of zwitterions during sewage treatment, in the absence of 
measurement data (Table A2.6). Accumulation of zwitterions into fish was assumed to 
be described by the regression for cations from Fu et al. [89], while accumulation in plants 
was estimated with the mechanism-based model for ionising substances described by 
Trapp [90], in which we assumed zwitterions of fluoroquinolones to be driven by normal 
diffusion, because of their total zero valency, and the uptake of zwitterions of tetracyclines 
to be similar to that of cations, because of their +1 valency.
2.2.3 Comparison with measurements
The predicted concentrations in the aquatic environment were compared to location-
specific surface water concentrations reported in literature. When part of the measurements 
for a substance-grid combination were below the limit of detection (LOD), they were 
substituted with values according to the method described by Swaving and de Vries [107] 
(Eq. 2.1). This method was applied only if at least 50% of the measurements were above 
the LOD, with a minimum of 5 values. Data sets with values below the LOD that did not 
meet these criteria were excluded from the comparison.
xi = LOD * (LOD ⁄ x0.9 ) (1-f)     Equation 2.1 
with xi = substitution value; LOD = limit of detection; x0.9 = 90th percentile of the 
measurement data; and f = fraction of the measurement data above the limit of detection.
Following these criteria, measurement data were obtained for 20 substance-grid 
combinations (Table 2.2), covering six substances (ciprofloxacin, erythromycin, ofloxacin, 
oxytetracycline, trimethoprim, tamoxifen) and locations in seven Member States (France, 
Germany, Italy, Poland, Spain, Sweden, United Kingdom). Based on State-specific 
information on antibiotics authorised for veterinary use [108, 109], distinction was made 
between pharmaceuticals exclusively used in human medicine and pharmaceuticals also 
used in the veterinary setting.
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TABLE 2.2
Measurement concentrations (ng/L)
Grid State Sub-
stance
Min Median Max N (>LOD) LOD Predicted Vet. 
use?
Source
285 Sweden TR 0.080 a 0.27 0.60 8 (7) 0.10 0.62 Yes [110]
397 UK TR 3.18 a 8.00 46.00 24 (19) 4.00 53.28 Yes [111, 112]
397 UK TA 1.60 a 45.00 212.00 24 (18) 4.00 0.0067 No [111, 112]
468 UK TR 1.94 a 23.00 569.00 6 (5) 4.00 51.28 Yes [111]
475 Germany E 30.00 35.00 40.00 2 (2) 20.00 7.89 Yes [113]
510 Germany E n/a n/a 40.00 1 (1) 20.00 1.10 Yes [113]
548 Germany E n/a n/a 40.00 1 (1) 20.00 2.89 Yes [113]
591 Germany E 30.00 30.00 30.00 2 (2) 20.00 2.39 Yes [113]
591 Germany TR 30.00 30.00 30.00 2 (2) 30.00 0.28 Yes [113]
598 Poland TR 8.00 17.50 27.00 2 (2) 1.50 0.033 Yes [114]
660 France TR 8.84 a 14.00 16.00 10 (7) 10.00 0.00 Yes [115]
661 France TR 9.27 a 11.00 45.00 12 (7) 10.00 0.00 Yes [115]
903 Italy CI n/a n/a 26.15 1 (1) 0.27 68.40 No [116]
903 Italy E n/a n/a 15.90 1 (1) 0.29 1.32 Yes [116]
903 Italy OX n/a n/a 19.20 1 (1) 0.072 0.00 Yes [116]
905 Italy E 0.12 a 1.15 3.92 12 (8) 0.29 0.47 Yes [116-118]
1035 Spain CI 8.32 18.17 28.02 2 (2) 3.95 146.28 No [119]
1035 Spain E 50.38 112.56 174.73 2 (2) 10.19 3.89 Yes [119]
1035 Spain OF 23.28 49.15 75.02 2 (2) 1.12 1.76 No [119]
1035 Spain TR 16.43 24.98 33.53 2 (2) 0.37 0.10 Yes [119]
a: Calculated with method presented by Swaving and de Vries [107] for replacement of values below limit of detection; 
LOD = limit of detection; Substance abbreviations: CI=ciprofloxacin; E=erythromycin; OF=ofloxacin; OX=oxytetra-
cycline; TR=trimethoprim; TA=tamoxifen.
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2.3 RESULTS
2.3.1 Aquatic environment
FIGURE 2.1 
Summed aquatic risk quotients (predicted surface water concentrations ÷ HC50) due to 
exposure to (A) antibiotics and (B) antineoplastics. The grids with the highest summed risk 
quotients are outlined with a solid black line.
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FIGURE 2.2 
Aquatic risk quotients (predicted surface water concentrations ÷ HC50) due to exposure to 
the individual substances in all grids. 
Red dots = median values; box = area between the 10th and 90th percentile; whiskers = minimum and  
maximum values. The percentages between brackets represent the fraction of the grids where the risk  
quotient for that specific substance was zero.
Figure 2.1 shows that the summed aquatic risk quotients due to exposure to antibiotics 
are substantially larger than those due to exposure to antineoplastics. For example, the 
maximum summed aquatic risk quotient for antibiotics is approximately 1000 times 
higher than that for antineoplastics. This pattern is also visible at the level of the individual 
compounds (Fig. 2.2). Appendix 2.11 contains the 100 exposure scenarios (combinations 
of location and substance) with the highest risk quotients. From this list and Figure 2.2, 
it shows that the highest risk quotients are calculated for three antibiotics: levofloxacin, 
doxycycline and ciprofloxacin.
The relatively high aquatic risk quotients due to exposure to these three substances 
can be explained from their aquatic toxicities (i.e. first, third and fourth most toxic of 
all compounds assessed; Table A2.12), as well as their very low removal in both STP 
and the environment. Whereas the characterisation of levofloxacin and doxycycline was 
235
Spatially explicit prioritisation of human antibiotics and antineoplastics in Europe
mainly based on worst-case assumptions, extrapolations and predictions, ciprofloxacin 
is one of the more data-rich substances (Table 2.1). In 2009, ciprofloxacin accounted for 
50% of total quinolone use in 20 countries and was the most frequently used quinolone 
in 26 countries out of the 32 countries who reported data to ESAC [120]. Furthermore, 
removal of ciprofloxacin in the environment is very small, as it undergoes only limited 
photodegradation [121] and no biodegradation [122]. Biodegradation of ciprofloxacin does 
not take place during sewage treatment either [123]. On the other hand, removal via sorption 
to primary and secondary sludge [124] and some of the tertiary treatment processes [125, 126] 
can be substantial.
Aquatic risk quotients due to antibiotics exposure in Greece are not the highest 
(Fig. 2.1A), although Greece has the largest per capita consumption of outpatient 
antibiotics in Europe [127]. This is mainly because from the set of antibiotics included 
in our study, only the Greek consumption of cefuroxime, the substance with the 13th 
highest aquatic toxicity, is the highest of all Member States. Instead, the highest summed 
aquatic risk quotients due to exposure to antibiotics were calculated for the Milan region 
in northern Italy (Fig. 2.1A). Levofloxacin dominates in this grid, as it contributes 
approximately 86% to the summed aquatic risk quotient. This can be explained from 
the high levofloxacin consumption in Italy, compared with the other EU Member 
States [120], and the high population density of the region. As a result of this population 
density, levofloxacin emissions in this grid represent 12% of the total Italian levofloxacin 
emissions. Levofloxacin exposure also causes relatively high risk quotients in some other 
areas in Italy and in a number of densely populated areas spread across Europe. Similar 
to levofloxacin, the high risk quotients of doxycycline and ciprofloxacin also occur in 
densely populated areas, containing for example the cities of Paris, London and Krakow 
and the German Ruhr area.
2.3.2 Human health
The list with the top 250 combinations of location, substance and exposure group 
(Appendix A2.11) shows that the highest risk quotients are estimated for elderly people 
in southern Portugal due to exposure to ciprofloxacin via conventionally treated drinking 
water and locally produced food. However, summed risk quotients are highest for infants 
that consume conventionally treated drinking water (Fig. 2.3; Appendix A2.10). Note 
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furthermore that the same spatial patterns at different risk levels can be observed for all 
age classes (Appendix A2.10). Figure 2.3 shows that the difference between the summed 
health risk quotients due to exposure to antibiotics and due to exposure to antineoplastics 
is not as large as is shown for the aquatic environment (Fig. 2.1). For example, the 
maximum summed human health risk quotient for antibiotics is approximately 10 times 
higher than that for antineoplastics. Figures 2.3 and 2.4 do show a large influence of 
food origin on the health risk quotients. Both the ranking of locations (Fig. 2.3) and 
substances (Fig. 2.4) of potential concern changes when a local or a Europe-wide food 
origin is considered.
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FIGURE 2.3 
Summed health risk quotients (predicted exposure ÷ HD50) for infants due to exposure to 
antibiotics and antineoplastics, after consumption of conventionally treated drinking water 
and either locally produced or Europe-wide food.
A = antibiotics and locally produced food; B = antineoplastics and locally produced food; C = antibiotics and 
Europe-wide food; D = antineoplastics and Europe-wide food. The grids with the highest summed risk  
quotients are outlined with a solid black line.
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FIGURE 2.4 
Health risk quotients (predicted exposure ÷ HD50) for infants due to exposure to individual 
substances in all grids after consumption of conventionally treated drinking water and 
either locally produced or Europe-wide food. 
Red dots = median values; box = area between the 10th and 90th percentile; whiskers = minimum and  
maximum values. The percentages between brackets represent the fraction of the grids where the risk 
quotient for that specific substance was zero (only applicable to scenarios where locally produced food is 
consumed).
If local food origin is taken as a starting point, the highest risk quotients occur due to 
exposure via food (especially fruits and vegetables; Fig. 2.5). They are estimated in grids 
where local conditions promote higher concentrations in agricultural soils. In the high-
ranking grids located in eastern Spain (Fig. 2.3A), sludge application on agricultural soils 
is high (i.e., 85% of all secondary sludge) [84, 85] and removal via run-off from agricultural 
soils is rather low because of the high evaporation rate.
Ciprofloxacin has the highest health risk quotients when a local food origin is 
considered (Fig. 2.4; Appendix A2.11). It is one of the more data-rich substances, as 
elaborated upon in Section 2.3.1.
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If a European average instead of a local food origin is considered, exposure via 
drinking water becomes more influential (Fig. 2.5). As a consequence, locations (i.e. 
Paris region; Fig. 2.3) and substance of highest concern change. Because anions have a 
lower sorption potential than cations, they tend to remain more in the water phase during 
sewage treatment. This explains the shift towards ceftriaxone as the substance with the 
highest human health risk quotients (Appendix A2.11). Although environmental removal 
of ceftriaxone does occur to some extent via photolysis and hydrolysis [128], it is barely 
biodegraded in the environment [128] or during sewage treatment [129]. Furthermore, no 
removal was assumed during drinking water purification (worst-case assumptions; Table 
2.1), with the exception of the process of ozonation [130] (based on removal in STP).
FIGURE 2.5 
Health risk quotients for infants (predicted exposure ÷ HD50) due to exposure via individual 
exposure routes after consumption of conventionally treated drinking water and either 
locally produced or Europe-wide food. 
Red dots = median values; box = area between the 10th and 90th percentile; whiskers = minimum and max-
imum values. The percentages between brackets represent the fraction of the grids where the risk quotient 
via that specific exposure route was zero (only applicable to scenarios where locally produced food is con-
sumed).
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FIGURE 2.6 
Comparison of predicted surface water concentrations with measured surface water 
concentrations of pharmaceuticals only used in human medicine (A) or used in both human 
and veterinary medicine (B).
Coloured lines represent range between minimum, median and maximum values; crosses represent de-
tection limits. Dots represent single measurement values. Black line represents the 1:1 line and dotted lines 
represent the 10:1 and 1:10 lines. 
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2.3.3 Comparison with measurement data
Figure 2.6A shows that predicted and measured surface water concentrations of 
pharmaceuticals that are only used in human medicine lie approximately within 1 order 
of magnitude difference, with the exception of the concentration of tamoxifen in one grid. 
Because of the selection criteria explained in Section 2.2.3, a bias towards relatively high 
measurement concentrations may have occurred. For example, the fact that tamoxifen 
concentrations were reported below the LOD in nine other grids [111, 112, 131] is not reflected 
in the dataset. Furthermore, calculations on tamoxifen are based on a substantial amount 
of worst-case assumptions (Table 2.1).
Pharmaceuticals that are used in both human and veterinary medicine are generally 
measured at higher concentrations than predicted (Fig. 2.6B). Veterinary emission 
probably also explains the occurrence of oxytetracycline and trimethoprim in surface 
waters where zero concentrations were predicted.
2.4 DISCUSSION
A tool was developed to prioritise human pharmaceutical emissions in Europe based on 
risk quotients for the aquatic environment and human health. It was applied in a case 
study considering 11 human antibiotics and 7 antineoplastics. In this section, we discuss 
the methodological limitations of our study and the implications for research and policy.
While the sorption of ciprofloxacin was based on measurement data [124], the sorption 
potentials of other pharmaceuticals of concern were estimated with QSARs on the 
relationship between KOW and KOC [104] and a default value for the fraction of organic 
carbon in the sludge [132]. This might especially be influential on the risk quotients for 
levofloxacin and doxycycline, two zwitterionic substances for which relatively high 
aquatic risk quotients were estimated and whose sorption estimations are uncertain 
(Section 2.2.2.3). Furthermore, these QSARs were also used for the estimation of solids–
water partitioning during fate calculations. However, after we characterised the sorption 
of zwitterions with a QSAR for anions instead of cations [104], the ranking of human health 
risk quotients changed only marginally (ρ = 0.97), even though the quotients became on 
average a factor of 2 higher.
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The application of sewage sludge in the form of biosolid forms the final step in the 
estimation of emissions to agricultural soil. European legislation regulates agricultural 
application of sewage sludge by obligating Member States to formulate quantity and time 
limits [133]. Such limiting conditions were not considered within our study, as we assumed 
a spatially and temporally homogenous application per Member State. Although Spain, 
where the grids identified as areas of concern are located, prohibits the application of 
biosolids on agricultural soil for a period of three weeks before harvest or grazing, it 
has not formulated quantitative limits [134]. Nevertheless, to reduce uncertainties, the 
prioritisation tool could benefit from a more detailed agricultural module. Next to 
temporal and spatial variation in sludge application practice, such a module might take 
into account tillage practice [135] and effects of irrigation [136-139].
Currently, only emissions resulting from human use are taken into account in the 
tool. Although most of the pharmaceuticals included in our study are only used in human 
medicine, some are also used in considerable amounts in the veterinary setting [109, 140, 141]. 
Other relevant sources of pharmaceuticals that have thus been identified besides human 
use are cattle farming [e.g., 142, 143, 144], fish farming [e.g., 145, 146, 147], and the pharmaceutical 
industry [e.g., 148, 149-151]. However, inclusion of these sources at the level of the individual 
Member States, as was done for the consumption of human use pharmaceuticals, will 
be difficult due to limited data availability on amounts [140, 152] and emission locations. 
Furthermore, the inclusion of veterinary use of pharmaceuticals will require the 
consideration of additional pathways into the environment (e.g., disposal of manure, 
watewater from fish farms; [153]) and into human contact media [e.g., 154].
The fate calculations introduce uncertainties due to assumptions underlying the 
SimpleBox multimedia fate model. SimpleBox assumes a steady-state homogenous 
distribution of substances over its compartments. Consequently, no spatial or temporal 
variation is taken into account within each grid. Because of the 100 ∗ 100 km2 scale 
of the grids, the comparison with local measurement data may be biased, especially if 
spatial and temporal variations within a grid are large and measurements were taken 
at non-representative locations. Nevertheless, predicted concentrations in surface waters 
approximately lie within one order of magnitude with measured concentrations, even 
though limited measurement data were available for the comparison.
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The identification of food as an important human exposure route necessitates an 
assessment of the uncertainties of the concentration estimations in these food items. 
Although ionisation was taken into account in the QSARs used for the estimation of 
bioconcentration into fish and uptake by plants [89, 90], zwitterions such as ciprofloxacin 
do not fall in their applicability domain. Because of the importance assigned to exposure 
via fruits and vegetables, further QSAR-specification for different crops [155] and 
validation of the tool with measured concentrations in these crops are recommended. 
Furthermore, ionisation is not considered in the BTFs that were used for the calculation 
of concentrations in meat and milk [91]. Hendriks et al. [156] compared mechanistic model 
predictions with BTF regressions from Travis and Arms [91] and others [157, 158]. They showed 
that a distinction between labile (including ionising substances) and stable chemicals 
improves predictions on their biotransfer into meat and milk. However, because meat 
and milk were not identified as important exposure routes, the influence of this lack of 
specification on the results is probably limited.
Drinking water was identified as a second important human exposure route. Because 
data on removal efficiencies during drinking water purification were scarce, the distinctive 
power of the three purification scenarios (Section 2.2.1.4) was limited. Consequently, the 
potential influence of the level of drinking water treatment was not highlighted in the 
results. Because of its identification as substance of concern for exposure via drinking 
water, further research on the removal of particularly ceftriaxone during purification is 
recommended.
Although interindividual variability is included at the exposure side of the human 
risk quotient, toxicity was assumed to be equal for all individuals. The inclusion of 
interindividual variability with respect to the vulnerability to a substance could give a 
more accurate identification of potential high-risk target groups. Examples of such groups 
could for instance be infants and children who have a potentially high vulnerability to 
antineoplastics that target cell division, or people with reduced metabolic functions due 
to aging. Furthermore, summed risk quotients were based on common concentration 
addition calculations. However, the tool could potentially be extended with for example 
synergistic or antagonistic interactions, which could lead to the identification of mixture 
hot-spots [e.g., 159]. Backhaus et al. [160] have shown that a considerable mixture effect 
can result, even if all components of a mixture of pharmaceuticals are present in low, 
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individually non-toxic concentrations. This is supported by Christensen et al. [161], who 
showed examples of combined effects from exposure to antibiotics that were higher than 
what would be predicted based on the assumption of concentration addition. Finally, the 
risk quotients only apply on the aquatic environment and human health, but leave out for 
example effects on wildlife [e.g., 28, 65], the marine environment [e.g., 162, 163] or the emergence, 
transfer and effects of antibiotic resistant bacteria [e.g., 55, 56, 57].
2.5 CONCLUSIONS
The tool presented here is to our knowledge the first that can be used to prioritise 
combinations of human pharmaceuticals, locations and exposure groups, in such a way 
that potential hot-spots and substances can be identified for future monitoring activities 
and future research in the framework of aquatic and human health risk assessment.
The case study on a selection of antibiotics and antineoplastics showed that 
substances and locations of interest might differ if one considers the aquatic environment 
or human health. The risk quotients for the aquatic environment were the highest for 
three antibiotics, i.e. levofloxacin, doxycycline and ciprofloxacin, located in northern 
Italy (levofloxacin) and other densely populated areas throughout Europe (all three 
substances). Levofloxacin and doxycycline were identified for future research on relevant 
substance properties (Table 2.1) to increase data availability for aquatic risk assessment, 
whereas ciprofloxacin was identified as a substance that should be included into (future) 
European environmental monitoring program.
With respect to human health, the identification of substances and locations of 
interest are less straightforward as risks also depend on exposure group characteristics. 
However, infants in eastern Spain who consume locally produced food and conventionally 
treated drinking water have the highest risk quotients, mainly due to exposure to 
ciprofloxacin via food consumption. When the consumption of food with a Europe-
wide origin is considered, the highest exposure group changes to infants from the region 
of Paris, mainly due to ceftriaxone exposure via drinking water. Similar to the aquatic 
environment, ciprofloxacin was identified for inclusion in (future) monitoring program. 
Further data should be gathered on the removal during sewage treatment and drinking 
water purification of ceftriaxone.
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ABSTRACT
A methodology was developed for the assessment and comparison of the 
environmental impact of two alternative pharmaceutical prescriptions. This 
methodology provides physicians with the opportunity to include environmental 
considerations in their choice of prescription. A case study with the two antibiotics 
ciprofloxacin and levofloxacin at three locations throughout Europe showed that the 
preference for a pharmaceutical might show spatial variation, i.e. comparison of two 
pharmaceuticals might yield different results when prescribed at different locations. 
This holds when the comparison is based on both the impact on the aquatic 
environment and the impact on human health. The relative impacts of ciprofloxacin 
and levofloxacin on human health were largely determined by the local handling of 
secondary sludge, agricultural disposal practices, the extent of secondary sewage 
treatment, and local food consumption patterns. The relative impacts of ciprofloxacin 
and levofloxacin on the aquatic environment were mostly explained by the presence 
of specific sewage treatment techniques, as effluents from sewage treatment plants 
(STPs) are the most relevant emission pathway for the aquatic environment.
49
Environmental impact assessment of pharmaceutical prescriptions: does location matter?
3
3.1 INTRODUCTION
Several factors play a role in a physician’s decision to prescribe a pharmaceutical, e.g. 
efficacy, tolerability [164], costs [165], and advertisement and promotion [166]. Additionally, 
environmental considerations have become of importance due to the increased 
awareness of the unintended impact of our pharmaceutical use on humans and the 
environment [e.g., 69]. This environmental awareness is reflected in concepts such as green 
pharmacy and pharmaECOvigilance [e.g., 167].
One way to support physicians to include environmental considerations in 
pharmaceutical prescription is the introduction of a decision support system. Vidaurre 
and Turcotte [168] assessed the need for such a system amongst European physicians 
and other stakeholders. A publicly available classification system for pharmaceuticals 
has already been implemented on a national scale in Sweden (www.fass.se) [169]. This 
system is based on the voluntary risk-based Swedish Environmental Classification and 
Information System [170], and consists of three levels of information. The first level contains 
a classification per substance (insignificant, low, moderate or high environmental risk), 
based on its PEC/PNEC ratio (PNECs according to ECB [171]; PECs according to EMA 
[33]). The second level contains additional information on PBT properties (persistence, 
bioaccumulation, toxicity), and the third gives detailed environmental information 
underlying the calculations. However, the system provides only limited guidance to end-
users who want to explore the need and possibility to substitute one pharmaceutical 
for another [172]. Furthermore, the system shows shortcomings in its accuracy and 
consistency [173], and data are often lacking or too scarce to enable a comparison that 
transcends a superficial comparison based on PBT properties [174, 175]. Because of these 
shortcomings and because it is perceived as too complicated and time consuming, the 
Swedish classification system is not extensively used by individual physicians [176].
Here, we present a methodology that can be used to compare two otherwise equivalent 
pharmaceutical prescriptions on the basis of their relative impact on both the aquatic 
environment and human health. It is based on a spatially explicit prioritisation tool for 
human pharmaceuticals in the environment [177]. Because the methodology is centred 
around the comparison to be made, it requires only limited end-user input, being (1) a 
selection of the pharmaceuticals to be compared, (2) the amounts intended to be prescribed, 
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and (3) the region where the pharmaceuticals will be used. This straightforward approach 
ensures that complexity and time constraints are restricted. The spatially explicit nature of 
the methodology, as reflected in the third input requirement, enables an assessment of the 
influence of spatial variation on the comparison of alternative pharmaceuticals. In other 
words: does location matter in the choice between alternative pharmaceuticals? We will 
answer this question in a case study with two fluoroquinolone antibiotics: ciprofloxacin 
and levofloxacin.
3.2 METHODOLOGY
3.2.1 Description of the methodology
The methodology for the environmental decision support system is similar to the 
previously developed screening tool for policy prioritisation [177], which is based on four 
consecutive steps: emission, fate, exposure and effect. It calculates regional (100 * 100 
km2 grid-scale) risk indicators throughout Europe for both the aquatic environment and 
human health. For a detailed description of the assumptions and calculations underlying 
the tool we refer to Oldenkamp et al. [177]. Furthermore, Appendix A3.1 contains a short 
summary of this publication and a visualisation of the tool. Below, the adaptations are 
explained.
Contrary to the original prioritisation tool, prescribed amounts instead of national 
consumption data form the starting point for the emission calculations. After all, the 
impact of one prescription cannot be deduced from the impact of the total consumption 
on a national level. By default, prescribed amounts are expressed in Defined Daily Doses 
(DDDs) [77], which enables a comparison of different pharmaceuticals. Optionally, they 
can also be expressed in grams.
Furthermore, emissions are assumed to take place in a limited geographical region, 
i.e. the location of prescription. The end-user has to select the grid in which the 
pharmaceutical is prescribed. Consequently, the resulting emissions to surface water 
also take place in this grid. Emissions to agricultural soil depend on state-specific sludge 
disposal practices and are expressed as per km2 agricultural soil. Under the assumption of 
a homogeneous disposal over the agricultural area in the Member State of concern, these 
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emissions are therefore not restricted to the grid of prescription, but can occur in every 
grid that contains agricultural soil. The multimedia fate model SimpleBox [86], adapted for 
ionising substances and spatially parameterised with data from Pistocchi and Pennington 
[87], subsequently calculates exposure concentrations in each grid where emissions take 
place. For each of these grids and for both pharmaceutical prescriptions, a grid-specific 
risk indicator is calculated, i.e. the ratio between the predicted exposure concentration 
and a reference value. Equations 3.1 and 3.2 specify this risk indicator for the aquatic 
environment and for human health, respectively:
Iaq,i,j = Csw,i,j ⁄ HC50,i    Equation 3.1
where Iaq,i,j is a measure for the impact of pharmaceutical i on the aquatic environment in 
grid j, Csw,i,j is the surface water concentration of pharmaceutical i in grid j, and HC50,i is 
the hazardous concentration of pharmaceutical i at which at least 50% of the individuals 
in 50% of aquatic species is affected.
Ihum,k,i,j = Dk,i,j ⁄ HD50,i   Equation 3.2
where Ihum,k,i,j is a measure for the impact of pharmaceutical i on human exposure group 
k in grid j, Dk,i,j is the dose of pharmaceutical i taken in by human exposure group k in 
grid j, and HD50,i is the hazardous dose of pharmaceutical i at which at least 50% of the 
individuals in 50% of mammalian species is affected.
When the impact is not limited to the grid of prescription, i.e. when agricultural 
disposal of sludge takes place, risk indicators for multiple grids need to be integrated. This 
can be done in different ways. Here, grid-specific aquatic risk indicators are integrated 
according to Eq. 3.3, and grid-specific risk indicators for human health according to Eq. 
3.4.
Iaq,i = ∑nj =1 (Vj ⁄ VMS*Csw,i,j ⁄ HC50,i )  Equation 3.3
in which n is the number of grids in the Member State of concern, Vj is the surface water 
volume in grid j (excluding sea water), and VMS is the total surface water volume in the 
Member State.
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Ihum,k,i = ∑nj =1 (Pj ⁄ PMS*Dk,i,j ⁄ HD50,i) Equation 3.4
in which Pj is the population size in grid j, and PMS is the total population in the Member 
State.
Previously, infants (0–1 years) that consume conventionally treated drinking 
water and locally produced foodstuffs were identified as the most sensitive human 
exposure group [177]. They were therefore selected as the human exposure group most 
suitable for the calculation of the impact on human health. Finally, relative impacts 
(Irel) are calculated to compare the two alternative pharmaceutical prescriptions. These 
represent the contribution of a pharmaceutical prescription to the total impact in case 
both pharmaceuticals would have been prescribed, normalised to 100% (Eq. 3.5). The 
calculation is the same for the aquatic environment and human health.
Irel,i = Ii ⁄ ( (I1+I2 ) )*100%  Equation 3.5
3.2.2 Selection of substances
Ciprofloxacin and levofloxacin, two second-generation fluoroquinolone antibiotics, 
were selected to illustrate the methodology in a case study. Because of their relatively 
high risk quotients, both substances were identified from a larger set of antibiotics 
and antineoplastics as being amongst the most interesting for future policy focus [177]. 
Additionally, ciprofloxacin and levofloxacin are comparable in terms of their medical 
application [178]. Table 3.1 provides an overview of the data quality of the relevant 
substance-specific input parameters, based on a four-step procedure to select input data 
which descends from high to low quality:
1. Experimental or measurement data;
2. Extrapolation from related data (e.g., from degradation rates in other 
environmental media);
3. Structure or property based predictions (e.g., the use of QSARs);
4. Worst-case assumptions.
If desired, the end-user can thus interpret the results by analysing the background 
of the substance-specific input data. This way, the relevance of the comparison can be 
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assessed in a more informed manner compared to excluding information on the quality 
of the input data.
TABLE 3.1
Data quality of the substance-specific input parameters for ciprofloxacin and levofloxacin
Parameters CIP LEV Parameters CIP LEV
Emissions - Sewage treatment Hydrolysis in soil 4 4
Sorption to primary STP-sludge 1 3 Photolysis in water 1 1
Sorption to secondary STP-sludge 1 3
Biodegradation in STP 1 4 Fate - Partitioning
N-removal techniques efficiency 1 4 Soil-water 3 3
P-removal techniques efficiency 1 4 Water-air 3 3
UV-treatment efficiency 1 4
Chlorination techniques efficiency 1 4 Exposure – Accumulation
Ozonation techniques efficiency 1 4 BCFs fish 3 3
Sand filtration techniques  
efficiency
1 4 RCFs vegetables 3 3
Microfiltration techniques  
efficiency
4 4 BTFs meat and milk 3 3
Emissions - Other Exposure – Drinking water treatment
Human excretion 1 1 Coagulation techniques efficiency 1 4
PAC techniques efficiency 4 4
Fate - Degradation Sand filtration techniques efficiency 2 4
Biodegradation in water 2 1 Chlorination techniques efficiency 1 4
Biodegradation in sediment 2 2
Biodegradation in soil 2 2 Effect
Hydrolysis in water 4 1 Aquatic toxicity 1 1
Hydrolysis in sediment 4 4 Human toxicity 1 1
1: experimental or measurement data; 2: extrapolation from related data; 3: structure or property based 
predictions; 4: worst-case assumptions.
3.2.3 Selection of locations
Three grids were selected for the case study with ciprofloxacin and levofloxacin. The first 
is located in the north of Italy, the second in the southeast of Spain, and the third in the 
east of Sweden (Fig. A3.2). The first two were selected because they have the highest 
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predicted aquatic and human health risk, respectively, due to environmental exposure 
to human antibiotics [177]. The third was selected because Sweden was identified as one of 
the countries with the lowest risks due to environmental exposure to human antibiotics. 
Table A3.1 contains the spatially differing characteristics of the three grids potentially 
relevant for the calculation of the grid-specific risk indicators. The extent to which certain 
sewage treatment techniques are applied forms one of the most profound differences 
between the grids. For example, while everybody in the Swedish grid is connected to 
primary treatment and P-removal techniques, this is not the case in the grids in Italy 
and Spain. On the other hand, other tertiary treatment techniques, such as chlorination 
or UV-treatment, are more extensively applied in the Italian and Spanish grids. Another 
profound difference between the grids lies in the percentage of secondary sludge disposed 
of on agricultural soils, i.e. 85% in Spain, compared with only 22% in both Italy and 
Sweden. Additionally, the grids differ in their environmental characteristics. For example, 
south-eastern Spain, with its semi-arid climate, has a higher average temperature and 
lower precipitation intensity than the other two grids. Also, the grid in northern Italy 
contains 25% of all Italian surface water, mainly attributed to Lakes Maggiore and Como, 
which is a much higher percentage than the other grids have.
3.2.4 Parameter importance analysis
All spatially varying characteristics were subjected to a parameter importance analysis 
with Spearman’s rank correlation coefficients. Since the relative impact is expressed on 
a 0–100% scale and sums to 100% for both substances, a higher relative impact for one 
substance always implies a lower relative impact for the other. Therefore, this analysis 
not only shows the influence of each parameter on the comparison, but also how they 
relate to the relative impacts of the alternative pharmaceutical prescriptions. However, 
it is important to keep in mind that this analysis does not provide information on the 
influence of the spatial parameters on the absolute value of the risk indicators.
3.2.5 Comparison with fass.se data
The existing Swedish classification system for pharmaceuticals (www.fass.se) [169] reports 
aquatic PEC/PNEC ratios on the national level for a range of pharmaceuticals, among 
which six of the seventeen pharmaceuticals that were selected within the PHARMAS 
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project. These were corrected to represent values per DDD, and relative impacts were 
subsequently calculated per pair of pharmaceuticals. Finally, these relative impacts were 
compared with the relative impacts for all Swedish grids, as calculated according to the 
procedure outlined in the present paper (Section 3.2.1).
3.3 RESULTS
3.3.1 Description and parameter importance analysis
When prescribed in northern Italy, the environmental impact of one DDD of levofloxacin 
is higher than that of one DDD of ciprofloxacin, regardless whether the aquatic 
environment or human health is considered (Fig. 3.1A). However, in eastern Sweden it 
is the other way around, i.e., the prescription of one DDD of ciprofloxacin turns out 
to have a higher environmental impact than one DDD of levofloxacin (Fig. 3.1C). The 
comparison for south-eastern Spain shows that the highest impact differs between the 
aquatic environment and human health: the prescription of one DDD of levofloxacin 
has the highest relative impact on the aquatic environment (i.e. 65%), while that of one 
DDD of ciprofloxacin has the highest impact on human health (i.e. 83%; Fig. 3.1B). This 
variation between European regions can be explained based on the spatial characteristics 
of the regions (Appendix A3.3) and the results of the parameter importance analysis (Fig. 
3.2).
Figure 3.2 shows that the aggregation of grid-specific impact values into a combined 
impact value constitutes an important step in the calculations. Indeed, the weighing 
factors assigned to the grid of prescription, i.e. water volume fraction (aquatic 
environment) and population fraction (human health), have the highest Spearman’s rank 
correlation coefficients of all parameters assessed. Consequently, a grid of prescription 
with a relatively large water body or population contributes to the combined impact at the 
expense of the other grids. However, if the ratio between the impacts of ciprofloxacin and 
levofloxacin is constant over the grids, then any variation in weighing factors is irrelevant.
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FIGURE 3.1 
Relative impact of ciprofloxacin and levofloxacin on the aquatic environment (AQ) and 
human health (HUM), in northern Italy (A), south-eastern Spain (B) and eastern Sweden (C).
Blue bars: relative impact of the prescription of one DDD of ciprofloxacin; Yellow bars: relative impact of the 
prescription of one DDD of levofloxacin.
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Furthermore, parameters related to the level of sewage treatment also influence 
the relative impact of ciprofloxacin and levofloxacin, especially the presence of P- and 
N-removal techniques (Fig. 3.2A), and of sand-filtration techniques and secondary 
treatment (Fig. 3.2B). The presence of techniques for P-removal, N-removal and sand-
filtration increases the relative impact of levofloxacin. Table 3.1 shows that this is due to the 
quality of the data underlying the STP-removal estimations. While ciprofloxacin removal 
efficiencies of most techniques are derived from measurement data, for levofloxacin they 
are based on worst-case no removal assumptions. For example, P-removal techniques 
have an efficiency of 74% for the removal of ciprofloxacin from the wastewater [126], which 
is in great contrast with the lack of removal assumed for levofloxacin.
FIGURE 3.2 
Importance analysis of spatially varying parameters on the relative impact of ciprofloxacin 
and levofloxacin on the aquatic environment (A) and on human health (B). Only parameters 
with ρ ≥ 0.3 (weak correlation; values shown in the bars) are displayed.
Blue bars: parameter is positively correlated with the relative impact of ciprofloxacin; Yellow bars: parameter 
is positively correlated with the relative impact of levofloxacin. GoP = grid of prescription; MS = Member 
State.
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Because human exposure occurs via multiple exposure routes, i.e. drinking water, 
surface water and a range of different foodstuffs, the calculation of the impact on human 
health is more complex than that on the aquatic environment. The extent of exposure via 
each of these routes depends on substance- and grid-specific characteristics. For example, 
when primary and/or secondary sewage treatment techniques are present, pollutants 
partly adsorb to the sludge, resulting in a decrease of surface water emissions. The extent 
to which this happens depends on the sorption potential (Kp) of the substance. However, 
while surface water emissions decrease, emissions to agricultural soil might increase 
due to the disposal of secondary sludge on agricultural lands. Therefore, sorption to 
secondary sludge can cause a shift from STP effluents to agricultural sludge disposal as 
the relevant emission pathway into the environment. Whether this subsequently leads to 
an in- or decrease in human exposure depends on local environmental conditions (e.g. 
temperature, precipitation), substance-specific characteristics (e.g. degradation rates in 
different media, the potential to transfer into foodstuffs), and population characteristics 
(e.g. consumption behavior).
Resulting from a shift in emission pathways as described above, the relevant human 
exposure routes for ciprofloxacin change considerably with the extent of secondary 
sewage treatment (Appendix A3.3), caused by the high sludge sorption potential of 
ciprofloxacin [124]. Interestingly, a higher level of secondary treatment does not result in 
a lower impact of ciprofloxacin on human health. Instead, under the specific conditions 
present in the three grids, the impact of a prescription of ciprofloxacin increases with 
increasing levels of secondary treatment. This can be attributed to the high accumulation 
rates of ciprofloxacin into food (estimated with QSARs for the accumulation in fish 
[89], plants [179], and meat and dairy products [91], respectively), its low degradation rates 
in both STPs [123] and the environment [121, 122], and its removal during drinking water 
purification (chlorination [180], UV-treatment [181]). Furthermore, this explains the 
relatively high impact of ciprofloxacin on human health in the Spanish grid, because 
here a high fraction of secondary sludge is disposed of on agricultural soils (Appendix 
A3.3). Because levofloxacin has a sorption potential around 10 times lower than that 
of ciprofloxacin (estimated with QSARs from Franco and Trapp [104]), exposure occurs 
mainly via drinking water, regardless of the extent of secondary sewage treatment 
(Appendix A3.3). Consequently, a number of spatially varying parameters are positively 
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correlated with the relative impact of ciprofloxacin on human health, such as the presence 
of secondary sewage treatment, the extent of agricultural disposal of secondary sludge, 
and the consumption of fish and dairy products (Fig. 3.2B). On the other hand, carbon 
content of the soil is positively correlated with the relative impact of levofloxacin: a higher 
carbon content increases the sorption of ciprofloxacin to a greater extent than that of 
levofloxacin, thus lowering its availability for plant uptake.
3.3.2 Comparison with fass.se data
Figure 3.3 shows that relative aquatic impacts derived from PEC/PNEC ratios for the 
whole of Sweden (www.fass.se) [169] are close to the Swedish grid-specific relative impacts 
calculated via the procedure described in the present paper, but that a substantial amount 
of spatial variation can exist that is not considered when a national instead of regional 
approach is taken.
FIGURE 3.3 
Comparison of grid-specific relative aquatic impacts in Sweden with relative aquatic 
impacts derived from PEC/PNEC ratios on the national level (www.fass.se) [169].
Green bars represent the range (min–max) of relative aquatic impacts for all grids in Sweden, calculated ac-
cording to the procedure outlined in the present paper; red crosses represent the relative aquatic impacts on 
the national level, derived from PEC/PNEC ratios on the national level (www.fass.se) [169]. 5FU = 5-fluorouracil; 
CT = ceftriaxone; CU = cefuroxime; CI = ciprofloxacin; TA = tamoxifen; TR = trimethoprim.
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3.4 DISCUSSION
This section is divided in two parts. The first discusses a number of methodological 
limitations and potential expansions of the decision support tool, based on the findings 
from the case study with ciprofloxacin and levofloxacin. The second reflects on the results 
for the two antibiotics and their implications.
3.4.1 Methodological limitations
The comparison between ciprofloxacin and levofloxacin revealed the influence of the 
extent to which sewage treatment techniques are applied. This raises the question whether 
spatial variation in drinking water purification techniques could be of importance too. 
Similar to sewage treatment techniques, drinking water purification techniques and the 
extent to which they are applied differ spatially throughout Europe. However, information 
on their spatial distribution was not available. Therefore, drinking water purification 
is currently restricted to a set of three potential levels of treatment, i.e. conventional, 
advanced, and no treatment, with the latter being applicable to small scale supplies with 
abstraction from groundwater sources only [177].
Additionally, STPs can vary in their substance-specific removal efficiency, even when 
applying the same techniques [e.g., 182]. Potentially influential factors that are not included 
in the tool are the sludge retention time [e.g., 183], rainfall [e.g., 184] and temperature [e.g., 185]. 
Thus, spatial variation in sewage treatment efficiencies is probably larger than estimated 
by the tool, which might have led to an underestimation of the importance of sewage 
treatment for the calculation of relative impacts.
Furthermore, the results show that agricultural sludge disposal and subsequent 
accumulation and transfer into foodstuffs influence the impact on human health. In our 
study, a spatially and temporally homogeneous per km2 application of sludge was assumed 
per Member State. However, Member States are in fact obliged via European legislation 
to formulate quantity and time limits for the agricultural application of sewage sludge 
[133]. To reduce uncertainties, the tool could thus benefit from a more detailed agricultural 
module, taking into account temporal and spatial variation in sludge application practice, 
and possibly also tillage practice [135] and effects of irrigation [139].
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3.4.2 Reflection on the results
The use of the methodology results in a percentage-wise comparison between the relative 
impacts of two alternative pharmaceutical prescriptions. The more one of the two 
pharmaceutical alternatives is identified as an environmentally better option, the more 
importance can be assigned to the results. Additionally, the results should be reflected upon 
in the light of the quality of the input data (Section 3.2.2). Indeed, when the substance-
specific data underlying the calculations are highly uncertain, for example due to a 
substantial amount of worst-case assumptions (e.g. levofloxacin removal during tertiary 
sewage treatment, Table 3.1), the validity of the results decreases. This classification of 
input data in different classes of quality thus gives an indication of the gaps of knowledge 
and the sources of uncertainty in the calculations. However, the methodology does not 
yet provide the possibility to quantify this uncertainty. In order to get insight in their 
significance, an uncertainty analysis could be performed on the relative impacts, for 
example via a probabilistic approach using Monte Carlo techniques [e.g., 50].
Furthermore, when a comparison shows one alternative pharmaceutical prescription 
to be an environmentally better choice than another, this conclusion becomes less relevant 
if absolute impacts are negligibly low. In that case, environmental considerations in the 
decision-making process become subordinate to other considerations. A lower limit of 
relevance might provide an indication of the importance that should be assigned to the 
relative impacts. This could be based on the measure of effect used in the comparison.
3.5 CONCLUSIONS
This paper shows that for the implementation of an environmental decision support system 
for physicians, a spatially explicit approach at a Europe-wide level could be relevant. Indeed, 
a case study with prescriptions of ciprofloxacin and levofloxacin showed that local spatial 
characteristics influence their relative environmental impact, resulting in prescription 
decisions that differ between locations if environmental conditions vary sufficiently. This 
is further supported by a comparison between relative impacts at the regional level and 
at the national level (derived from PEC/PNEC ratios reported at www.fass.se), which 
shows that, although both approaches yield similar results, a substantial amount of spatial 
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variation can exist that is ignored when a national approach is taken (Fig. 3.3). The spatial 
characteristics most influential are related to the level of sewage treatment, the Member 
State specific sludge disposal practice and environmental factors like temperature and 
surface water volume. For other pairs of pharmaceuticals, however, spatial variation 
might be less influential, especially when they largely differ in those properties that do not 
depend on environmental conditions (e.g. toxicity, dosage). To further assess the relevance 
of a spatially explicit approach when incorporating environmental considerations in the 
decision-making process of prescribing pharmaceuticals, a wider range of combinations 
of pharmaceuticals should be studied.
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ABSTRACT
The selection of priority APIs (Active Pharmaceutical Ingredients) can benefit 
from a spatially explicit approach, since an API might exceed the threshold of 
environmental concern in one location, while staying below that same threshold 
in another. However, such a spatially explicit approach is relatively data intensive 
and subject to parameter uncertainty due to limited data. This raises the question 
to what extent a spatially explicit approach for the environmental prioritisation of 
APIs remains worthwhile when accounting for uncertainty in parameter settings. 
We show here that the inclusion of spatially explicit information enables a more 
efficient environmental prioritisation of APIs in Europe, compared with a non-
spatial EU-wide approach, also under uncertain conditions. In a case study with nine 
antibiotics, uncertainty distributions of the PAF (Potentially Affected Fraction) of 
aquatic species were calculated in 100 * 100 km2 environmental grid cells throughout 
Europe, and used for the selection of priority APIs. Two APIs have median PAF 
values that exceed a threshold PAF of 1% in at least one environmental grid cell in 
Europe, i.e., oxytetracycline and erythromycin. At a tenfold lower threshold PAF 
(i.e., 0.1%), two additional APIs would be selected, i.e., cefuroxime and ciprofloxacin. 
However, in 94% of the environmental grid cells in Europe, no APIs exceed either 
of the thresholds. This illustrates the advantage of following a location-specific 
approach in the prioritisation of APIs. This added value remains when accounting 
for uncertainty in parameter settings, i.e., if the 95th percentile of the PAF instead 
of its median value is compared with the threshold. In 96% of the environmental 
grid cells, the location-specific approach still enables a reduction of the selection of 
priority APIs of at least 50%, compared with an EU-wide prioritisation.
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4.1 INTRODUCTION
Because of their widespread use and increasingly effective analytical techniques, active 
pharmaceutical ingredients (APIs) are being detected in a range of environmental media 
around the world [18, 26, 61-63, 186, 187]. Their specific modes of action make them substances 
of concern, even at the relatively low concentrations at which they are generally present.
European legislation for new APIs has been implemented, requiring an environmental 
risk assessment to be performed for their registration and approval [33]. However, legacy 
APIs are not being covered by this legislation. There is a clear need for prioritisation 
of legacy APIs based on environmental concerns, e.g., within the context of the Water 
Framework Directive (WFD) [188]. This has been identified by Boxall et al. [35] as one of 
the key outstanding issues concerning APIs in the environment. Models can play an 
important role in this prioritisation exercise since reliable monitoring data and accurate 
detection techniques are lacking for many APIs. Several methods for the prioritisation of 
APIs have been developed and proposed [36, 37, 41, 189-191]. We have previously developed a 
spatially explicit prioritisation tool for human pharmaceuticals in the environment [177], 
and demonstrated in a case study with 11 antibiotics and 7 anticancer drugs that the 
spatial dimension should not be neglected. We showed that the estimated environmental 
impact of these APIs differs at different locations throughout Europe. Spatial differences 
in the estimated environmental impact can result from varying API-specific consumption 
volumes [e.g., 192], differences in population density, behavioral characteristics such as 
compliance with treatment [e.g., 193] and disposal of leftover pharmaceuticals [e.g., 81], design 
and removal capacity of local sewage treatment plants (STPs) [e.g., 194], and disposal 
practice of sewage sludge on agricultural soils [195]. After APIs are emitted to surface 
water or agricultural soil, further spatial differentiation results from local environmental 
characteristics, e.g., spatial differences in the size and physicochemical characteristics of 
the receiving surface water or the fraction organic carbon in soil. 
From a policy perspective, adequate identification of priority APIs is crucial to prevent 
misguided allocation of resources. Application of a non-spatial EU-wide modelling 
approach for prioritisation can be expected to result in a relatively large set of priority 
APIs since non-spatial models often rely on conservative assumptions to deal with spatial 
variability. In the present paper, we investigate whether location-specific prioritisation of 
68
Uncertainty and variability in environmental risk assessment of human pharmaceuticals
4
legacy APIs based on a spatially explicit EU-wide modelling approach has added value 
compared to a non-spatial EU-wide prioritisation. Such a modelling approach could for 
example be used to identify substances of possible concern for inclusion on the WFD 
watch list, especially if accurate monitoring data and/or detection techniques are lacking.
Data on physicochemical and environmental properties of APIs, as well as location-
specific data on emission volumes, are typically limited. Perforce, parameterisation is 
often based on suboptimal data, estimation methods, or worst-case assumptions. The 
prioritisation of APIs is thus subject to uncertainty, which might result in a more extensive 
set of priority APIs if a certain level of confidence is desired about the exceedance of their 
respective environmental thresholds. This raises the question to what extent a spatially 
explicit approach for the local environmental prioritisation of APIs remains worthwhile 
when accounting for this uncertainty.
Here, we investigate the added value of a spatially explicit EU-wide modelling 
approach for the local prioritisation of legacy APIs based on their risks for the aquatic 
environment. We do this for a set of nine antibiotics, with and without the consideration 
of uncertainty in input parameters. Prioritisation results are derived with the spatially 
explicit prioritisation tool [177] for environmental grid cells of 100 * 100 km2 throughout 
Europe. Uncertainty in substance-specific and country-specific input parameters is 
propagated into aquatic risks using Monte Carlo simulation techniques. This assessment 
should provide insight in the extent to which the local selection of priority APIs changes, 
once parameter uncertainty is included in the calculations.
4.2 METHODOLOGY
4.2.1 Spatially explicit prioritisation tool
The spatially explicit prioritisation tool for human APIs in Europe [177] is based on the four 
consecutive steps of emission, fate, exposure and effect. It estimates regionalised relative 
risk quotients throughout Europe for both the aquatic environment and human health, 
using consumption data that represent dispensed amounts at the level of the individual 
EU Member States. These dispensed amounts can enter the wastewater either as a result 
of non-compliance and disposal via flushing, or as a result of actual consumption and 
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excretion as parent compound via urine or faeces. Pharmaceutical residues in wastewater 
are first estimated at the level of individual Member States, and are then divided over 
individual agglomerations, based on their population size. Generally, this wastewater is 
discharged into the surface water after passage through a sewage treatment plant (STP). 
However, part of the wastewater might also be discharged into the surface water directly, 
depending on the local level of STP-connectivity. Indirect emissions, i.e., after passage 
through an STP, are calculated at the level of the individual STPs, and depend on STP 
design (i.e., size and treatment techniques applied) and API-specific removal efficiencies 
corresponding with these treatment techniques. Furthermore, the prioritisation tool 
also estimates emissions of APIs to agricultural soils, which depend on pharmaceutical 
levels in secondary sewage sludge and Member State specific surplus sludge disposal 
practices. Other factors that might influence local surplus sludge disposal practices, 
e.g., water industry company strategies, are not taken into account in the prioritisation 
tool. Emissions to surface water and agricultural soils are subsequently aggregated at 
the level of 100 * 100 km2 environmental grid cells and subjected to multimedia fate 
calculations, resulting in yearly averaged steady-state surface water concentrations. 
Aquatic risk quotients are then calculated as the ratio between these concentrations 
and API-specific HC50 values, i.e., the hazardous concentration at which 50% of the 
individuals in 50% of the species is being affected. Finally, these risk quotients are used 
to derive a grid cell-specific prioritisation of the APIs assessed. Ecological risks in other 
environmental media are not included in the prioritisation tool, e.g., risks for soil- or 
sediment-dwelling organisms, and neither are risks for high order wildlife species due to 
food chain accumulation. Prioritisation based on human health risk quotients requires 
additional exposure calculations, including estimations of the transfer of pharmaceutical 
residues into foodstuffs and drinking water, and age- and location-specific behavioral and 
consumption patterns. However, in this study we focus on the aquatic prioritisation of 
APIs, leaving out potential human health risks.
Two improvements were made to the original prioritisation framework described 
earlier [177]. Firstly, sorption and biodegradation during secondary sewage treatment 
were estimated with the most recent version of the SimpleTreat model (version 4.0) [196], 
which was specifically developed for calculations with ionising compounds. Secondly, 
log-normal species sensitivity distributions (SSDs) were used [197], enabling a risk 
70
Uncertainty and variability in environmental risk assessment of human pharmaceuticals
4
characterisation not only based on the central tendency of the effect, but also on the 
shape of the dose-response curve. The potentially affected fraction of species (PAF) [e.g., 198, 
199] for each API was calculated as a percentile of this SSD, corresponding to the predicted 
local surface water concentration. Then, these PAFs were compared with a threshold PAF 
upon which the selection should be based. Here, we considered two threshold values for 
illustrative purposes, being a PAF of 1% and a PAF of 0.1%. Thus, the previously used 
HC50 values were replaced by HC1 and HC0.1 values, i.e., the hazardous concentration at 
which 50% of the individuals in 1% and 0.1% of the species is being affected, respectively.
4.2.2 Selection of priority APIs
Nine antibiotics were included in this study, of which three fluoroquinolones, i.e., 
ciprofloxacin (CIP), levofloxacin (LEV), and ofloxacin (OFL), three tetracyclines, i.e., 
chlortetracycline (CTC), oxytetracycline (OTC), and tetracycline (TC), one cephalosporin, 
i.e., cefuroxime (CFU), one macrolide, i.e., erythromycin (ERY), and trimethoprim 
(TMP). These APIs were part of a larger set of APIs selected within the framework of the 
EU FP7 project PHARMAS (http://www.pharmas-eu.net), which specifically focused on 
environmental risk assessment of antibiotics and anti-cancer drugs. Anti-cancer drugs 
were not included in the present study because reliable EU-wide consumption data were 
not available, and differences between countries in consumption characteristics were 
judged too unpredictable to justify extrapolation [192]. Moreover, only those antibiotics 
were selected for which sufficient effect data were available to derive species sensitivity 
distributions [200] (see Section 2.4). The set of nine antibiotics selected serves as proof of 
principle. 
A Monte Carlo simulation with 1,000 iterations was performed to calculate the 
uncertainty in the PAF for all nine APIs in all environmental grid cells of the spatially 
explicit prioritisation tool, using uncertainty distributions for the input parameters. Per 
environmental grid cell, the probability for an API to exceed the threshold PAF was then 
represented by the corresponding percentile of its uncertainty distribution. We assume 
that the most likely PAF (PAFP50) represents the PAF without the inclusion of uncertainty. 
Then, the grid cell-specific local set of priority APIs comprises all APIs for which this 
probability is > 0.5, i.e., for which the most likely PAF (PAFP50) exceeds the threshold PAF. 
When uncertainty is included in the prioritisation, however, the local set of priority APIs 
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extends to all APIs for which the probability of exceeding the threshold PAF is > 0.05, i.e., 
for which the upper confidence limit of the uncertainty distribution of the PAF (PAFP95) 
exceeds the threshold PAF.
For each of the four model scenarios (HC1 with PAFP50, HC1 with PAFP95, HC0.1 with 
PAFP50, and HC0.1 with PAFP95), all regionalised sets of priority APIs were combined into 
a maximum set of priority APIs. This set of priority APIs is assumed to represent the set 
that could have been considered for prioritisation in a non-spatial EU-wide appraoch, 
since such an approach would be based on conservative assumptions and each of these 
APIs exceeds the threshold PAF in at least one environmental grid cell in Europe. Per 
environmental grid cell, the added value of taking location-specific information into 
account was then expressed by calculating a “Selection Reduction Factor” (SRF). This 
SRF was calculated as one minus the ratio between the size of the set of priority APIs 
for that specific grid cell and the size of the maximum set of priority APIs (Eq. 4.1). The 
SRF ranges between 0 and 1, with a value of 0 indicating no added value for local water 
management in using a spatially explicit approach (i.e., the local and maximum set of 
priority APIs are equal), and a value of 1 meaning a 100% reduction (i.e., none of the 
maximum set of priority APIs is selected as a local priority API).
SRFi = 1 - Gi / Gmax    Equation 4.1
in which Gi reflects the local set of priority APIs for grid cell i; Gmax reflects the maximum 
set of priority APIs on EU level; and SRFi reflects the selection reduction factor for grid 
cell i (ranging between 0 and 1).
4.2.3 Parameter importance analysis
The results of the Monte Carlo simulation were subjected to two parameter importance 
analyses with Spearman’s rank correlation coefficients. In the first analysis, spatially 
varying parameters, e.g., population density or sewage treatment techniques applied, were 
correlated with grid cell-specific PAFP50 values for all APIs in the maximum set of priority 
APIs at a threshold PAF of 0.1%. This analysis was performed to identify the parameters 
contributing most to the spatial variation of the environmental impact of priority APIs 
throughout Europe. The second parameter importance analysis was performed to identify 
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the uncertain input parameters most relevant for the uncertainty in the estimation of 
the PAF. Therefore, uncertain parameters, e.g., API-specific physicochemical properties 
or aquatic toxicity, were correlated with the uncertainty distributions of the PAF for all 
APIs in the maximum set of priority APIs at a threshold PAF of 1%. In this analysis, only 
environmental grid cells were included where the PAFP95 exceeded the threshold PAF.
4.2.4 Uncertainty distributions
Three types of input parameters are at the basis of the spatially explicit prioritisation 
tool: substance-specific parameters (e.g., physicochemical properties), country-specific 
parameters (e.g., consumption volumes), and grid cell-specific parameters (e.g., 
precipitation rates). Probability distributions were assigned to the first two categories, 
but not to the latter. The prioritisation tool uses the multimedia fate model SimpleBox 
[e.g., 86] to calculate grid cell-specific yearly averaged surface water concentrations. Inherent 
to such multimedia fate models are the assumptions of a steady-state situation and 
a spatially homogeneous distribution of environmental media within each grid cell. 
Because of these assumptions, grid cell-specific parameters are temporally averaged, 
e.g., yearly average temperatures, as well as spatially averaged, e.g., average surface water 
depth. Hence, parametric uncertainty in grid cell-specific parameters was considered to 
be limited compared to substance-specific and country-specific parameters, especially 
considering the extensive data used for the parameterisation of the grid cells [201].
Substance- and country-specific input parameters were assigned probability 
distributions that were preferably constructed from empirical data reported in literature. 
A distinction was made between fractions (e.g., the fraction excreted as parent compound) 
and continuous parameters without defined upper limits (e.g., degradation rates or 
sorption coefficients). Fractions were assigned a beta distribution if n>1, or a betaPERT 
distribution if n=1. If empirical data were lacking, fractions were assigned a uniform 
distribution between 0 and 1. The other parameters were either assigned a log-normal or 
a normal distribution, depending on whether they were limited at a value of zero (e.g., 
degradation rates, sorption coefficients), or not (e.g., acid dissociation constant pKa). If 
n=1, default uncertainty distributions were assigned, as proposed by Jager et al. [202, 203]. 
If empirical data were lacking, QSARs were preferably used to estimate the mean of the 
distribution, and the RMSD (root mean square deviation) was then used to characterise 
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the standard deviation. This was only done for the organic carbon-water partitioning 
coefficient (KOC) of cefuroxime, for which a QSAR for anionic compounds was used 
[104]. When no suitable QSARs were available for parameters lacking empirical data, a 
bootstrapping approach was followed. Per iteration, a (log)normal distribution was fitted 
on the values drawn from the distributions of the other APIs (i.e., those with sufficient 
data). Then, a value was drawn from this distribution. This approach was followed for the 
KOC in soil (for levofloxacin), hydrolysis rates in water (for erythromycin and ofloxacin), 
and degradation rates in soil (for cefuroxime, levofloxacin, ofloxacin) and in sediment 
(for chlortetracycline, erythromycin, levofloxacin, ofloxacin, tetracycline).
Exceptions to the approach described above relate to:
1. the country-specific yearly in- and outpatient consumption volumes of the 
nine APIs. Consumption volumes are divided between volumes consumed 
within hospitals and healthcare facilities (inpatient consumption), and volumes 
consumed in an ambulatory setting (outpatient consumption). Country-specific 
in- and outpatient consumption volumes were considered absolute (i.e. not 
uncertain), because they were gathered within the extensive survey project 
ESAC [e.g., 127], which finished in 2011 and is continued as ESAC-Net at ECDC 
[76]. However, for Austria, the Czech Republic, Germany, Lithuania, Spain, and 
the United Kingdom, consumption volumes were only available as total volumes, 
i.e., not specified as in- and outpatient volumes. Therefore, the per capita in- and 
outpatient consumption in other countries was used to construct a distribution 
describing the fraction of the total volume being consumed in the outpatient 
setting (fop),
2. the substance-specific removal efficiency during primary and secondary 
sewage treatment. Contrary to removal efficiencies of tertiary sewage treatment 
techniques, uncertainty in the removal efficiency during primary and secondary 
treatment was not described with a single distribution per API. Instead, primary 
and secondary treatment removal efficiencies were estimated with the spreadsheet 
model SimpleTreat 4.0 [196]. Uncertainty in these removal efficiencies was taken 
into account via uncertainty distributions on the parameters of SimpleTreat 4.0, 
e.g., sludge loading rate, pH, organic carbon fraction in sludge, parameterised 
according to Franco et al. [204], and
74
Uncertainty and variability in environmental risk assessment of human pharmaceuticals
4
3. the substance-specific species sensitivity distributions (SSD) used for the 
derivation of grid cell-specific PAF values. Substance-specific log-normal species 
sensitivity distributions with uncertain parameters were used, derived via 
hierarchical Bayesian modelling with a larger set of antibiotics, as described by 
Oldenkamp et al. [200].
An overview of all probability distributions can be found in Tables A4.1-A4.4 of Appendix 
4.
4.2.5 Comparison with measurements
Predicted concentrations were compared with surface water concentrations reported in 
literature. Previously gathered data [177] were supplemented with data from measurement 
studies as extensively reviewed by [205]. Studies were included if at least 50% of the 
measurements were above the limit of detection (LOD), with a minimum of 5 values. 
Then, values below the LOD were substituted with values according to the method 
described by Swaving and de Vries [107] (Eq. 4.2). Data sets with values below the LOD 
that did not meet these criteria were excluded from the comparison.
xi = LOD * (LOD ⁄ x0.9 ) (1-f)   Equation 4.2
in which xi reflects substitution value; LOD reflects the limit of detection; x0.9 reflects the 
90th percentile of the measurement data; and f reflects the fraction of the measurement 
data above the limit of detection.
Following these criteria, measurement data were obtained for 29 combinations of grid 
cell and API (Table A4.5). The data cover seven APIs (chlortetracycline, ciprofloxacin, 
erythromycin, ofloxacin, oxytetracycline, tetracycline, and trimethoprim) and locations 
in eight countries (France, Germany, Italy, Luxembourg, Poland, Spain, Sweden, and the 
United Kingdom). A distinction was made between antibiotics exclusively used in human 
medicine and antibiotics also used in veterinary medicine [109, 140, 152].
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4.3 RESULTS
4.3.1 Priority setting
For oxytetracycline and erythromycin, the most likely PAF (PAFP50) exceeds a value of 
1% in one or more environmental grid cells (Fig. 4.1, panels IA and IIA, respectively), 
while for the other seven pharmaceutical ingredients the PAFP50 remains below 1% 
for all grid cells. Hence, these two APIs would be considered for prioritisation at the 
European level, if no parameter uncertainty would be taken into account. At a threshold 
PAF of 0.1%, cefuroxime and ciprofloxacin would also be considered (Fig. 4.1, panels 
IIIB and IVB, respectively), extending the set of priority APIs to four. The locations of 
concern are typically limited to grids in the United Kingdom (e.g., the regions of London 
and Manchester), and Romania (e.g., the region of Bucuresti), and the probabilities of 
a PAF over 1% or even 0.1% are in general much lower than 50% in other grid cells. 
Consequently, a grid cell-specific approach would achieve 100% reduction of the set of 
priority APIs in the vast majority of the environmental grid cells. Indeed, 99% of the 
environmental grid cells have an SRF of 1 at a threshold PAF of 1% (Fig. 4.2, panel IA). At 
a threshold PAF of 0.1%, this is 94% of the environmental grid cells (Fig. 4.2, panel IB). 
This emphasises the advantage of following a location-specific prioritisation of these nine 
legacy APIs based on a spatially explicit EU-wide modelling approach.
When prioritisation is based on the upper confidence limit of the uncertainty 
distribution of PAF (PAFP95), the maximum set of priority APIs at a threshold PAF of 1% 
increases to four (i.e., oxytetracycline, erythromycin, cefuroxime, ciprofloxacin; Fig. 4.1), 
and to all nine APIs at a threshold PAF of 0.1% (Figs. 4.1 and A4.1). Logically, the inclusion 
of parameter uncertainty in the prioritisation leads to a lower amount of environmental 
grid cells where a 100% reduction in the set of priority APIs can be reached (Fig. 4.2). 
Nevertheless, SRFs are still substantial for the majority of the environmental grid cells, 
especially in Scandinavian countries such as Sweden. Even at a threshold PAF of 0.1%, 
96% of the environmental grid cells have an SRF > 0.5 (Fig. 4.2, panel IIB).
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4.3.2 Parameter importance analysis
The parameter importance analysis with Spearman’s rank correlation coefficients showed 
that spatial variability in PAF values for oxytetracycline is mostly influenced by country-
specific outpatient and inpatient per capita consumption (Fig. 4.3A). Indeed, large variation 
in the per capita consumption of oxytetracycline exists between European countries, with 
the United Kingdom being the largest per capita consumer by far. Erythromycin and 
ciprofloxacin, and to a lesser extent cefuroxime, have a relatively even distribution of 
per capita consumption volumes throughout Europe compared with oxytetracycline. The 
spatial variability of PAF values for these three APIs is mainly influenced by population 
density and related characteristics (i.e., the number of STPs present in a specific grid cell 
and the surface area of urban soil) (Fig. 4.3B-D). Additionally, the extent to which STP 
influents are subjected to specific tertiary sewage treatment techniques is relevant for 
the spatial variability of PAF values of oxytetracycline and erythromycin (Fig. 4.3A-B). 
Grid cell-specific characteristics related to mobility in soils are relevant for the spatial 
variability of PAFP50 values for cefuroxime and ciprofloxacin (i.e., agricultural soil 
surface area, carbon content of the soil, and soil erosion) (Fig. 4.3C-D). Finally, between-
cell variability in surface water volume (i.e., surface water depth and area) explains a 
substantial part of the spatial variation in PAFP50 values for ciprofloxacin (Fig. 4.3D). 
The uncertainty distributions of the PAF with an upper confidence limit (PAFP95) 
larger than 1% were also subjected to a parameter importance analysis. This analysis 
showed that uncertainty in toxicity parameters mainly contributes to the uncertainty 
in PAFs (Fig 4.4). For the four priority APIs, the large majority of the uncertainty in 
PAFs stems from uncertainty in both the interspecies spread in sensitivity, with average 
contributions ranging from 69% to 77%, and the average sensitivity of species, with 
average contributions ranging from 7% to 21%. Other input parameters contribute 
relatively little to the uncertainty of PAFs (Fig. 4.4).
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FIGURE 4.1 
The spatial distribution of the probabilities for oxytetracycline (I), erythromycin (II), cefuroxime 
(III), and ciprofloxacin (IV) to exceed a threshold PAF of 1% (A) or 0.1% (B).
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4.3.3 Comparison with measurements
Figure 4.5A shows that average surface water concentrations of pharmaceuticals only used 
in human medicine fall inside the 95% confidence interval of the predicted concentrations, 
except for the average ofloxacin concentration in a grid cell in north-eastern Spain [119]. 
López-Serna et al. [119] measured ofloxacin at two locations in the Llobregat river, one 
upstream and one downstream from the discharge point of a large STP. These locations 
might be considered not representative for the average concentration in the whole 100 * 
100 km2 grid cell, causing discrepancy between measured and predicted concentrations.
Pharmaceuticals used in both human and veterinary medicine are generally measured 
at higher concentrations than predicted (Fig. 4.5B). Veterinary emissions probably also 
explain the occurrence of chlortetracycline, oxytetracycline, tetracycline and (to a lesser 
extent) trimethoprim in surface waters where zero concentrations were predicted.
FIGURE 4.2 
The spatial distribution of Selection Reduction Factors (SRFs), based on the threshold 
exceedance of PAFP50 (I) or PAFP95 (II), at threshold PAF values of 1% (A) or 0.1% (B).
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FIGURE 4.3 
Spatially varying parameters that explain at least 5% of the spatial variability of PAFP50 
values throughout Europe, for (A) oxytetracyline (B) erythromycin, (C) cefuroxime, and (D) 
ciprofloxacin. 
Tertiary sewage treatment is considered as the fraction of the STP influents in a grid cell that receives the 
specified treatment. STP: sewage treatment plant; Outpatient consumption: consumption in ambulatory 
setting; Inpatient consumption: consumption within healthcare facilities.
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FIGURE 4.4 
Importance of uncertain parameters for the estimation of PAF in grid cells where the upper 
confidence limit (PAFP95) exceeds 1%. Only input parameters are displayed that explain more 
than 1% of the uncertainty in PAFs in at least one of these grid cells. A: oxytetracycline (34 
grid cells); B: erythromycin (18 grid cells); C: cefuroxime (124 grid cells); D: ciprofloxacin (3 
grid cells). 
Bars represent the average importance; error bars represent minimum and maximum values. SSD: species 
sensitivity distribution; µlogEC50: mean over the log-transformed EC50 values; τlogEC50: interspecies variation in 
log-transformed EC50 values, here expressed as the precision (i.e., the reciprocal of the variance); pc: parent 
compound; API: active pharmaceutical ingredient.
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FIGURE 4.5 
Comparison of predicted and average measured surface water concentrations of 
pharmaceuticals only used in human medicine (A) or used in both human and veterinary 
medicine (B). 
Coloured lines represent range between 2.5th percentile, median and 97.5th percentile of predicted concentra-
tions, Crosses represent measurements where zero concentrations are predicted. Black line represents the 1:1 
line and dotted lines represent the 1:10 and 10:1 lines.
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4.4 DISCUSSION
The added value of the incorporation of spatial information in the prioritisation of human 
APIs for local water management was assessed in the light of uncertainty in the input 
parameters of the prioritisation framework. In this section, methodological limitations 
are discussed, followed by an indication of the implications for research and policy.
4.4.1 Methodological limitations
Uncertainty distributions were assigned to substance-specific and country-specific input 
parameters, but not to grid cell-specific parameters. This decision was based on the 
assumptions that underlie multimedia fate modelling, i.e., steady state concentrations 
and a spatially homogeneous distribution of environmental media. Moreover, region-to-
region variability has been previously shown to be relatively small compared with inter-
chemical variability in multimedia fate modelling [206]. Variance in the environmental fate 
of chemicals, assessed via multimedia fate calculations, is therefore typically driven by 
uncertainty in their chemical properties, rather than by uncertainties in environmental 
characteristics [207]. 
This is supported by the results of the parameter importance analysis on spatially 
varying parameters (Fig. 4.3), which show that emission-related parameters, rather than 
environmental characteristics, influence the spatial variation in the environmental impact 
of the nine APIs. However, these results partly depend on the spatial scale considered 
(i.e., 100 * 100 km2 grid cells). Because of the assumptions underlying the multimedia fate 
modelling, spatial variability is ignored within each grid cell. Instead, spatial variability 
is only considered as variability between environmental grid cells. Consequently, 
between-cell variability in concentrations becomes larger at smaller cell size, related to 
the increased variability in environmental characteristics [208]. Klepper and den Hollander 
[209] showed that multimedia fate concentration predictions at a European scale might 
underestimate the average surface water concentrations resulting from a spatially explicit 
approach with smaller grid cells, i.e., 25 * 25 km2. The spatial variability between these 
grid cells was substantial (with maximum values approximately a factor of 1000 above the 
European box model average). These studies show that cell size is an important factor in 
the methodology presented, and that the prioritisation of APIs may change at a grid cells 
smaller than 100 * 100 km2, with other factors influencing this prioritisation.
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Consequently, while nested multimedia box models may adequately predict between 
cell variation in chemical concentrations, they do not lend themselves for the identification 
of local hot-spots. Instead, once a set of priority APIs is identified in a grid cell, a spatially 
more detailed local study could be performed to identify such local hot-spots.
Removal of APIs during primary and secondary sewage treatment was estimated with 
the SimpleTreat 4.0 model [196], and distributions as derived by Franco et al. [204] were 
assigned to the parameters of the model to take uncertainty in this removal into account 
(Table A4.3). Per iteration, one removal fraction was calculated per API, and used for all 
STPs throughout Europe that apply such treatment. Similarly, per API one European-wide 
value was used for the removal efficiency of tertiary treatment techniques. Thus, removal 
efficiencies were considered uncertain, but not variable between STPs. In reality, however, 
variability between STPs in their capacity to remove the same API can be considerable 
[e.g., 194]. Consequently, spatial variability in the environmental impact of APIs might have 
been underestimated in our study.
4.4.2 Implications for research and policy
A grid cell-specific approach might be highly relevant for a meaningful and efficient local 
prioritisation of APIs. Indeed, it enables national and regional regulators to decrease the 
risk of misguided allocation of resources to APIs of no local environmental concern. 
Conversely, it allows to focus risk management options to where they may be expected 
to be most effective. If a PAF of 1% would be considered a threshold of environmental 
concern, oxytetracycline and erythromycin should be selected as priority APIs in some 
regions in the United Kingdom (Fig. 4.1, panels IA and IIA). Moreover, it is important 
to notice that tetracyclines are not only consumed by humans, but are also extensively 
used in the veterinary setting [152]. While a limitation of oxytetracycline and erythromycin 
consumption in these regions would be most effective to reduce the environmental 
impact, current European legislation does not provide a regulatory basis for such source-
based options. Indeed, end-of-pipe management is still the main regulatory option to 
reduce potential environmental risks of APIs. Instead, voluntary source-based actions 
might be sought. For example, environmental considerations might be taken into account 
by physicians in their choice between otherwise equivalent pharmaceuticals, using the 
previously developed decision support tool [210]. When taking uncertainty into account, 
84
Uncertainty and variability in environmental risk assessment of human pharmaceuticals
4
cefuroxime and ciprofloxacin are also included in the set of priority APIs. The largest 
contributor to uncertainty of these APIs is by far the estimation of their toxicity parameters 
(Figs. 4.4C and 4.4D). Further research into their aquatic toxicity could largely decrease 
the uncertainty in the model predictions, and provide insight into whether cefuroxime 
and ciprofloxacin should indeed be included as priority APIs.
We found that spatial differences in PAFP95 values of individual APIs are larger 
than spatial differences in PAFP50 values (Figs. 4.1 and A4.1). In each environmental 
grid cell, PAFP50 values depend on the most likely values of the chemical-specific input 
parameters only. PAFP95 values, however, derive from both the most likely values of the 
chemical-specific input parameters, as well as the uncertainty range in these parameters. 
Additionally, different input parameters might be relevant in different environmental 
grid cells. For example, parameters related to the removal efficiency of a certain sewage 
treatment technique are only relevant in locations where this technique is actually applied. 
This complicated interplay between spatially varying characteristics and uncertain input 
parameters results in more unique local sets of priority APIs when parameter uncertainty 
is taken into account. As a consequence, the maximum set of priority APIs, which 
comprises all unique local sets of priority APIs, contains a larger portion of the total 
amount of APIs assessed.
The choice of a threshold PAF can be very influential for the selection of priority 
APIs and therefore also for the justification of using a location-specific approach. Because 
species sensitivity distributions are largely conceptual constructs in which reality is 
simplified, justification of the choice of a threshold PAF based on its ecological relevance 
is difficult. Zijp et al. [211] aimed to address this through the setting of boundary conditions 
for chemical pollution footprints based on (acute) EC50-based SSDs. They proposed a 
methodology for the derivation of both ecosystem vulnerability based boundaries 
(i.e., natural boundaries), and chemical management based boundaries (i.e., policy 
boundaries). Natural boundaries were derived from food web data models as described 
by Mulder et al. [212]), resulting in a threshold PAF of 3%. Policy boundaries were derived 
from (chronic) NOEC-based SSDs, extrapolating the 95%-protection criterion generally 
used in chemical management policies to their (acute) EC50-based equivalent. This 
resulted in a threshold PAF value of 0.1%. 
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Here, we selected threshold PAF values of 1% and 0.1%, but these were mainly chosen 
for illustrative purposes. We therefore shortly assessed the influence of using threshold 
values higher than 1% and 0.1%. This assessment showed that a location-specific approach 
would still be worthwhile at threshold PAF values as high as 7.5%: this value is still exceeded 
by the PAFP95 of one single API (oxytetracycline) in one single environmental grid cell 
(the region of London). Finally, the level of confidence required for the prioritisation 
influences the range of relevant threshold values. Here, we selected the 95th percentile of 
the uncertainty distribution of PAF as its upper confidence limit, but a higher percentile 
can also be chosen when more confidence is desired. For example, when using the 99th 
percentile of the uncertainty distribution of PAF as its upper confidence limit, minimum 
SRFs of 2/7 and 1/9 are reached at threshold PAF values of 1% and 0.1%, respectively.
4.5 CONCLUSIONS
The inclusion of spatially explicit information enables a more efficient local environmental 
prioritisation of APIs in Europe, compared to a non-spatial EU-wide approach. When 
parameter uncertainty is taken into account in the assessment, the added value of 
this approach remains, and in some cases even increases due to the interplay between 
spatially varying parameters on the one hand and uncertain parameters on the other. 
Indeed, probabilistic spatially explicit environmental models can add a lot of pertinent 
information, from highlighting both basic data uncertainties that could be decreased 
by generating additional experimental data, to uncertainties within the model, a better 
understanding of which allows an improved characterisation of the confidence that can 
be attributed to the model predictions. On a more practical level, spatially explicit models 
can pinpoint both priority APIs and also priority grid cells, providing guidance for further 
in-depth investigation and risk management measures.
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ABSTRACT
The present study evaluated the potential environmental concentrations of 4 cytostatic 
(also known as cytotoxic) drugs in rivers. The antimetabolite 5-fluorouracil (5FU) 
and its pro-drug capecitabine were examined based on their very high use rates, 
cyclophosphamide (CP) for its persistence, and carboplatin for its association with 
the metal element platinum. The study combined drug consumption information 
across European countries, excretion, national water use, and sewage removal rates 
to derive sewage effluent values across the continent. Results showed considerable 
variation in the popularity of individual cytostatic drugs across Europe, including 
a 28-fold difference in 5FU use and 15-fold difference in CP use. Such variations 
could have a major effect on the detection of these compounds in effluent or river 
water. Overall, capecitabine and CP had higher predicted levels in effluent than 
5FU or carboplatin. Predicted effluent values were compared with measurements 
in the literature, and many non-detects could be explained by insufficient limits of 
detection. Linking the geographic based water resources model GWAVA with this 
information allowed water concentrations throughout 1.2 million km of European 
rivers to be predicted. The 90th percentile (worst case) prediction indicated that, with 
the exception of capecitabine, more than 99% of Europe’s rivers (by length) would 
have concentrations below 1 ng/L for these cytostatic drugs. For capecitabine, 2.2% 
of river length could exceed 1 ng/L.
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5.1 INTRODUCTION
The discharge of pharmaceuticals in wastewater into the aquatic environment has 
been a source of discussion and concern in scientific and regulatory circles for more 
than a decade [14, 213]. Chemotherapy drugs in the group known as cytostatic, cytotoxic, 
or antineoplastic (hereafter referred to collectively as cytostatic) are often featured on 
lists of pharmaceuticals of concern that are discharged into our river systems [39, 61]. 
These compounds are now an increasingly popular subject of environmental research 
and discussion [214-216]. Relatively little information is available, however, on the toxicity 
of cytostatic drugs to aquatic organisms. The information that is available suggests 
that cytostatic drugs are not particularly toxic to a variety of aquatic organisms [217-219]. 
However, long-term exposure studies, particularly studies of fish that include more than 
1 generation, have not yet been conducted. Therefore, it is premature to conclude that 
environmental concentrations of cytostatic drugs pose no risk to aquatic organisms.
A greater focus has been on the potential of these drugs to harm humans through 
water recycling. This scenario occurs when rivers are used both to receive sewage effluent 
and as a source of drinking water. A significant difference between humans and aquatic 
wildlife is that the former are protected by a range of water purification technologies [220, 
221]. Although this is reassuring, there is some evidence to suggest that some of the water-
soluble cytostatic drugs such as cyclophosphamide (CP) may still survive ozonation and 
pass through into drinking water [222]. Many would still consider that this is not a concern, 
as even the most pessimistic predictions indicate exposure to these drugs would still be 
considerably below levels of concern [29, 223]. Another angle to this issue is that the unborn 
child in the womb might be particularly vulnerable to inadvertent exposure to cytostatic 
drugs due to the drugs’ teratogenic potential [224]. A comprehensive study, however, 
indicated that exposure during the fetal development phase of the second trimester 
onward carried little risk of harmful effects to the unborn child [225]. Nevertheless, 
exposure in the embryogenesis period, which occurs in the first trimester (approximately 
the first 12 wk following conception) could lead to a range of malformations [226].
Key to any assessment of the risks involved are the concentrations likely to be found 
in surface (drinking) water. Several studies have been conducted to detect and analyse 
cytostatic drugs in sewage effluent and surface water in recent years, with mixed levels 
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of success. This is not an unreasonable exercise, given the common administration of 
chemotherapy in the outpatient departments of most city hospitals [216]. However, a high 
proportion of these studies failed to find the selected cytostatic drugs [116, 227-232], leaving the 
reader not knowing whether the drug was not actually used in the city/country studied, 
was eliminated successfully in sewage treatment, or was present but at a concentration 
below the limit of detection (LOD).
Several authors have reviewed the considerable number of cytostatic drugs used 
in chemotherapy, which, when discharged, might have harmful consequences for 
the environment [214-216]. Some are used more frequently than others because they are 
associated with treating the most common cancers or are used for a diverse range of 
cancers. The present study has selected 4 cytostatic drugs for further study based on their 
high consumption, their persistence in the environment, or their novelty. The cytostatic 
drug 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide, 
better known as cyclophosphamide (CP), is a commonly used alkylating agent dating 
to the late 1950s. It is typically given intravenously, although low doses may be given 
orally. It needs to be metabolised by cytochrome P450 enzymes in the liver to liberate 
alkylating metabolites such as nor-nitrogen mustard, which can crosslink DNA [233-235]. 
It has been used to treat a range of cancers including brain, bone, and leukemia, as well 
as some autoimmune diseases [233]. This drug has received considerable interest from 
environmental scientists over the years due to its apparent persistence [236-238].
The cytostatic drug cis-diammine-1,1-cyclobutane dicarboxylate platinum (II), also 
known as carboplatin, is a relatively recent cytostatic drug with clinical trials carried 
out successfully in the mid-1980s [239]. Carboplatin is always administered intravenously. 
The major cytostatic activity of carboplatin is binding with DNA to form intrastrand 
crosslinks and adducts that cause changes in the conformation of the DNA and affect 
DNA replication. Its use has been promoted because it has fewer side effects on patients 
than other Pt drugs, such as cisplatin [239]. As a representative of the Pt-containing group 
of cytostatic drugs, it may be a source of Pt contamination of the aquatic environment 
[240].
The antimetabolite 5-fluorouracil (5FU) and its pro-drug capecitabine are often found 
near the top of the consumption list for many countries. Following the observation that 
cancer tissues incorporated uracil much more than non-malignant tissues, 5-fluorouracil 
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(5FU) was synthesised as an antimetabolite chemotherapy drug in 1957 [241]. It is typically 
given to the patient intravenously. Due in part to the need to give the drug via the 
intravenous route, it appears to be less popular than its prodrug capecitabine, which can 
be given orally. Indeed, 5FU does not now appear to be used at all in Finland. The 5FU 
pro-drug pentyl [1-(3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1H-
pyrimidin-4-yl]carbamate, commonly known as capecitabine, is a drug popularly used to 
treat colorectal and breast cancers [242]. Unlike 5FU, it is well absorbed when taken orally 
and is metabolised in the liver through a series of intermediates to form 50-deoxy-5-
flourouridine, which is then converted to 5FU by the thymidine phosphorylase enzyme. 
This enzyme tends to be over expressed in tumor tissue [243], thus giving capecitabine 
greater selectivity than 5FU.
The present study attempted to predict the range of possible cytostatic drug 
concentrations in sewage effluent and surface waters for various countries in the European 
Union. The method used publically available consumption data, literature data on human 
excretion values, and sewage removal rates. The major refinement on previous studies 
was the use of varying national consumption values and wastewater discharge values. The 
following questions were addressed to predict surface water concentrations throughout 
Europe using a geographic-based water quality model: How different are national per 
capita cytostatic drug consumption values? What range of concentrations in effluents 
might be expected given different per capita wastewater discharge rates? How well do 
national predicted values correspond to published measured concentrations?
5.2 METHODOLOGY
5.2.1 Assessing per capita consumption rates
The approach to estimating concentrations in effluent takes the drug consumption per 
capita for a specific nation, less that prevented from being excreted as the free parent 
compound, less that removed in sewage treatment. The concentration in effluent is then 
calculated by dividing this figure by the per capita wastewater discharge for that nation 
as follows (Eq. 5.1):
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W = (C-E-S) / D    Equation 5.1
where C is consumption of the drug (ng/cap/d), E is the amount of the drug that is not 
excreted (ng/cap/d), S is the amount of the drug that is prevented from escaping into 
sewage effluent (ng/cap/d), D is the diluting volume of wastewater (L/cap/d), and W is 
the concentration in effluent (ng/L).
The most critical part of any model to assess concentrations of human-derived 
chemicals in water is obtaining accurate information on usage. Fortunately, some 
national annual consumption data on cytostatic drugs are publically available. These can 
be interrogated to assess a per capita consumption value, given the population of the 
country at a particular time (Table 5.1). The data available ranged from as recent as 1 yr 
ago to 15 yr old. Data on drug consumption for England was a summary of the responses 
from the major 34 health trusts, with the data originally cited as mg/1000 people over a 
6-mo period in 2005 [244].
5.2.2 Assessing per capita excretion rates and sewage removal rates
The next stage in modelling environmental concentrations of a pharmaceutical is 
to ascertain how much of the parent compound the patient excreted unchanged. Not 
surprisingly, humans vary in their excretion behavior, with such factors as age, health, 
and co-medication all influencing the percentage excreted. It is therefore advisable to 
survey as wide a range of literature as possible on excretion rates before arriving at a mean 
value. Similarly, natural variations in sewage performance can influence pharmaceutical 
removal rates in treatment. Unfortunately, the literature on removal in sewage treatment 
for many of the cytostatic drugs is still meagre, which must be considered a weak point in 
modelling these compounds.
5.2.2.1 Cyclophosphamide
In the 7 references covering 74 patients receiving CP, there was a relatively small range 
in the reported percentages of CP excreted over a 24-h period (Table 5.2). The amount 
of original CP excreted unchanged ranged from 11% to 20%, with a weighted mean of 
15.9%. Thus, these values can be used as upper, lower, and mean excretion rate values. 
There is considerable agreement that CP is a persistent compound in both sewage and 
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river water [236-238]. Thus, a simple prediction of CP concentration in sewage effluent can be 
made, assuming the per capita wastewater discharge volume is known and no significant 
attenuation occurs after excretion.
5.2.2.2 Carboplatin
A proportion of the carboplatin taken by the patient is excreted unchanged, and several 
studies have attempted to measure the percentage of the parent molecule in the urine 
over a 24-h period. Some of the reports can at first be misleading, because they measure 
only platinum; but it is possible to identify several references where the parent compound 
itself was measured in the urine. In the 5 references covering 50 patients, the amount of 
original carboplatin excreted unchanged ranged from 14% to 69%, with a weighted mean 
of 31.7% (Table 5.2).
Few studies have examined the fate of carboplatin in the environment, but several 
medical researchers have noted that it is not persistent in urine. The only reference that 
provides data that can be used on this topic was a study in which 5 activated sludge plants 
were studied, which recorded an average elimination from the effluent of 72% and a range 
of 59% to 85% [245]. 
5.2.2.3 5-Fluorouracil
As might be expected with a polar drug, the major route of excretion is in the urine, with 
faecal excretion believed to be unimportant [246]. A potential complication with choosing 
an appropriate excretion rate is that some treatments, such as those combined with 
eniluracil, give markedly higher urinary excretion of unchanged 5FU [247, 248]. However, 
the most used combination therapies appear to be with methotrexate or leucoverin [241], 
which do not seem to have a dramatic effect on the 5FU amount excreted in the urine. 
Also, excretion of unchanged 5FU is much higher when the drug is given orally, which 
probably explains the preference for intravenous use [249]. We identified 4 references in 
which the parent compound was measured in the urine in treatments without eniluracil. 
In the 4 references covering 32 patients examined, there was a fairly wide range reported 
in percentages excreted (Table 5.2). The amount of original 5FU excreted unchanged 
ranged from 2% to 39% with a weighted mean of 4.6%. Thus, these values could be used 
as upper, lower, and mean excretion rate values. However, before moving on to national 
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predictions for 5FU in sewage effluent, the contribution from patients taking capecitabine 
also needs to be taken into account. The amount of 5FU excreted from patients receiving 
capecitabine ranged from 0.5% to 0.8%, with a weighted mean of 0.7% (Table 5.2).
There have been a number of studies on the biodegradability of 5FU that give the 
general impression that significant removal in sewage treatment is probable (Table 5.3). 
Removal would depend strongly on biodegradation, as sorption to sewage particles appears 
to be low [250]. However, the studies were typically carried out at high concentrations with 
adapted microbial populations over long time periods and probably at room temperature, 
circumstances that may well not be typical of operational sewage treatment plants in 
Europe. Of these studies, those reported by Kiffmeyer et al. [236] and Mahnik et al. [250] 
probably come closest to replicating the activated sludge environment most typical of 
European wastewater treatment, albeit at μg/L rather than the ng/L concentrations, which 
might have been more realistic. These studies were most probably carried out at room 
temperature, which would tend to overestimate removal in winter. Given a probable 
range of 90% to 99% removal from these studies, a removal rate of 95% was selected. 
To estimate 5FU concentration in sewage effluent, the predicted value deriving from 
both 5FU consumption (following excretion and removal in sewage treatment) and from 
capecitabine consumption (with its unique excretion of 5FU and sewage removal) must 
also be included.
5.2.2.4 Capecitabine
Fortunately, several references exist in which unchanged capecitabine was measured in 
the urine following administration to patients (Table 5.2). The amount of capecitabine 
excreted unchanged from patients receiving the drug ranged from 2.6% to 3.4%, 
with a weighted mean of 3.1%. It is very difficult to predict the fate of capecitabine in 
sewage, however, because no references were found on the topic other than some high-
concentration Organisation of Economic Co-operation and Development laboratory 
studies carried out by Roche [223], in which it was described as slowly degradable. For this 
modelling exercise, it was assumed 50% would be removed in sewage treatment.
The summary of deduced excretion and removal rates for all the drugs is shown in Table 
5.4. Given consumption, excretion, and sewage removal information, all that remains is a 
national per capita wastewater discharge value to predict a concentration in effluent. A per 
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capita wastewater discharge value was assumed to be the same as the national per capita 
water use value. Per capita water use values are provided in several reports, including 
Eurostat from the European Union, the Environment Agency of England and Wales, the 
United Nations (UN) Development Programme, and Environment Canada. Notably, 
these reports do not always agree with one another. Where available, the Eurostat values 
have been used in the present study. Such predicted values are likely to be conservative 
because many sewage treatment plants also receive industrial waste, which would further 
dilute the wastewater and hence lower the concentrations.
5.2.2.5 European river water modelling
To examine potential concentrations of these cytostatic drugs throughout European 
surface waters, the geographic-based Global Water Availability model (GWAVA) was 
used [251]. The geographic database of this model includes the location and size of the 
human European population and the association of those populations with sewage 
treatment plants. The flows through these plants are incorporated with other flows and 
abstractions into the hydrological model. The hydrology is driven by monthly climate 
over the period 1970 to 2000. The chemical inputs of per capita drug consumption and 
removal in sewage were provided by the present study. The model calculates the water 
concentrations through a series of 177 470 grid squares of approximately 6 km * 9 km 
(5 * 5 Arc minutes) dimensions. The GWAVA model summates all the inputs and 
dilutions within a cell to give a value at the downstream “outflow” location of that cell. 
This does not necessarily represent the highest concentration that could occur at some 
point within that cell. However, at the scale of the European continent portrayed by the 
model, this scale is considered to be the best compromise and will reveal the exposures 
that the majority of aquatic wildlife will most likely face.
The main variables in modelling these cytostatic drugs were, therefore, consumption, 
excretion, sewage removal and dilution (Table 5.4). Although GWAVA can also modify 
the concentrations by including a water column attenuation rate, in the absence of such 
information for these compounds, they were assumed to be conservative once in the 
rivers.
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TABLE 5.2 
Proportion of cytostatic drug excreted unchanged by patients.
Drug excreted Reference No.  patients
Mean 
age Cause
Dose 
(g/d)
Excretion 
(%)a
Cyclophosphamide [235] 2 NG NG 1-26 14.5
[254] 12 43 Autoimmune 0.8-1.7 19
[255] 16 26 Bone marrow 3.5-4.2 14
[256] 4 48 Breast cancer 4.2 16.5
[257] 19 NG NG 4.2 14
[234] 6 NG Autoimmune 1.7 11
[258] 15 44 NG 6.8-10 20
Carboplatin [239] 14 NG Healthy volunteers 0.03-0.9 32
[259] 3 59 Multiple cancers 0.27-0.68 69
[257] 19 30 Bone marrow 3.9 14
[260] 7 55 Ovarian cancer 0.49-0.63 41
[261] 7 64 Lung cancer 0.17 54
5-fluorouracil [262] 1 NG Colon cancer 1.00 39
[263] 1 NG Colorectal cancer 0.75 11
[246] 8 NG NG 0.85 6.5
[249] 22 61 Largely colorectal cancer 3.9 2.0
5-fluorouracil from 
capecitabine
[243] 7 59 Range of cancers 2.0 0.5
[264] 13 56 Range of cancers 2.1 0.7
[265] 23 63 Range of cancers 2.0 0.7
[266] 60 60 Colorectal cancer 4.25 0.8
Capecitabine [243] 7 59 Range of cancers 2.0 2.9
[264] 13 56 Range of cancers 2.1 2.6
[265] 23 63 Range of cancers 2.0 2.7
[266] 60 60 Colorectal cancer 4.25 3.4
a: where 2 excretion values were given for separate days of treatment, the average value is reported. NG = no 
information provided
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5.3 RESULTS AND DISCUSSION
5.3.1 Predicted concentrations in European sewage effluent 
Although the incidence rates of different cancers are unlikely to be very different across 
European countries, the selection of drugs to treat these diseases does vary. Indeed, the 
popularity of certain cytostatics can vary across different regions in the same country 
[244]. For example, CP is more than twice as popular in Sweden than any other European 
country for which data were obtained, with a 15-fold difference in possible use across 
Europe (Table 5.1, Fig. 5.1). There is an 8-fold difference in carboplatin consumption 
between the European countries examined and a 4-fold difference for capacitabine (Table 
5.1, Fig. 5.1). The greatest variation is with 5FU, with a 28-fold difference in use (Fig. 
5.1). The predicted mean concentrations in effluent ranged from 2 ng/L to 40 ng/L for 
CP, from 0.8 ng/L to 2.5 ng/L for carboplatin, from 0.3 ng/L to 2.5 ng/L for 5FU, and from 
8.5 ng/L to 87 ng/L for capecitabine. These reflect the original consumption preferences 
and differences in national per capita wastewater discharge (88–230 L/cap/d; Fig. 5.2).
FIGURE 5.1 
Variations in per capita cyclophosphamide (CP), carboplatin (Carb), 5-fluorouracil (5FU), and 
capecitabine (Cap) consumption between different European nations. These values do not all 
come from the same year.
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5 FIGURE 5.2 
Predicted mean cyclophosphamide (CP), carboplatin (Carb), 5-fluorouracil (5FU), and 
capecitabine (Cap) concentrations in sewage effluent for European nations, taking into 
account differing national per capita wastewater discharge values.
These model predictions suggest that chemists wishing to monitor CP in sewage 
effluent must achieve LODs below 1.7 ng/L, expect a European mean concentration of 
11 ng/L, and travel to Sweden to find the highest concentrations in effluent. Those wishing 
to monitor carboplatin in sewage effluent must achieve LODs below 0.8 ng/L and expect 
a European mean concentration of 2.4 ng/L. Carboplatin is not recorded on the medical 
databases for The Netherlands, Norway, and Finland and thus may not be officially 
prescribed in those countries. Those wishing to monitor 5FU in sewage effluent must 
achieve LODs below 0.3 ng/L and expect a European mean concentration of 1.0 ng/L, 
with the highest predicted value of 2.5 ng/L being found in the Czech Republic. Those 
wishing to monitor capecitabine in sewage effluent must achieve LODs below 8.5 ng/L 
and expect a European mean concentration of 29.3 ng/L, with the highest predicted value 
of 87 ng/L being found in the Czech Republic.
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5.3.2 Comparing predicted and measured concentrations in effluent
A major objective of the present study was to compare and corroborate measured cytostatic 
drug concentrations with those predicted here. Thirteen studies on CP in sewage effluent 
were examined. The per capita wastewater discharge values used to predict the results 
were calculated from the authors’ own data, Eurostat 2012, UN 2006, or Environment 
Canada. Where it was not known, the mean European per capita consumption for CP was 
used. Of the 6 references that reported non-detects, 3 can be explained simply by having 
LODs above the predictable levels (Table 5.5). Where the LOD was below the predicted 
concentration and yet still no detection was made [116, 229, 230], the possibility still exists that 
wastewater flow was greater than expected on that sampling day. Of the 8 detections, 5 of 
the predictions using the method described in the present study were within an order of 
magnitude of those reported.
Three studies were found in which the chemists tried to measure 5FU in sewage 
effluents in Spain, Switzerland, and the United States, but these resulted in no detections 
[232, 270, 271]. The reported LODs were 15 ng/L to 21 ng/L; but using the prediction method 
described above, the mean effluent values would be expected to be 0.6 ng/L to 1.0 ng/L, 
which would appear to explain why 5FU was not detected. No studies on carboplatin or 
capecitabine concentrations in domestic sewage effluent could be found.
5.3.3 Predicting European river concentrations
The GWAVA model provides predictions for 1.2 million km of European rivers receiving 
the waste from 602.8 million people. As such, a single run of the model with its 177000 
grid squares and 31 yr of climate data generates 66 million results per chemical. All of 
the variables discussed will play a role; but it is clear that the most important factor in 
correctly predicting river concentrations, apart from consumption, is dilution (Table 
5.4). Different interpretations on human excretion, or sewage removal rates, could 
change the values by up to 20-fold, but dilution could change the values by up to 1000-
fold. The results from model runs can be displayed in several different ways, such as a 
map showing the 50th percentile concentrations across Europe for CP based on a mean 
excretion rate and mean sewage treatment removal (Fig. 5.3). This is broadly equivalent 
to the concentration that would be recorded at a median flow for that part of a river and, 
as such, might represent the typical exposure for surface waters. In this case, the CP hot 
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spots reflect not only the geography and hydrology of Europe, but also the popularity of 
the drug. This helps explain the relatively low predicted concentrations in Italy compared 
with southern Sweden (Fig. 5.3). The results can also be displayed as cumulative frequency 
curves, such as all the 90th percentile concentration values for all the cells based on the 
highest possible human excretion rates and lowest sewage treatment removal (Fig 5.4). 
These predictions could be considered as potential worst-case river concentrations such 
as might be associated with low summer flows. In this river scenario, the simulations 
indicate that 99% of European river locations would be below 0.2 ng/L for carboplatin 
and below 0.6 ng/L for 5FU. With CP, only 0.1% of locations could exceed 1 ng/L, whereas 
for capecitabine, 2.2% could exceed 1 ng/L in rivers (with 0.2% in the 3–41 ng/L bracket). 
It should be remembered that the highest possible concentrations would be undiluted 
sewage effluent (Fig. 5.2).
FIGURE 5.3 
Predicted cyclophosphamide (CP) concentrations in surface water based on mean excretion 
rate, mean sewage treatment removal, and 50th percentile flow across the European 
continent, taking into account differing national per capita consumption and wastewater 
discharge values from the Global Water Availability model (GWAVA).
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FIGURE 5.4
Predicted 90th percentile concentrations for cyclophosphamide (CP), carboplatin (Carb), 
5-flourouracil (5FU), and capecitabine (Cap) in surface water assuming high excretion rates 
and low sewage treatment removal across the whole European continent from the Global 
Water Availability model (GWAVA) plotted as cumulative frequency curves.
TABLE 5.5 
Comparing literature measured cyclophosphamide with predicted values for sewage 
effluents.
Reference Location Calculated 
water use 
(L/cap/d)
LOD 
(ng/L)
Reported 
value 
(ng/L)
Predicted 
value 
(ng/L)
Comments on 
simulation
[229] Oslo STP 722 2 <2 2.0 Acceptable
[228] 6 * STP UK 160 23 <23 10.4 Agree
[272] 7 * STP Beijing, China 160 0.8 8.5-14.5 10.4 Agree
[238] Zurich STP 630 0.3 2.1-4 3.3 Agree
[227] 18 * STP Canada 527 100 <100 3.2 Agree
[273] Montreal STP, Canada 329 0.5 12 5.1 Agree
[274] Windsor STP, Canada 329 1 2.5-4 5.1 Agree
[275] ASP H UK 200 0.04 0.2 8.3 Fail
Biol filt L UK 300 0.12 3.6 5.5 Agree
[116] Po & Lambro R, Italy 203 0.01 <0.01 1.4 Fail
[276] 9 * STP Italy 203 NA 0.6 2.7 Acceptable
[270] 1 * STP Spain 153 1.7-2.3 0.6 10.9 Fail
[230] 3 * STP Spain 153 3.1 <3.1 10.9 Acceptable
[231] 1 * STP Australia 480 125 <125 3.5 Agree
ASP = activated sludge plant; STP = sewage treatment plant; LOD = limit of detection; NA = information not 
provided.
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5.4 CONCLUSIONS
Overall, the availability of fairly recent drug consumption data from reliable sources 
and excretion data from the medical literature has placed this model in a strong starting 
position. The potential impact on modelling differences in consumption, human 
excretion, sewage removal, and dilution range from only 1.3-fold to 1000-fold (Table 5.4). 
Getting good information on all of these factors is important for precision, of course, 
but differences in consumption and hydrology are the most critical to get correct. The 
good correlation between values predicted in the present study and those observed in 
sewage effluent for CP provide grounds for encouragement. We anticipate that further 
refinement of the model will be possible in the future as more information on the fate and 
behavior of these compounds becomes available.
Returning to the original objectives of the study, we found a surprising difference in 
the popularity of these cytostatic drugs across European nations, with differences of up to 
28-fold. The predicted mean concentrations in effluent ranged from 2 ng/L to 40 ng/L for 
CP, from 0.8 ng/L to 2.5 ng/L for carboplatin, from 0.3 ng/L to 2.5 ng/L for 5FU, and from 
8.5 ng/L to 87 ng/L for capecitabine. In the majority of cases, where data are available, it is 
possible to predict CP concentrations in sewage effluent to within an order of magnitude 
of that observed. By linking with the geographic-based water quality model, it is expected 
that the majority of European rivers would have concentrations below 1 ng/L for these 
cytostatic drugs.
The predicted river concentrations are considerably below concentrations reported to 
have effects on aquatic wildlife [217, 218]. Notably, even in the 90th percentile prediction, 
approximately 80% of European surface waters for these drugs were largely below 0.1 ng/L; 
as such, there does not appear to be any widespread threat to European aquatic wildlife 
based on current knowledge. The issue of water abstraction for drinking water and foetal 
health may still require further research. Given its potentially high concentrations in 
effluent and good oral absorption by humans, capecitabine certainly seems worthy of 
further environmental research.
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ABSTRACT
Human exposure limits for chemicals with a toxicological threshold are traditionally 
derived using default assessment factors that account for variations in exposure 
duration, species sensitivity and individual sensitivity. The present paper elaborates 
a probabilistic approach for human hazard characterisation and the derivation of 
human exposure limits. It extends the framework for evaluating and expressing 
uncertainty in hazard characterisation recently proposed by WHO-IPCS, i.e., by the 
incorporation of chemical-specific data on human variability in toxicokinetics. The 
incorporation of human variability in toxicodynamics was based on the variation 
between AOPs (Adverse Outcome Pathway). Furthermore, sources of interindividual 
variability and uncertainty are propagated separately throughout the derivation 
process. The outcome is a two-dimensional human dose distribution that quantifies 
the population fraction exceeding a pre-selected critical effect level with an estimate 
of the associated uncertainty. This enables policy makers to set separate standards 
for the fraction of the population to be protected and the confidence level of the 
assessment. The main sources of uncertainty in the human dose distribution can be 
identified in order to plan new research for reducing uncertainty. Additionally, the 
approach enables quantification of the relative risk for specific subpopulations. The 
approach is demonstrated for two pharmaceuticals, i.e. the antibiotic ciprofloxacin 
and the antineoplastic methotrexate. For both substances, the probabilistic human 
exposure limit is mainly influenced by uncertainty originating from: (1) the 
point of departure (PoD), (2) extrapolation from sub-acute to chronic toxicity, 
and (3) interspecies extrapolation. However, when assessing the tails of the two-
dimensional human dose distributions, i.e. the section relevant for the derivation of 
human exposure limits, interindividual variability in toxicodynamics also becomes 
important.
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6.1 INTRODUCTION
Human exposure limits (HELs), also called Acceptable Daily Intakes (ADIs) or Reference 
Doses (RfDs), are derived to protect the human population from adverse health effects 
caused by exposure to chemicals that are assumed to have a toxicological threshold. Such 
limits are generally based on toxicity data from experiments with laboratory animals or 
from epidemiological studies. These data are then extrapolated to represent an exposure 
level at which the general population is sufficiently protected. Traditionally, default 
assessment factors (AFs) are being used to cover for differences in exposure duration, 
interspecies sensitivity and/or interindividual sensitivity [277]. However, the use of default 
AFs comes with a number of drawbacks.
First, the empirical basis of the default AFs is weak. Originally, this empirical basis was 
completely lacking; AFs were merely justified retrospectively to represent interspecies and 
interindividual variability [277-280]. In a later stage, their validity has been assessed in meta-
analyses on both interspecies variability [e.g. 281] and interindividual variability (extensively 
reviewed by Dorne [282]). These studies show that a number of situations can be identified 
in which a default AF provides insufficient protection for specific subpopulations, such as 
poor metabolizers [e.g. 283], children [e.g. 284] and elderly people [e.g. 285].
Second, default AFs are generic values that cover a wide spectrum of chemicals and 
toxic mechanisms. It has been recognised that preferably more specific mechanistic 
information should be incorporated in the extrapolation, resulting in less uncertainty 
in the derivation process. Renwick [286] proposed to subdivide the default AFs for 
interspecies and interindividual differences into separate subfactors for toxicokinetics 
and toxicodynamics, enabling the incorporation of pathway-specific information.
Third, default AFs generally are conservative deterministic values. Consequently, if 
individual AFs for multiple extrapolation steps are combined, this will lead to a stacking 
of conservative values which may result in an unrealistically low HEL of which the 
provided protection level remains unknown. 
To address these drawbacks, probabilistic approaches have been proposed in which 
uncertainties in the derivation process are characterised with statistical distributions 
[277, 287-291]. This has culminated in a guidance document on evaluating and expressing 
uncertainty in hazard characterisation, recently published as part of the Harmonisation 
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Project from the World Health Organisation (WHO) International Programme of 
Chemical Safety (IPCS) [292]. It describes a probabilistic approach consisting of three tiers, 
of which the third tier represents a full probabilistic Monte Carlo simulation [i.e., 45]. The 
approach incorporates uncertainties in all extrapolation steps into one final distribution 
of the target human dose HDMI. The HDMI is defined by the WHO-IPCS [292] as the human 
dose at which a fraction I of the population shows an effect of magnitude (or severity) 
M or greater (for the critical end-point considered). Within the probabilistic framework, 
default distributions are formulated for each of the extrapolation steps in the derivation 
process, which can be adapted when chemical-specific data are available.
Here we elaborate a systematic approach for the incorporation of chemical-specific 
data on human variability in toxicokinetics and toxicodynamics into the generic 
probabilistic framework as proposed by WHO-IPCS. It extends this framework at three 
points:
1. Uncertainty and interindividual variability are propagated separately throughout 
the assessment process via nested Monte Carlo simulations [58, 59]. The main 
difference with the WHO-IPCS approach is that the population fraction I is not 
predefined, but included in the analysis. The end result shows the relationship 
between I and the preferred level of confidence. Therefore, we use the term HDM 
instead of HDMI in this paper. 
2. Secondary (sampling) uncertainty in the distribution parameters is included in 
the analysis. This uncertainty stems from the limited number of studies available 
for the characterisation of human toxicokinetics and toxicodynamics, as well as 
from the limited amount of volunteers per study.
3. Potentially sensitive subpopulations are included in the derivation process. 
Rather than using one equipotent dose ratio between the median and the sensitive 
individual to describe the interindividual variability in toxicokinetics, a two-step 
approach is proposed in which the median individual in the general population 
is first extrapolated towards the median individual in the subpopulation, before 
the variability within this subpopulation is taken into consideration.
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Interindividual variability in toxicodynamics is characterised via an AOP-based 
approach (Adverse Outcome Pathway) [293], assuming that substances that share the same 
human (drug) target and physiological effect also show the same extent of interindividual 
variability in toxicodynamics.
The chemical-specific approach is demonstrated in a case study with two relatively 
data-rich pharmaceutical compounds, i.e., ciprofloxacin and methotrexate, and compared 
with an assessment using default distributions proposed by the WHO-IPCS [292].
6.2 METHODOLOGY
6.2.1 Selection of compounds
Ciprofloxacin and methotrexate were selected for a case study; two oral pharmaceuticals 
which were both part of a set of substances studied in the EU FP7 PHARMAS project (http://
www.pharmas-eu.net). This selection was based on the high ranking of ciprofloxacin in 
an earlier spatial prioritisation study [177], and the relatively high outpatient consumption 
of methotrexate [120, 294]. Although regulations do not require (non-occupational) HELs to 
be derived for pharmaceutical compounds, they form a suitable group of substances to 
demonstrate the derivation of probabilistic HELs because of their high data availability. 
Moreover, several human risk assessment studies previously derived HELs such as ADIs 
(Acceptable Daily Intakes) for pharmaceutical compounds [e.g., 29, 32, 66, 68, 295, 296].
6.2.2 Probabilistic derivation of target human dose
The extrapolation process from toxicity data to the distribution of the target human dose 
(HDM) is depicted in Figure 6.1. The extrapolation steps that are part of this process are:
1. Derivation of a Point of Departure (PoD);
2. Extrapolation from sub-acute or sub-chronic exposure towards chronic exposure;
3. Interspecies extrapolation for (a) allometric differences and (b) remaining 
differences in toxicokinetics and toxicodynamics;
4. Interindividual extrapolation for (a) toxicokinetics and (b) toxicodynamics. 
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First, an uncertainty distribution is derived for the PoD (Step 1), which represents 
the dose inducing a pre-selected magnitude of effect (M) in the typical (= median) test 
animal. This step is described in more detail in Section 6.2.2.1. The resulting uncertainty 
distribution is then extrapolated towards the dose inducing that same pre-selected 
magnitude of effect in the median human individual, covering for differences in exposure 
duration (Step 2) and interspecies sensitivity (Step 3). During these steps we used the 
default uncertainty distributions as proposed by the WHO-IPCS guidance document 
[292]. The default distribution for Step 2, when extrapolating from sub-chronic to chronic 
exposure, is based on oral sub-chronic to chronic BMD (benchmark dose) ratios for 
studies with matching endpoints and matching species [297]. When extrapolating from 
sub-acute to chronic exposure, the default distribution for Step 2 is based on oral sub-
acute to chronic NOAEL ratios for studies with matching species [298-300]. The default 
distribution for the allometric scaling factor used in Step 3a, i.e., extrapolation for 
generic body size differences between test animal and humans, is based on the scientific 
consensus that this factor should lie somewhere between 0.66 (scaling based on surface 
area) and 0.74 (scaling based on metabolic requirements). The default distribution for 
Step 3b, i.e., extrapolation for potential chemical-specific interspecies differences in 
toxicokinetics and –dynamics, is based on BMD ratios between rats and mice studies 
with matching endpoints [281]. The final step involves the extrapolation from the median 
human individual towards the sensitive human individual (Step 4). This step is described 
in more detail in Section 6.2.2.2. The characteristics of all default and chemical-specific 
distributions are presented in Table 6.1.
All steps contain sources of variation, either representing uncertainty (U; Steps 1-3) 
or a combination of uncertainty and interindividual variability (IV; Step 4). Uncertainty 
and interinvidual variability were separately propagated throughout the process by 
means of nested Monte Carlo simulation [58, 59], a two-step iterative procedure in which 
first all uncertain parameters are sampled and fixed (outer loop), followed by a Monte 
Carlo simulation with a number of iterations on the variable parameters (inner loop). 
This process is then repeated a number of times with each time a new set of uncertain 
parameters. The variance found in the inner and outer loops reflect variability and 
uncertainty, respectively. Nested Monte Carlo simulations have been broadly applied 
before in the context of risk assessment [50, 301-305]. Here, we applied 1,000 * 1,000 nested 
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Monte Carlo simulations. The relative contributions of all sources of uncertainty and 
interindividual variability to the final HDM distribution were calculated via Spearman’s 
rank correlation coefﬁcients. This was done both for the full HDM distribution and for 
the lowest 10% HDM values of this final distribution [306], since the lower percentiles are 
most relevant for the derivation of HELs. Because Step 4 contains both variability and 
uncertainty, the values sampled from the variability distributions depend on the values 
sampled from the (nested) uncertainty distributions. To determine the Spearman rank 
correlation coefficient exclusively related to variability, the values sampled from the 
variability distribution were transformed into percentile scores [301, 307].
6.2.2.1 Point of Departure
The derivation of a HEL should ideally be based on chronic human toxicity data, since 
this avoids the inclusion of the second and third extrapolation steps (Fig. 6.1), most 
likely decreasing the influence of uncertainty in the derivation process. While human 
toxicity data are not available for the vast majority of chemicals, pharmaceuticals form 
an exception. The available information on human toxicity for methotrexate, however, 
relates to incidental high-dose exposure and subsequent acute effects [308]: data that are 
not considered suitable for the derivation of a chronic dose-response relationship. For 
ciprofloxacin, a human surveillance study showed that 6 out of 679 patients suffering from 
drug induced liver injury could be attributed to treatment [309]. This study was, however, 
also not considered suitable for establishing a dose-response relationship due to a lack of 
information on dosing and magnitude of the effects. Additionally, human exposure limits 
have been previously derived for ciprofloxacin, based on its microbiological toxicity, 
i.e., its effect on the human intestinal flora [32, 310]. This was done by using Minimum 
Inhibitory Concentration (MIC) data for human intestinal flora. While the relatively 
sensitive endpoint of disturbance of the human intestinal flora is a logical starting point 
for the derivation of a HEL, the characterisation of interindividual variability (Step 4) 
for this type of non-physiological toxicity would require an approach very different from 
the WHO-IPCS framework, because interindividual variability in sensitivity would then 
relate to variability in the composition of the intestinal flora rather than variability in 
toxicokinetics and toxicodynamics.
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We therefore decided to use toxicity data from experimental animal studies as a 
starting point. Chronic carcinogenicity studies have not reported significant effects 
after either methotrexate [311, 312] or ciprofloxacin exposure [313]. Instead, a 28-day study 
on myelosuppression in mice [314] and a 7-day study on chondrotoxicity in rats [315] were 
selected for methotrexate and ciprofloxacin, respectively. Endpoints used were red blood 
cell count (RBC; an indicator of anemia) and white blood cell count (WBC; an indicator 
of leucopenia) for methotrexate, and thickness of the femoral articular cartilage for 
ciprofloxacin. For the latter, data were visually derived from Figure 1 of the publication 
[p. 1264 in 315]. The Point of Departure (PoD) was derived from these toxicity data using a 
benchmark dose (BMD) approach, first introduced by Crump [316] as an alternative for 
the NOAEL approach. For continuous endpoints, the PoD reflects the BMD at which 
a critical effect size (CES) is reached. The CES was defined as the acceptable change 
in the median response in the exposed population, compared to the modelled median 
background response in the non-exposed population [290]. This CES is similar to the 
magnitude of effect (M) as used in the WHO-IPCS guidance [292]. For both methotrexate 
and ciprofloxacin, a CES of 5% was used, based on studies with endpoints of red and 
white blood cell count [317] and developmental skeletal deformations [318].
Statistical uncertainty in the PoD can come from the limited sample size of the dose-
response data used for its derivation, and experimental errors therein. We quantified 
uncertainty in the PoD via an iterative bootstrap procedure consisting of 10,000 
iterations (see Slob and Pieters [290], Slob [319] and Slob and Setzer [320]). Considering that 
the responses within each dose group are expected to follow a lognormal distribution, 
the sample variance of the log-transformed responses is uncertain with an inverse chi-
square distribution, and the sample mean of the log-transformed responses is uncertain 
with a normal distribution with the Standard Error of the Mean (SEM) based on the value 
drawn from this inverse chi-square distribution [45].
Because the toxicity data were reported as arithmetic means and standard deviations 
on the normal scale, they were first transformed into geometric means (GMs) and 
geometric standard deviations (GSDs) on the log-scale [319, 321]. Shao et al. [322] have shown 
that the use of such reconstructed GMs and GSDs on the log-scale leads to only minor 
deviations in the outcomes of a BMD analysis.
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The influence of experimental error was quantified by resampling the distributions 
of the log-transformed responses for each dose-response group. Subsequently, two four-
parameter models were fitted on these resampled log-transformed dose-response data 
via maximum log-likelihood estimations, i.e., an exponential model and a Hill model. 
These models are considered to describe dose-response data with continuous responses 
adequately and equally well [320, 323]. In each bootstrap iteration, a PoD was derived for both 
models. However, a PoD could not always be derived, since the resampled dose-response 
values did not always show a negative trend (Mann-Kendall trend test with p<0.1). In 
these iterations, the non-existence of an adverse relationship between dose and effect was 
accounted for by assigning an infinitely large value to the PoD.
6.2.2.2 Interindividual extrapolation
Extrapolation steps 1 to 3 result in an uncertainty distribution of the dose that induces 
a pre-selected magnitude of effect in the median human individual (Fig. 6.1). In the 
fourth and final step in the derivation of the HDM distribution, this dose is extrapolated 
towards the sensitive human individual. The variability in sensitivity between individuals 
is divided into variability in toxicokinetics and variability in toxicodynamics, as proposed 
by Renwick [286].
6.2.2.2.1 Toxicokinetics
The variation in internal doses between individuals that were administered the same 
external dose was used as a metric for interindividual variability in toxicokinetics. 
Different metrics are currently being used for internal dose, such as Cmax (maximum 
serum concentration) and AUC (area under the concentration-time curve). Here, we 
applied the substance-specific AUC from t=0 to infinity (mg*h/L) as a measure of internal 
dose because it relates to chronic exposure. AUC data were collected from controlled 
experiments following administration of a single oral dose in healthy volunteers (Tables 
6.2 and 6.3). To increase data availability, studies in patients were also included as their 
diseases were deemed unlikely to alter their toxicokinetic characteristics. Data that 
were reported as arithmetic means and standard deviations on the normal scale were 
transformed into GMs and GSDs on the log-scale [321], i.e., ln(GMAUC) and ln(GSDAUC), 
assuming that interindividual variability in toxicokinetics follows a lognormal 
distribution.
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Pharmaceuticals are typically administered as a fixed amount (mg), as an amount per 
bodyweight (mg/kg), or as an amount per body surface area (BSA) (mg/m2). Since we 
assume that AUC scales linearly with caloric demand and with BSA, part of the variation 
measured in studies administrating fixed amounts or amounts per bodyweight stems 
from variability in body size. To correct for this, the ln(GMAUC) and ln(GSDAUC) were 
allometrically adjusted (see Appendix A6.1).
TABLE 6.2
Toxicokinetic data on methotrexate. Values are arithmetic mean values (± SD).
Reference n AUC0-∞ (mg*h/L) BW (kg) Dose (mg)
Adult studies
[324] 10 2.08 (0.54) 1.83 (0.24) 17.75 (5.30)
[325] 21 1.20 (0.30) 1.90 (0.24) 7.5
[326] 5 1.00 (0.19) 1.60 (0.07) 7.5
[327] 10 1.54 (0.66) 1.77 (0.15) 10
[328] 27 0.87 (0.24) 1.84 (0.22) 7.5
Children studies n AUC0-∞ (mg*h/L) BW (kg) Dose (mg/m
2)
[329] 13 0.59 (0.26) - 1.67 (0.27)
[330] 14 1.17 (0.53) - 14.71 (5.88)
[331] 16 1.52 (0.40) - 15
[332] 19 2.89 (1.15) - 30
[333] 11 1.58 (0.56) - 18.64 (3.14)
BW: Bodyweight; AUC0-∞: area under the concentration-time curve from t=0 to infinity; 
TABLE 6.3
Toxicokinetics data on ciprofloxacin. Values are arithmetic mean values (± SD).
Reference n AUC0-∞ (mg*h/L) BW (kg) Dose (mg)
Adult studies
[334] 28 17.67 (4.49) 67.73 (10.62) 750
[335] 11 12.30 (5.40) 69.40 (10.60) 750
[336] 12 9.96 (9.49) 68.00 (10.60) 462.5
[337] 12 10.60 (2.31) 74.80 (-) 500
[338] 12 8.77 (6.30) 71.23 (6.90) 250 >>
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[339] 8 18.60 (4.82) 68.00 (-) 15a
[340] 10 9.87 (4.10) 67.80 (8.10) 250
[341] 6 9.90 (2.43) 78.00 (-) 500
[342] 18 12.20 (3.00) 78.00 (-) 500
[343] 12 16.70 (5.10) 75.90 (8.50) 750
[344] 8 17.80 (3.30) 76.00 (10.00) 750
[345] 12 11.53 (2.21) 63.80 (9.90) 750
[346] 7 16.18 (4.64) 77.83 (12.67) 750
[347] 24 5.58 (1.56) 63.83 (9.50) 500
[348] 8 5.64 (4.32) 78.10 (10.40) 462.5
[348] 8 7.03 (5.94) 61.30 (3.60) 462.5
[349] 11 11.07 (3.43) 52.08 (9.15) 500
[350] 12 10.00 (2.78) 62.00 (7.00) 500
[351] 12 13.75 (4.89) 73.00 (6.70) 625
[352] 8 7.50 (3.43) 69.40 (6.10) 375
[352] 8 10.10 (4.07) 76.90 (13.90) 375
[353] 12 11.58 (2.06) 77.80 (7.00) 500
[354] 24 13.10 (4.40) 73.00 (-) 600
[355] 10 7.13 (0.97) 63.20 (-) 200
[356] 12 15.09 (2.10) 74.30 (6.30) 500
[357] 12 11.90 (1.89) 72.50 (9.34) 500
[358] 12 10.40 (1.95) 68.30 (-) 500
[359] 12 19.90 (5.62) 71.90 (-) 1000
[360] 27 16.38 (3.91) 74.00 (-) 1000
[361] 6 9.90 (2.43) 73.70 (-) 500
[362] 6 13.22 (4.39) 72.70 (6.90) 750
Children studies n AUC0-∞ (mg*h/L) BW (kg) Dose (mg/kg)
[363] 4 10.80 (1.28) 7.2 (1.0) 10
[363] 3 7.70 (1.09) 11.0 (0.3) 10
[363] 6 9.00 (1.33) 15.9 (2.7) 10
[363] 3 8.10 (1.44) 22.5 (1.3) 10
[364] 7 16.14 (6.85) 5.5 (1.0) 15
[364] 9 5.34 (3.08) 12.4 (2.7) 15
[365] 52 24.80 (12.40)b 6.9 (-) 20
BW: Bodyweight; AUC0-∞: area under the concentration-time curve from t=0 to infinity;  
a: dose in mg/kg; b: AUC0-24h instead of AUC0-∞.
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At this point, multiple subpopulations can be included in the extrapolation process, as 
visualised in Figure 6.2. The division of the total population into specific subpopulations 
not only depends on the presumption of their potential sensitivity, e.g., due to less efficient 
toxicokinetics, but also on the availability of data to characterise such subpopulations. Here, 
we included a potentially sensitive subpopulation of (young) children and a presumably 
non-sensitive adult subpopulation. First, the allometrically adjusted ln(GMAUC) and 
ln(GSDAUC) values from the individual studies were aggregated into separate distributions 
for each of the subpopulations (in Fig. 6.2 denoted as Ch and Ad, respectively), based on 
the number of participants per study [366] (see Appendix A6.1). Second, the median AUC 
value in the general population (denoted Mgen in Fig. 6.2) was calculated from those in 
the subpopulations (denoted Mad and Mch, respectively). This calculation was based on the 
relative contributions of the subpopulations to the general population [366], i.e., based on 
the demographics of the Dutch population [367] (see Appendix A6.1).
The first three extrapolation steps result in a dose that represents the sensitivity 
of the median individual in the general population. Therefore, the ratio between the 
median individual in a specific subpopulation and the median individual in the general 
population has to be accounted for before the variability within that subpopulation can 
be addressed. These ratios are represented by the dashed arrows in Figure 6.2. A ratio 
above one indicates that the median individual within the specific subpopulation is more 
sensitive than the median individual within the general population (i.e., the equipotent 
dose is higher in general). Whether this then also holds for the sensitive individual in 
the specific subpopulation depends on the variation in toxicokinetics present within the 
subpopulations (in Fig 6.2 denoted as IVad and IVch).
Since the parameters of the subpopulation distributions are estimated from a limited 
data set, they are subject to secondary (sample) uncertainty. The aggregated variance 
ln(GSDagg)2 is uncertain with an inverse chi-square distribution based on nparticipants-1 
degrees of freedom, with nparticipants being the total number of participants in the underlying 
controlled experiments; the aggregated ln(GMagg) is uncertain with a normal distribution 
with SEM based on the value drawn from this inverse chi-square distribution (Table 6.1) 
[45]. 
123
6
Uncertainty and variability in human exposure limits – a chemical-specific approach for ciprofloxacin and methotrexate
6.2.2.2.2 Toxicodynamics
To assess interindividual variability in toxicodynamics, internal exposure needs to be 
related to a magnitude of effect. However, compared to toxicokinetic data, toxicodynamic 
data are far more scarce [e.g. 368]. Consequently, a substance-specific approach is often 
unfeasible. Therefore, we followed an approach based on data for multiple substances that 
share a similar Adverse Outcome Pathway (AOP) [283]. An AOP represents the existing 
knowledge concerning the linkage between a direct molecular initiating event and an 
adverse outcome at a biological level of organisation relevant to risk assessment [293]. 
Substances with the same human (drug) target and physiological effect share the same 
AOP. We assumed that their toxicodynamics also show the same extent of interindividual 
variability, which can be characterised with an AOP-specific GSD [283]. This GSD describes 
the variation between individuals in effect experienced at equal internal exposure, and 
is subject to secondary (sampling) uncertainty due to the limited number of studies 
available for its characterisation. Such a GSD was not available for the AOPs of the toxic 
effects assessed in our case study. Therefore, we identified 26 other AOPs via the Small 
Molecule Pathway Database (at http://www.smpdb.ca), which were assigned log(GSD) 
values based on studies reported by Renwick and Lazarus [283]. These log(GSD) values 
were subsequently aggregated into one lognormal distribution (see Appendix A6.2), 
based on Hattis and Lynch [369]. This distribution reflects both the variation between AOPs 
in their log(GSD)s, and the uncertainty in these log(GSD)s due to limited data availability. 
As such, the distribution reflects the additional uncertainty that is introduced when the 
interindividual variability in toxicodynamics is estimated for any unspecified AOP.
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FIGURE 6.2 
Extrapolation for interindividual differences in toxicokinetics, via the inclusion of multiple 
subpopulations.
Ad: distribution of the adult subpopulation; Ch: distribution of the subpopulation of (young) children; Mgen, 
Mad, and Mch: median AUC in the general population, the adult subpopulation, and the children subpopula-
tion, respectively; IVad and IVch: interindividual variability within the adult and the children subpopulations, 
respectively; U: uncertainty.
6.3 RESULTS
The iterative nested Monte Carlo simulations generated two-dimensional HDM 
distributions in which uncertainty and interindividual variability were separated. When 
these distributions are used for the derivation of a HEL, protection and confidence levels 
first have to be defined. 
Each individual simulation on the variable parameters, i.e., each simulation based on a 
different set of fixed uncertain parameter values, resulted in one possible HDM distribution 
of the modeled subpopulation. Per possible HDM distribution, a specific percentile of the 
subpopulation can be selected that represents the desired level of protection. For example, 
a protection level of 99% results in a HDM at which 1% of the subpopulation exceeds 
the pre-selected magnitude of effect (HDM0.01). Subsequently, a specific percentile can be 
selected from all simulated HDM0.01 values that represents the desired level of confidence. 
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For example, a protection level of 99% combined with a confidence level of 95% results in 
a HEL for which a 5% probability exists that it overestimates the true HDM0.01. 
The results in the main text are based on PoD distributions derived with a Hill dose-
response model (Fig. 6.3), since these led to more conservative HELs. For the same 
reason, the results for methotrexate are based on the endpoint of white blood cell count. 
The other results can be found in Appendix A6.3. Figures 6.4 and 6.5 contain kernel 
probability density plots (PDFs) representing the uncertainty in the estimation of the 
HDM0.5 and HDM0.01 for methotrexate and ciprofloxacin, respectively. These PDFs are used 
to visualise the derivation of a HEL for both substances, based on a protection level of 
99% and a confidence level of 95%. 
The starting point for derivation of the HEL is the median HDM0.01 of all possible 
HDM0.01 values, which is the best estimation of the HDM at the protection level chosen. 
The ratio between this median HDM0.01 and the median HDM0.5, i.e., the best estimation 
of the HDM for the typical individual, describes the relative influence of interindividual 
variability on the HEL. Here, this ratio ranges from 4 to 7 for methotrexate (Fig. 6.4), and 
has a value of 7 for ciprofloxacin (Fig 6.5). A comparison of the median HDM0.01 with the 
HDM0.01 at a confidence level of 95%, results in a ratio that describes the relative influence 
of uncertainty on the HEL. It ranges from 21 to 24 for methotrexate (Fig. 6.4), and from 
25 to 32 for ciprofloxacin (Fig. 6.5).
These ratios indicate that the contribution of uncertainty to the two-dimensional 
HDM distributions is larger than that of interindividual variability, regardless of 
substance, endpoint or subpopulation assessed. A parameter importance analysis with 
Spearman’s rank correlation coefficients showed that the majority of this uncertainty 
can be attributed to the extrapolation from sub-acute to chronic toxicity and to a lesser 
extent the extrapolation for interspecies uncertainty (Table 6.4). This explains the general 
agreement between the HELs derived via the method presented here, and those derived as 
proposed by the WHO-IPCS [292] (Figs. 6.4 and 6.5). Indeed, both methods used the same 
default distributions for the most uncertain extrapolation steps (Table 6.1). Additionally, 
the lower 10% of the final HDMs are also influenced by other sources of variation, namely 
uncertainty in the derivation of a PoD (specifically relevant for ciprofloxacin), and 
(uncertainty in the estimation of) interindividual variability in toxicodynamics (Table 
6.4). 
126
6
Uncertainty and variability in environmental risk assessment of human pharmaceuticals
Furthermore, the HDM for the typical individual (HDM0.5) differs for the adult and 
children subpopulations (Figs. 6.4 and 6.5, Table 6.1). Remarkably, this difference has 
opposite directions for the two substances: at equal exposure, median pediatric blood 
concentrations of ciprofloxacin are higher than those in the general population (a factor of 
1.25), while for methotrexate they are lower (a factor of 2). An explanation for this difference 
might be found in the absorption and elimination kinetics of the two substances. The 
absorption of methotrexate after oral exposure happens via active transport, mediated by 
the saturable transporter RFC1 (reduced folate carrier 1) [370]. After absorption, only 10% of 
methotrexate is converted to 7-hydroxymethotrexate in the liver [370], indicating that renal 
excretion is the major elimination pathway of methotrexate. Ciprofloxacin, on the other 
hand, is well absorbed after oral administration, with moderate to excellent bioavailability 
[371]. Furthermore, hepatic metabolism (via CYP1A2 enzyme) constitutes approximately 
60% of the total elimination of ciprofloxacin [372]. Thus, less developed kinetics, as could 
be expected in children, might result in either elevated or lowered blood concentrations, 
depending on whether these concentrations are mainly driven by metabolising processes 
(ciprofloxacin) or active absorption processes (methotrexate), respectively. Furthermore, 
the difference between the general population and the population of children might have 
been (much) higher, had we only included toxicokinetic data for neonates in our case 
study [e.g. 373]. Unfortunately, limited data availability made the inclusion of studies with 
older children inevitable. 
Finally, from the HELs derived for all subpopulations, the lowest is selected as the 
relevant HEL for the general population. The results show that the HEL for methotrexate 
at a 99% protection level and a 95% confidence level is lowest when based on the adult 
subpopulation (Fig. 6.4A; 0.0048 mg/kgbw/d). This is higher than the HEL based on 
the default WHO-IPCS distributions (Fig. 6.4C; 0.0036 mg/kgbw/d), indicating that a 
HEL based on these default distributions achieves a protection level that is higher than 
desired, i.e., with a non-protected fraction smaller than 0.01. For ciprofloxacin, however, 
the lowest HEL is the one based on the subpopulation of children (Fig. 6.5B; 0.29 mg/
kgbw/d) , which is lower than the HEL based on the default WHO-IPCS distributions (Fig. 
6.5C; 0.36 mg/kgbw/d). This indicates that a HEL based on these default distributions will 
achieve a protection level lower than desired.
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FIGURE 6.3 
Distributions of the Point of Departure (PoD) after iterative bootstrapping of a Hill dose-
response model on experimental toxicity data for methotrexate (A) (endpoint: white blood 
cell count), and ciprofloxacin (B) (endpoint: femoral articular cartilage thickness), both at a 
CES of 5% decrease. 
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FIGURE 6.4 
Derivation of a HEL for methotrexate (endpoint: white blood cell count, Hill dose-response 
model, CES of 5% decrease) at a protection level of 99% and a confidence level of 95%, 
based on either the adult (A; blue lines) or children subpopulation (B; red lines), or based 
on default uncertainty distributions only (C: grey lines) [292].
Solid line: kernel probability density function (PDF) of uncertainty distribution of HDM
0.01; dotted lines: kernel 
PDF of uncertainty distribution of HDM
0.5. These kernel PDFs represent 92% of all possible HDMs, because 8% 
of the iterations resulted in an infinitely large PoD (see Section 6.2.2.1). IV: interindividual variability as the 
ratio between median HDM
0.5 and median HDM
0.01; U1P: uncertainty as the ratio between median HDM
0.01 and 
1st percentile of HDM
0.01 kernel PDF.
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FIGURE 6.5 
Derivation of a HEL for ciprofloxacin (endpoint: femoral articular cartilage thickness, Hill 
dose-response model, CES of 5% decrease) at a protection level of 99% and a confidence 
level of 95%, based on either the adult (A; blue lines) or children subpopulation (B; red 
lines), or based on default uncertainty distributions only (C: grey lines) [292]. 
Solid line: kernel probability density function (PDF) of uncertainty distribution of HDM
0.01; dotted lines: kernel 
PDF of uncertainty distribution of HDM
0.5. These kernel PDFs represent 93% of all possible HDMs, because 7% 
of the iterations resulted in an infinitely large PoD (see Section 6.2.2.1). IV: interindividual variability as the 
ratio between median HDM
0.5 and median HDM
0.01; U1P: uncertainty as the ratio between median HDM
0.01 and 
1st percentile of HDM
0.01 kernel PDF.
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TABLE 6.4
Contribution of the extrapolation steps to the total variance in the human dose distributions; 
methotrexate endpoint: white blood cell count; Hill dose-response models. First percentages: 
contribution to total HDM distribution; second percentages: contribution to lowest 10% of 
HDMs.
Contribution to variance in HDM distribution (%)
Methotrexate Ciprofloxacin
Extrapolation step Type Adult Children Default Adult Children Default
1. PoD derivation U 4; 4 4; 2 4; 1 10; 67 10; 64 9; 69
2. Sub-acute/chronic U 65; 43 57; 42 60; 44 58; 4 53; 8 54; 8
3a. Allometric scaling factor U <1; 1 <1; <1 <1; <1 <1; <0 <1; <1 <1; <1
3b. Remaining interspecies 
differences
U 16; 14 15; 17 16; 6 17; 3 15; 3 15; 1
4a. Toxicokinetics U <1; 1 <1; <1 <1; 2 <1; 1 <1; 1 <1; 1
IV 4; 1 14; 6 7; 5 7; <1 14; 6 7; 1
4b. Toxicodynamics U <1; 12 <1; 15 <1; 18 <1; 14 <1; 8 <1; 4
IV 10; 24 10; 17 13; 24 8; 11 8; 10 14; 15
Total contribution U 86; 75 76; 77 80; 71 85; 89 78; 84 79; 84
Total contribution IV 14; 25 24; 23 20; 29 15; 11 22; 16 21; 16
6.4 DISCUSSION
We presented a case study in which the WHO-IPCS framework for evaluating and 
expressing uncertainty in hazard characterisation was extended by the incorporation of 
chemical-specific data on human variability in toxicokinetics, the incorporation of human 
variability in toxicodynamics based on the variation between AOPs, and the separate 
propagation of interindividual variability and uncertainty throughout the derivation 
process. In this section, methodological limitations are discussed, followed by an analysis 
of the implications for research and policy. 
6.4.1 Methodological limitations
The toxicity studies on methotrexate and ciprofloxacin were selected as a starting point 
for the derivation process, because they were considered to represent the most sensitive 
endpoint found in the available literature (e.g., studies on chronic carcinogenicity did not 
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report significant effects for either of the two chemicals). However, the omission of other 
potentially useful toxicity data might introduce additional uncertainty. A more extensive 
probabilistic assessment in which multiple datasets and endpoints are incorporated could 
provide insight in the magnitude of this source of uncertainty. The inclusion of additional 
datasets and endpoints might also reduce the occurrence of non-response during the 
resampling of the dose-response data, being 7.5% of the iterations for methotrexate and 
6.7% of the iterations for ciprofloxacin (Fig. 6.3). 
Additionally, the 7-day experimental study in rats [315] which was used in the case 
study with ciprofloxacin, is too short to be considered sub-acute according to formal 
standards [374]. This means that the systematic difference between sub-acute and chronic 
toxicity, as well as the already large uncertainty in this extrapolation step (Table 6.4), may 
have been underestimated in our study. 
In the first step of the process, the selection of a CES is very influential. Ideally, 
the CES represents the border between an acceptable and an unacceptable effect 
size, implying a management choice. In our study, a CES of 5% was used for both 
methotrexate and ciprofloxacin. Obviously, different HDM distributions would have 
been obtained if a different CES (e.g., 1% or 0.1%) would have been selected. Next to 
normative considerations, the selection of a CES should also be based on information 
on the mechanism and possible irreversibility of the effects studied, and knowledge 
derived from prior studies about the form of the dose response relationship. However, 
scientific understanding and international consensus on the magnitude of the CES are 
still not reached [375, 376], and the exact effect size to consider acceptable is often difficult to 
determine. For ciprofloxacin, for example, the irreversibility of its chondrotoxic effects [377, 
378] raises the concern that repeated episodes of modest damage could cumulate over time 
into unacceptable effects. Considering this uncertainty, a lower choice of CES might be 
deemed appropriate based on the precautionary principle [43], especially since the existence 
of sensitive subpopulations is expected. Additionally, the endpoint corresponding to the 
CES might not always represent an adverse effect at the level of the individual, but rather 
a precursor for such an effect (e.g. red blood cell count as a precursor for anaemia). Then, 
differences in the level of precursor required to prompt an actual adverse effect form an 
additional source of interindividual variability that might be explicitly included in the 
calculations or accounted for via the choice of a lower CES. 
132
6
Uncertainty and variability in environmental risk assessment of human pharmaceuticals
During the extrapolation step for toxicokinetic differences, allometrically adjusted 
AUC data, resulting from short-term high dose exposure, were used to characterise 
interindividual variability in human toxicokinetics. This raises the question whether 
these data are representative for the chronic low dose environmental exposures that are 
relevant for human risk assessment of chemicals. Therefore, testing the possible influence 
of dose and exposure duration on the interindividual variability in toxicokinetics is 
recommended. Additionally, the measure of internal exposure used for the characterisation 
of interindividual variability in toxicokinetics, e.g., the AUC, should be coherent with 
the toxicity process underlying the effect assessed, e.g., cumulative non-threshold effects. 
Other measures of internal exposure might be more suitable for non-cumulative threshold 
effects, e.g., the maximum serum concentration Cmax. Nevertheless, Hattis et al. [368] showed 
that the average interindividual variability in toxicokinetics is equal when calculated with 
either AUC data or Cmax data. Finally, allometric scaling was used to correct the AUC 
values for interindividual differences not related to toxicokinetics. The main assumption 
here is that toxicokinetics and the underlying physiological properties scale linearly with 
body size. However, it is reasonable to expect that this does not necessarily hold for all 
physiological properties potentially relevant for toxicokinetics, e.g., tissue lipid content. 
Consequently, additional data adjustments might be implemented for specific chemicals 
for which detailed information on their toxicokinetics is available. 
We included only one potentially sensitive subpopulation in our case study, i.e., the 
subpopulation of (young) children. Other potentially sensitive subpopulations, such as 
poor metabolizers or elderly people, were not included because of a lack of data. Therefore, 
it remains uncertain whether the most sensitive part of the general population is actually 
captured in the HDM distributions. Nevertheless, the exclusion of poor metabolizers 
can be justified based on the existence of monomorphism for CYP1A2 [282], the main 
metabolising enzyme for ciprofloxacin, and a relatively low interindividual variability in 
renal elimination [379], the main elimination pathway for methotrexate. The exclusion of 
elderly people from the ciprofloxacin case study can be justified based on their CYP1A2 
metabolism, which is in general very similar to that of healthy adults [285]. However, renal 
elimination differs markedly between elderly people and healthy adults [285], as a result of 
an age-dependent decrease in renal functioning [380]. 
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On a more fundamental level, the probabilistic assessment demonstrated in this paper 
is limited to the influence of statistical uncertainty, i.e., uncertainty that can be described 
adequately in statistical terms [44]. However, other uncertainties that are less easily 
quantified, such as model or context uncertainties, might be of importance, and should 
be considered qualitatively in the evaluation of the results. A typical example of model 
uncertainty relates to the suitability of the lognormal distribution to describe statistical 
uncertainty in extrapolation steps, although this choice is theoretically supported by the 
central limit theorem, i.e., the product of a large number of independent variables will 
be lognormally distributed. Besides, ratios of equipotent doses, e.g., interspecies or sub-
chronic to chronic [281], as well as interindividual variability in toxicokinetics, are found to 
be generally consistent with lognormality. Similarly, the choice of a dose-response model 
to derive a PoD distribution from the available experimental toxicity data introduces 
model uncertainty. Table 6.1 shows that the use of a Hill dose-response model introduces 
more uncertainty into the assessment than the use of an exponential dose-response 
model (i.e., its PoD distribution has a higher standard deviation). Consequently, HELs 
based on a Hill dose-response model are generally lower. However, because the use of a 
Hill dose-response model also results in a higher average PoD (Table 6.1), this difference 
remains relatively small at a factor of 1.1 to 1.3 (Figs. 6.4, 6.5, A6.1, A6.4). Also, secondary 
(sampling) uncertainty has a relatively large influence on estimations made at higher 
protection levels. In other words, HDMs estimated for the sensitive individual in a (sub)
population are more uncertain than those estimated for the median individual in the 
same (sub)population. The impact of this is directly related to the sampling uncertainty 
in the parameters of the variability distributions. In our case study with methotrexate 
and ciprofloxacin, this sampling uncertainty is small with respect to their toxicokinetics, 
but considerable with respect to their toxicodynamics (Table 6.1). Estimations based on 
toxicodynamics distributions with unlikely large GSD values are thus more prevalent in 
the lowest 10% of the resulting HDMs, and the influence of uncertainty in the estimation 
of variability in toxicodynamics becomes larger when the lowest 10% of the HDMs are 
considered (Table 6.4). The importance of secondary (sampling) uncertainty at higher 
percentiles of the uncertainty distribution will become even more relevant when (non-
pharmaceutical) chemicals are assessed that generally are more limited in their data 
availability.
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Finally, it should be noted that the approach presented is specifically applicable to 
continuous toxicity endpoints. Contrary to continuous toxicity endpoints, quantal toxicity 
endpoints are determined on the population level rather than the level of the individual, 
i.e., each individual is considered to either show a response or not. Consequently, the 
dose-response relationship derived from experimental toxicity data (Section 6.2.2.1) 
depends on the intraspecies variation in the test animal, and so will the magnitude of 
effect.
6.4.2 Implications for research and policy
The chemical-specific approach described in this paper results in human exposure limits 
(HELs) for methotrexate and ciprofloxacin that are in general slightly less conservative 
compared to those derived via the third tier with default uncertainty distributions as 
proposed in the WHO-IPCS guidance [292] (Figs. 6.4, 6.5, A6.1-A6.4). While the HELs 
presented here are based on specific protection and confidence levels of 99% and 95%, 
respectively, other protection and confidence levels show a similar difference. This 
indicates that the chemical-specific approach could potentially function as an additional 
tier in the hazard characterisation process of the WHO-IPCS guidance [292]. Whether a 
chemical-specific approach for the derivation of a HEL is actually worth the effort or 
whether an approach with default uncertainty distributions suffices, mainly depends 
on two criteria: 1) the slightly more conservative HEL derived via default uncertainty 
distributions should at least be in the vicinity of realistic exposure levels, and 2) a 
substantial reduction in uncertainty should be achieved when using the chemical-specific 
approach.
Results from a previous study show that the first criterion is met by neither methotrexate 
nor ciprofloxacin: even the highest exposure estimations in Europe are still 6-7 orders of 
magnitude lower than the HELs shown in Figures 6.4C and 6.5C [177]. Moreover, Table 6.4 
shows that most uncertainty in the HDM distributions is introduced during extrapolation 
step 2, i.e., extrapolation for exposure duration, followed by extrapolation step 3, i.e., 
extrapolation for interspecies differences. Since no chemical-specific distributions were 
defined  for these extrapolation steps, default distributions were used [292]. This means that 
the use of a chemical-specific approach for the derivation of a HEL does not result in a 
substantial uncertainty reduction when based on (sub-)acute toxicity data, and that the 
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second criterion is therefore also not met by methotrexate or ciprofloxacin. Consequently, 
uncertainty in the derivation of a HEL can be greatly reduced when chronic instead of 
(sub)acute toxicity data are used. When such data are not available, a better understanding 
of the relationship between (sub-)acute toxicity and chronic toxicity could improve the 
assessment, for example via the use of information on the specific toxic mode of action 
(TMoA) of the substance under assessment. Additionally, the added value of a chemical-
specific approach can be further increased with a better understanding of the processes 
underlying interspecies differences in sensitivity, for example via insights obtained in 
genomics research [e.g., 381].
An advantage of the chemical-specific approach presented here compared with the 
use of default distributions, is the inclusion of specific subpopulations in the assessment. 
This not only enables the identification of the most sensitive subpopulation, but also 
provides information on the rate with which the affected fraction of individuals in 
that subpopulation will increase with increasing daily exposure (i.e., the influence of 
interindividual variability within the subpopulation). However, the combined uncertainty 
in the complete derivation process makes it yet very difficult to pinpoint the daily dose 
at which adverse effects will occur for sensitive individuals in any subpopulation. 
Moreover, it is currently not possible to identify these sensitive individuals in advance, 
since that would require knowledge on the mechanisms and principles underlying the 
variation in sensitivity between individuals (i.e., what makes one person more sensitive 
than another?). Nevertheless, the inclusion of a specific subpopulation is recommended 
when the endpoints considered in the assessment relate to adverse effects that are 
especially relevant for that specific subpopulation. For example, the irreversibility of the 
chondrotoxic effects of ciprofloxacin [377, 378], makes the protection of earlier life stages 
from ciprofloxacin’s chondrotoxicity especially important. Although this subpopulation 
makes up only part of the total population, and a 99% protection level based on the 
subpopulation of children thus protects more than 99% of the total population, with time 
these irreversible effects will be present within the same fraction of the total population.
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6.5 CONCLUSIONS
In this study, we showed how chemical-specific data can be used to extend the methodology 
proposed by the WHO [292], and how this affects the derivation of probabilistic human 
exposure limits. Sources of interindividual variability and uncertainty, including 
secondary (sampling) uncertainty, were separately propagated throughout the assessment. 
Additionally, the chemical-specific approach enables the inclusion of potentially sensitive 
subpopulations in the assessment and makes an informed judgment possible about 
whether separate HELs should be considered for specific subpopulations. This approach 
is especially relevant when the use of default distributions results in estimations that are 
in the vicinity of realistic exposures, and when uncertainty in the non-chemical-specific 
extrapolation steps is limited.
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ABSTRACT
Species in the aquatic environment differ in their toxicological sensitivity to the 
various chemicals they encounter. In aquatic risk assessment, this interspecies 
variation is often quantified via species sensitivity distributions. Because the 
information available for the characterisation of these distributions is typically 
limited, optimal use of information is essential to reduce uncertainty involved 
in the assessment. In the present study, we show that the credibility intervals on 
the estimated potentially affected fraction of species after exposure to a mixture 
of chemicals at environmentally relevant surface water concentrations can be 
extremely wide if a classical approach is followed, in which each chemical in the 
mixture is considered in isolation. As an alternative, we propose a hierarchical 
Bayesian approach, in which knowledge on the toxicity of chemicals other than 
those assessed is incorporated. A case study with a mixture of 13 pharmaceuticals 
demonstrates that this hierarchical approach results in more realistic estimations 
of the potentially affected fraction, as a result of reduced uncertainty in species 
sensitivity distributions for data-poor chemicals.
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7.1 INTRODUCTION
Species vary in their sensitivity to chemical substances. Under the assumption that this 
spread in sensitivities can be described by a statistical distribution, it is often quantified 
using chemical-specific species sensitivity distributions (SSDs) [197]. SSDs are typically 
constructed based on a sample of toxicity data reflecting the relative sensitivities of 
individual species. A common choice for this is the median effect concentration (EC50), 
which is the concentration having a specified effect for 50% of the individuals of a single 
species. If the concentration of a chemical in the environment is known, SSDs can be 
used to predict the fraction of species for which the EC50 is being exceeded. This is the 
so-called potentially affected fraction of species, or PAF [198, 199].
The PAF cannot only be calculated for single chemicals, but also for a mixture and it 
is then referred to as the multi-substance PAF (msPAF) [382]. To aggregate the individual 
contributions of single chemicals into an msPAF, the principles of response addition [383] 
and concentration addition [384] can be followed, or a hybrid form of the two in which 
concentration addition principles are followed for chemicals with the same toxic mode 
of action (TMoA), and response addition principles for chemicals that have a different 
TMoA [199, 385-387]. 
The confidence that can be attributed to an msPAF depends, among other things, on 
how accurately the parameters of the underlying SSDs can be estimated from the available 
data, i.e., how well the sample of test species represents the community of interest [388]. The 
results of single substance SSD analyses appear to stabilise at 10-15 data points [389], but 
chemicals for which less toxicity data are available may show highly uncertain PAF values. 
This is evident when an environmentally realistic mixture consisting of a large amount of 
chemicals is being assessed. In earlier studies [390, 391], application of the classical approach 
has led to the conclusion that adverse effects on all aquatic life cannot be excluded (i.e., 
msPAF = 1). However, empirical data show that a large number of species are currently 
doing relatively well in European surface waters such as the river Rhine. This triggers 
the question whether estimations using only toxicity data on the mixture chemicals, i.e., 
considering them in isolation, adequately reflects our state of knowledge on the toxicity 
of complex mixtures. One option to improve upon the current approach is by including 
our extensive knowledge on the toxicity of other chemicals via a hierarchical Bayesian 
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approach. Bayesian inference of SSD parameters in single substance analysis has been 
applied before, e.g. using non-informative prior distributions [392, 393], prior distributions 
based on expert elicitation [394], or informative priors based on data from other chemicals 
[395-397]. Similarly, Roelofs et al. [398] derived PNEC values via Bayesian inference of acute-
to-chronic assessment factors from a limited set of acute toxicity data and informative 
prior distributions derived from an ecotoxicological database.
The aim of the present paper is to explore whether and how credibility intervals 
on msPAF values for realistic mixtures can be reduced using a hierarchical Bayesian 
model. This is done in a case study in which aquatic msPAF values are calculated for 
a realistic mixture of antibiotics (ABs) and anticancer drugs (ACs), based on surface 
water concentrations predicted for the Ruhr area in Western Germany. This location was 
chosen because it is relatively densely populated, and because all pharmaceuticals in the 
mixture are actually prescribed in Germany. The hierarchical model is populated with a 
chemical data inventory containing toxicity data on more than 2000 chemicals. Different 
data (sub)sets of this inventory are used to populate the hierarchical model, in order 
to assess the influence of the representativeness of these data for the chemicals in the 
mixture. The uncertain msPAF values are calculated based on the principles of response 
addition, concentration addition, and a hybrid form of the two.
7.2 METHODOLOGY
7.2.1 Species sensitivity distributions and msPAF calculations 
The use of species sensitivity distributions (SSDs) is based on the assumption that for 
each chemical, the interspecies variation in sensitivity can be described by a statistical 
distribution. The available toxicity data are considered a sample from this distribution 
and are used to estimate the parameters of the SSD [197]. The resulting SSD can be used 
to assess the potentially affected fraction (PAF) of all species at a certain environmental 
concentration. Statistical distributions that are commonly used to describe the spread in 
sensitivity between species are the log-normal [392, 399, 400], the log-logistic [401-403], and the 
Burr Type III distribution [404]. Here we assume log-normal SSDs, based on the central 
limit theorem (i.e., the product of a large number of independent variables will be log-
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normally distributed). Additionally, well-known sampling distributions are available for 
the characterisation of the uncertainty in the parameters of the log-normal distribution 
[45]. 
We use EC50 values as a measure of the relative sensitivity of individual species. While 
EC50s have been criticised for their lack of ecological relevance [405, 406], they are relatively 
widely available and statistically preferable over other toxicity values such as NOECs [407, 
408]. The log-normal SSDs are described by the location parameter µlogEC50 (i.e., the mean 
over the log-transformed EC50 values) and the scale parameter σlogEC50 (i.e., the standard 
deviation over the log-transformed EC50 values). In our case study, single chemical Toxic 
Units (TUs; Eq. 7.4) and PAFs are calculated at realistic environmental concentrations, 
and integrated into msPAFs based on principles of response addition (msPAFra; Eq. 7.1) 
[199], and concentration addition (msPAFca; Eq. 7.2) [386], respectively. Response addition 
is based on the supposition of dissimilar action, i.e., all chemicals in the mixture act 
independently and exert their own toxic effect. Concentration addition, on the contrary, 
is based on the supposition of similar action, i.e., all chemicals in the mixture act in the 
same way and only differ in their potency [42]. Additionally, a hybrid form of the two 
is used in which concentration addition principles are applied to chemicals sharing the 
same TMoA and response addition principles are applied to aggregate these groups of 
chemicals (msPAFhyb; Eq. 7.3) [386]. 
msPAFra = 1 - ∏i (1 - PAFi) Equation 7.1
msPAFca =                          * ∫0TU e                            * dTU Equation 7.2
msPAFhyb = 1 - ∏j (1 - msPAFca,j ) Equation 7.3
In Eq. 7.1, PAFi denotes the potentially affected fraction for chemical i. In Eq. 7.3, 
msPAFca,j denotes the msPAFca for chemicals sharing the same TMoA j. In Eq. 7.2, σ 
denotes the average spread in log-transformed toxic sensitivity between species over 
all chemicals in the mixture, and the Toxic Unit (TU) is calculated as the sum of the 
chemical-specific Hazard Units (HUi):
σ*√2π*TU*ln 10
1 (- 12    *                ) ( log (TU) )2σ
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TU = ∑iHUi = ∑i (Ci / 10μ              ) Equation 7.4
where Ci is the surface water concentration of chemical i.
TABLE 7.1
Names, CAS registration numbers (CAS RN), number of species for which EC50s are available 
(nspecies), SSD (sample) parameters (x ̅ logEC50 and slogEC50), predicted surface water concentrations 
(C), and Hazard Units (HUs; Eq. 7.4) based on x ̅ logEC50  and C for the 13 active pharmaceutical 
ingredients (APIs) in the Ruhr area in Germany. 
Name CAS RN nspecies  x ̅ logEC50 slogEC50 C (mg/L) HU
Antibiotics
Cefuroxime 55268-75-2 2 0.79 1.70 6.66*10-4 1.07*10-4
Chlortetracycline 57-62-5 9 -0.23 3.05 3.26*10-9 5.59*10-9
Ciprofloxacin 085721-33-1 8 -0.29 0.99 9.70*10-5 1.89*10-4
Erythromycin 114-07-8 25 0.07 1.42 2.08*10-5 1.77*10-5
Levofloxacin 100986-85-4 6 -0.35 1.21 1.08*10-4 2.39*10-4
Ofloxacin 82419-36-1 13 -0.15 1.24 3.55*10-6 5.05*10-6
Oxytetracycline 79-57-2 22 0.49 2.18 3.99*10-7 1.30*10-7
Tetracycline 60-54-8 11 0.46 1.12 5.09*10-5 1.77*10-5
Trimethoprim 738-70-5 13 1.52 0.83 1.92*10-6 5.75*10-8
Anticancer drugs
Cyclophosphamide 50-18-0 2 3.03 0.09 2.64*10-7 2.47*10-10
5-Fluorouracil 51-21-8 7 -0.55 2.11 9.12*10-7 3.22*10-6
Methotrexate 59-05-2 5 2.36 0.58 9.56*10-7 4.13*10-9
Tamoxifen 10540-29-1 5 -1.75 1.56 4.51*10-8 2.51*10-6
7.2.1 Selection of chemicals and location
The msPAF was calculated for a set of 13 active pharmaceutical ingredients (APIs), 
as selected within the PHARMAS project (http://www.pharmas-eu.net). From 
these 13 APIs, 9 are antibiotics and 4 are anticancer drugs (Table 7.1). Experimental 
species-specific EC50 values on these APIs were derived from publicly available 
databases [99, 100, 409-411], and are listed in Appendix A7.1. When multiple data were available 
for a combination of API and species, the EC50 for the most sensitive endpoint was used. 
When multiple data were available for the same endpoint, their geometric mean was 
log EC50,i
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used [412]. Table 7.1 contains the SSD sample mean (x ̅ logEC50) and sample standard deviation 
(slogEC50) for all 13 APIs, based on the available EC50 data. Additionally, this table contains 
the surface water concentrations that are used in the calculations. These concentrations 
are taken from earlier work [177], in which they were estimated for 100 * 100 km2 grids 
covering Europe. A spatial grid in the Ruhr area in Western Germany was selected as 
case study location (Fig. 7.1), because 1) it is one of the most densely populated areas in 
Europe, and 2) only in Germany all 13 APIs are actually being prescribed. 
FIGURE 7.1
The 100 * 100 km2 grid in the Ruhr area, Germany, selected for calculating the msPAF based 
on predicted concentrations for 13 different active pharmaceutical ingredients (APIs).
7.2.2 Uncertainty analysis – classical approach
The classical approach in risk assessment of chemicals has been that each individual 
chemical is considered in isolation, i.e., it is treated as if it were the first chemical ever 
to be assessed. Uncertainty assessments are thus based upon observations on the one 
chemical of concern, considering observations on other chemicals irrelevant. Here, we 
focus on uncertainties in the SSD parameters µlogEC50 and σlogEC50 as a result of limited data 
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availability. The uncertainties in these parameters are propagated into msPAF values via 
Markov Chain Monte Carlo (MCMC) simulations with the program OpenBUGS [413-415]. 
Two chains of 200.000 iterations were run, after which the first half of the iterations was 
discarded based on the burn-in principle [416]. To check for convergence, potential scale 
reduction factors (PSRFs) were calculated for the remaining 100.000 iterations [417, 418]. 
Appendix A7.3 of the Supporting Information contains the syntax of the model and a 
graphical representation in the form of a Directed Acyclic Graph (DAG).
Since it is required by OpenBUGS, the parameterisation of (log-)normal distributions 
is done with precision τ, which is the reciprocal of variance σ2. The SSD parameters of 
each individual chemical in the mixture are separately assigned non-informative prior 
distributions. Their µlogEC50 is assigned a normal prior distribution with mean µ and 
precision τ, expressed as N(µ, τ); and their τlogEC50 is assigned a gamma distribution with 
shape α and rate β, expressed as Γ(α, β). These non-informative prior distributions should 
reflect the complete absence of prior knowledge associated with the classical approach. 
Ideally, this would imply improper normal and gamma prior distributions like N(0, 0) 
and Γ(0, 0). However, since OpenBUGS does not accept improper prior distributions, 
we approach them in the model with proper prior distributions that are sufficiently wide 
to be considered non-informative, i.e., N(0, 1*10-5) and Γ(1*10-5, 1*10-5). Subsequently, 
these non-informative prior distributions are transformed into posterior distributions 
for every chemical in the mixture using their respective available toxicity data (Appendix 
A7.1), which are then used in the calculation of msPAFra, msPAFca and msPAFhyb.
7.2.3 Uncertainty analysis – hierarchical approach
Contrary to the classical approach, the hierarchical approach that we propose here 
places the assessment of each individual chemical in a broader context, i.e., as part of a 
larger population of chemicals. Under the assumption that the variation in µlogEC50 and 
τlogEC50 within this population of chemicals can be described by a statistical distribution, 
each individual chemical can be considered a random draw from that distribution. 
Consequently, the non-informative prior distributions on µlogEC50 and τlogEC50 from the 
classical approach, are replaced with distributions that reflect the potential range of values 
for µlogEC50 and τlogEC50, based on the larger population of chemicals. Here, we assume that 
the inter-chemical variation in µlogEC50 can be described by a normal distribution with 
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mean µ and precision τ, expressed as N(µ, τ), and that the inter-chemical variation in 
τlogEC50 can be described by a gamma distribution with shape α and rate β, expressed as 
Γ(α, β). The validity of these assumptions is supported with quantile-quantile (Q-Q) plots 
based on the sample mean x ̅ logEC50 and sample precision tlogEC50 of data-rich chemicals 
from the larger population (i.e., chemicals with nspecies ≥ 30) (Fig. 7.2). The parameters 
of these distributions, i.e., µ, τ, α and β, are themselves assigned non-informative prior 
distributions which should reflect the initial absence of knowledge: N(0, 1*10-5) for µ, and 
Γ(1*10-5, 1*10-5) for τ, α and β. Subsequently, these non-informative prior distributions 
are updated with toxicity data from a chemical inventory. This chemical inventory 
contains EC50, LC50 and IC50 values gathered from e-toxBase [101] in earlier studies [386, 
419], supplemented with toxicity data for APIs from publicly accessible databases [100, 409-
411, 420] and the ECHA chemicals registry [421]. When multiple data were available for a 
combination of chemical and species, the value for the most sensitive endpoint was used. 
When multiple data were available for the most sensitive endpoint, their geometric mean 
was used [412]. All chemicals with nspecies>1, for which x ̅ logEC50  and tlogEC50 (i.e., sample mean 
and sample precision) could be calculated, were included in the inventory. The resulting 
inventory consists of a total of 2043 chemicals, including 106 APIs, of which 24 ABs and 
9 ACs (Appendix A7.2). 
FIGURE 7.2 
Q-Q plots for the normal distribution on sample mean x ̅ logEC50  (A) and gamma distribution on 
sample precision tlogEC50 (B), based on a set of 115 chemicals with nspecies ≥ 30.
Since the sample mean x ̅ logEC50  and sample precision tlogEC50 values in the chemical 
inventory are approximations of the population mean µlogEC50 and population precision 
τlogEC50 values, they cannot be used directly to update the prior distributions. Instead, 
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the accuracy of these approximations should be taken into account first. This accuracy 
depends on the amount of data used for the calculation of x ̅logEC50  and tlogEC50. To account 
for this, the tlogEC50 values in the inventory were first expressed as sample variance s2logEC50 
values (i.e., the reciprocal of tlogEC50). These s2logEC50 values follow a chi-square sampling 
distribution with nspecies-1 degrees of freedom. The x ̅  logEC50  values in the inventory follow a 
normal distribution with a sampling precision of the sampling mean based on nspecies and 
the value drawn from this chi-square distribution [45].
We formulate three hypotheses on the toxicity of the individual chemicals in the 
mixture. The hypotheses are based on the assumption that the SSD parameters estimated 
for (a subset of) substances with sufficient available toxicity data, are representative 
for the range of possible SSD parameters of the chemical of concern. For each toxicity 
hypothesis, the prior distributions are updated with a different (sub)dataset from 
the chemical inventory, resulting in different posterior distributions and subsequent 
distributions of msPAFra, msPAFca and msPAFhyb. Increasing in their level of specificity, 
these hypotheses are:
1. The SSD parameters for all 2043 chemicals in the chemical inventory are 
representative for the range of possible SSD parameters for the 13 active 
pharmaceutical ingredients (APIs) considered.
2. The SSD parameters for the 106 APIs in the chemical inventory are representative 
for the range of possible SSD parameters for the 13 APIs considered.
3. The SSD parameters for the 24 antibiotics (ABs) in the chemical inventory are 
representative for the range of possible SSD parameters for the ABs in the set of 
13 APIs considered; the SSD parameters for the 9 anticancer drugs (ACs) in the 
chemical inventory are representative for the range of possible SSD parameters 
for the ACs in the set of 13 APIs considered.
Similar to the classical approach, MCMC simulations with two chains of 100.000 
iterations after convergence are performed with the program OpenBUGS [413-415], 
propagating the uncertainties in the SSD parameters of the individual chemicals in the 
mixture into the msPAF values. The syntaxes and DAGs of the hierarchical models can 
be found in Appendix A7.3.
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7.3 RESULTS
The classical and the hierarchical models all show convergence after 100.000 iterations, 
with potential scale reduction factors (PSRFs) close to 1 for the SSD parameters of all APIs 
(i.e., PSRF < 1.1). Additionally, Figure 7.3 contains the posterior secondary probability 
distributions of µlogEC50 and τlogEC50, i.e., the distributions of the inter-chemical distributions 
of µlogEC50 and τlogEC50. They describe the inter-chemical variation in the larger population of 
chemicals for each of the toxicity hypotheses, and are derived according to Aldenberg and 
Jaworska [392]. The MCMC simulation produces 100.000 possible posterior distributions 
of the inter-chemical variation in µlogEC50 and τlogEC50. At a fixed value for µlogEC50 or τlogEC50, 
these distributions each return one specific probability density value. From these 100.000 
probability density values, the 5th and 95th percentiles as well as the median are derived at 
a range of µlogEC50 and τlogEC50 values, and plotted as curves in Figure 7.3. Consequently, the 
outer curves represent the 90% credibility interval of the inter-chemical distributions of 
µlogEC50 and τlogEC50. These outer curves are not probability density functions, since they do 
not integrate to one. Figure 7.3 shows that the inter-chemical variation tends to decrease 
with increasing specificity of the toxicity hypothesis. Simultaneously, the estimation of 
this inter-chemical variation becomes less accurate with increasing specificity of the 
toxicity hypothesis, due to lower data availability to populate the hierarchical model. 
Furthermore, Appendix A7.4 contains the cumulative density functions (CDFs) of 
the posterior distributions of the SSD for all 13 chemicals in the mixture, after inference 
via the classical approach and via the hierarchical approach for each of the three toxicity 
hypotheses. More specifically, Figure 7.4 shows how the inclusion of information on 
the larger population of chemicals influences the posterior distribution of SSDs and the 
subsequent single substance PAF for the antibiotic cefuroxime. Cefuroxime was chosen 
as an example because of its low data availability (only two largely differing EC50 values; 
Table 7.1, Appendix A7.1). The figure contains the CDF of the posterior distribution 
of SSDs for cefuroxime, derived via the classical approach (7.4A) as well as via the 
hierarchical approach with the third toxicity hypothesis, i.e., based on all antibiotics in 
the chemical inventory (7.4B). Additionally, it contains a vertical slice of each of these 
CDFs at the predicted surface water concentration (Table 7.1). These slices represent the 
PDF of the posterior PAF for cefuroxime derived via the classical approach (7.4C) and via 
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the hierarchical approach with the third hypothesis (7.4D). Figure 7.4 clearly shows that 
the inclusion of information on the larger population of chemicals might significantly 
reduce both the credibility interval on the PAF and its median value. 
The calculations of the msPAF, based on the principles of response addition (RA), 
concentration addition (CA), and a hybrid form of the two, result in PDFs as shown in 
Figure 7.5. Regardless which principles are followed, the classical approach always results 
in very wide 90% credibility intervals, i.e., 0.02 – 0.67 for RA, 0.01 – 0.94 for CA, and 0.01 
– 0.91 for the hybrid form. When a hierarchical approach is taken, both median values 
and credibility intervals decrease. This decrease is largest when concentration addition or 
a hybrid form of concentration and response addition is applied. Concentration addition 
assumes the same interspecies variation in sensitivity for all chemicals in the mixture, i.e., 
the individual values are averaged into one generally applicable value (Eq. 7.2). Therefore, 
less uncertainty in τlogEC50 for one chemical affects the estimations for all other chemicals 
in the mixture, something that does not hold for calculations based on response addition. 
Similarly, this inter-chemical dependency of τlogEC50 also explains why the posterior 
distributions from the classical approach show a peak at msPAF of 1 when concentration 
addition or the hybrid form is applied (Fig. 7.5). A highly uncertain τlogEC50 value for one 
chemical affects the estimations for all other chemicals in the mixture, increasing the 
possibility of an msPAF of 1.
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FIGURE 7.3 
Posterior secondary distributions of µlogEC50 (1) and τlogEC50 (2) describing the inter-chemical 
variation in the larger population of chemicals, based on A) the total chemical inventory, B) 
all APIs in the chemical inventory, C) all ABs in the chemical inventory, and D) all ACs in the 
chemical inventory. 
Solid line: 50th percentile; dashed lines: 5th and 95th percentiles; dots: chemical-specific sample mean x ̅ logEC50 and 
sample precision tlogEC50 data.
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FIGURE 7.4
The influence of using a hierarchical approach and third toxicity hypothesis (i.e., based on all 
antibiotics in the chemical inventory) on the posterior distribution of SSDs and PAF for the 
antibiotic cefuroxime. CDFs of the posterior distribution of SSDs for cefuroxime, derived via 
the classical approach (A) and the hierarchical approach (B); kernel PDFs of the posterior PAF 
at the predicted surface water concentration (Table 7.1), derived via the classical approach 
(C) and the hierarchical approach (D). 
Green lines: 50th percentile (solid line) and 5th and 95th percentiles (dashed lines) of the posterior distribution of 
SSDs; red dots: cefuroxime log(EC50) data.
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FIGURE 7.5 
Kernel probability density functions of the msPAF for a mixture of antibiotics (ABs) and 
anticancer drugs (ACs). A: aggregation based on response addition; B: aggregation based on 
concentration addition; C: aggregation based on a hybrid form of response and concentration 
addition.
Blue lines: msPAF derived via classical approach; red lines: msPAF derived via hierarchical approach and tox-
icity hypothesis 1 (i.e., based on the total chemical inventory); green lines: msPAF derived via hierarchical ap-
proach and toxicity hypothesis 2 (i.e., based on all APIs in the chemical inventory); purple lines: msPAF derived 
via hierarchical approach and toxicity hypothesis 3 (i.e., based on all ABs and ACs in the chemical inventory). 
Arrows represent 90% credibility intervals; dots represent median msPAF values.
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7.4 DISCUSSION
The case study with a realistic mixture of 13 APIs in the aquatic environment in the 
Ruhr area in Western Germany (Fig. 7.1), showed that the use of a hierarchical model 
results in a median potentially affected fraction of ~0.01 when concentration addition 
principles are assumed, and of ~0.01-0.02 when response addition principles are 
assumed or a hybrid form of these two is applied. Contrary to this hierarchical approach, 
the classical approach leads to high msPAF estimations with much wider credibility 
intervals (Fig. 7.5). This will become even more relevant for environmentally realistic 
mixtures, generally consisting of large numbers of chemicals with often scarcely available 
data [385, 390]. When studying realistic mixtures consisting of a large number of chemicals, 
however, the hybrid form of concentration and response addition applied here could 
become unfeasible since it requires chemical-specific knowledge of the TMoA for all 
chemicals present in the mixture. 
At the basis of the hierarchical model lies the assumption that all chemicals in the 
mixture are part of a larger population of chemicals. The chemical inventory used to 
populate the hierarchical model should thus consist of a representative sample of that 
population. General practice in chemical risk assessment, however, implies that more 
toxic chemicals are tested more often than chemicals that show little initial toxicity. 
Consequently, relatively non-toxic chemicals might be underrepresented in our chemical 
inventory, leading to a potential overestimation of the actual msPAF. 
Although uncertainties due to limited nspecies were taken into account in the 
hierarchical model via the inclusion of sampling distributions on x ̅ logEC50 and s2logEC50, 
intertest variability was not included as a source of uncertainty [422]. When multiple 
toxicity data were available for a combination of chemical, species, and endpoint, we used 
their geometric mean as input. However, Craig [395] showed that the difference between 
two separate measurements of the same chemical-species combination is approximately 
a factor 0.3, with a considerable amount of cases where this factor exceeds 1. Moreover, 
we implicitly assume that all species are a priori exchangeable. Each toxicity value is thus 
considered a random sample from the SSD, regardless of the species measured [396, 397]. 
However, evidence shows that non-exchangeability is a reality for at least one standard 
test species [396]. 
155
Hierarchical Bayesian approach to reduce uncertainty in the aquatic effect assessment of realistic chemical mixtures
7
Finally, model structure uncertainty [44] plays a role in our assessment, mainly in 
the selection and parameterisation of the (hyper)distributions at different levels of the 
hierarchical model. First, at the level of the individual chemicals in the mixture, it relates 
to the choice for the log-normal species sensitivity distribution. Since there seems to be no 
good reason to prefer one distribution type over another based on theoretical grounds [392, 
395], and since it is impossible to statistically differentiate between different distributions 
at small sample size [423], this choice is difficult to justify based on the data available for 
the chemicals in the mixture. However, the CDFs of the posterior distribution of SSDs 
for all chemicals in the mixture (Appendix A7.4) do show relative agreement between 
model and data. Future analysis could include other distribution types to assess the 
importance of this source of model structure uncertainty. Second, at the level of the 
larger population of chemicals, model structure uncertainty relates to the choice for the 
log-normal and gamma distributions to describe the inter-chemical variation in µlogEC50 
and τlogEC50, respectively. However, Q-Q plots based on x ̅ logEC50 and tlogEC50 values of 115 
data-rich chemicals (nspecies ≥ 30) support this choice (Fig. 7.2). Third, at the hierarchical 
model’s highest level, model structure uncertainty relates to the parameterisation of the 
non-informative prior distributions. Especially when data to populate the hierarchical 
model are scarcely available, these distributions can be more informative than desired, 
with posterior distributions dependent on the hyperparameter choices [424]. To assess the 
relevance of this in our study, we ran the hierarchical model with three different sets 
of hyperparameters: one set as described, one set of smaller hyperparameters, i.e., N(0, 
1*10-8) and Γ(1*10-8, 1*10-8), and one set of larger hyperparameters, i.e., N(0, 1*10-2) and 
Γ(1*10-2, 1*10-2). The model simulations show stable posterior distributions of µlogEC50 and 
τlogEC50 for all chemicals in the mixture (Appendix A7.5), and the chemical inventory thus 
seems extensive enough for posterior distributions to not depend on hyperparameter 
choices. 
In this paper we have proposed a hierarchical Bayesian approach for the derivation of 
probabilistic msPAFs. We have shown that such an approach could be a suitable method 
for probabilistic multi-substance aquatic effect assessments. While the classical approach 
may result in a counterintuitive representation of the actual uncertainty in msPAF of large 
but realistic mixtures, we feel that a hierarchical approach incorporating information on 
the larger population of chemicals addresses this uncertainty in a more realistic way. 
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However, whether this conclusion remains valid when a larger mixture of compounds is 
assessed at higher water concentrations, for example in the effluent of sewage treatment 
plants, requires further investigation. Additionally, if this approach would be applied in 
the context of aquatic risk assessment, uncertainty in the exposure concentrations should 
also be addressed in order to get a complete view of the influence of uncertainty. 
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7.7 APPENDICES
Appendices related to this chapter can be accessed online via doi: 10.1021/acs.est.5b02651.
A7.1 Toxicity data for the 13 APIs in the mixture or http://www.ru.nl/environmental 
science/staff/individual-staff/oldenkamp/.
A7.2 Toxicity data for the chemicals included in the chemical inventory
A7.3 Description and syntax of the OpenBUGS model
A7.4 Posterior distributions of the SSDs of the chemicals in the mixture
A7.5 Posterior distributions of the SSD parameters at different sets of hyperparameters
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CHAPTER 8
General discussion
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As postulated in Paragraph 1.4, the aim of this thesis was to demonstrate how 
aquatic and human health risks, related to exposure to human active pharmaceutical 
ingredients (APIs), can be assessed probabilistically. Therefore, novel methodologies 
and tools were developed, as described in Chapters 2 – 7. While the case studies 
in the individual chapters relate to a limited number of antibiotics and anticancer 
drugs, the methods developed are in principal applicable to a wider range of 
human pharmaceuticals. Section 8.1 discusses probabilistic risk assessment, 
focusing specifically on different types of uncertainty (Section 8.1.1) and variability 
(Section 8.1.2). Moreover, Section 8.1.3 discusses the relative roles of uncertainty 
and variability and the interface between the two. In addition, Table 8.1 provides 
an overview of the sources of uncertainty and variability quantified in this thesis. 
Finally, Section 8.2 discusses the main conclusions and recommendations that can 
be drawn from the work presented in the thesis. 
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8.1 PROBABILISTIC RISK ASSESSMENT
In regulatory practice, a probabilistic approach becomes useful when unacceptable 
risks cannot be excluded based on conservative deterministic risk estimations. Then, 
a more realistic estimation of risk can be achieved by the inclusion of uncertainty and 
variability in the assessment, e.g., the inclusion of chemical-specific information about 
differences in sensitivity throughout the human population, as described in Chapter 
6 of this thesis. Uncertainty and variability are two sources of variation that are often 
considered simultaneously in probabilistic risk assessment. This is mainly because 
they can be described statistically in a similar way (i.e., using a variance), and because 
variability can result in uncertainty, depending on the perspective taken [425]. However, 
for a meaningful probabilistic risk assessment it is important to address uncertainty and 
variability separately as argued below. 
An analysis of uncertainty can give insight into the likelihood of an adverse event, 
and as such provide guidance for the allocation of future research efforts to improve 
model predictions. For example, multiple studies have shown that the variance in the 
environmental fate of chemicals is generally driven by uncertainties in their chemical 
properties, rather than by variability in environmental characteristics and exposure 
properties [207, 208]. This was also shown in Chapter 4 of this thesis, where we identified 
the prediction of aquatic toxicity as the main source of uncertainty for the determination 
of aquatic risks of APIs. In Chapter 6, a parameter importance analysis with Spearman’s 
rank correlation coefficients showed that the extrapolation for interspecies differences 
and for exposure duration introduce most uncertainty during the probabilistic derivation 
of human exposure limits, at least for the two APIs assessed in the case study (i.e., 
methotrexate and ciprofloxacin). 
On the other hand, an analysis of the relevant variability can give insight into the 
magnitude of the adverse event, and as such provide guidance for the allocation of future 
monitoring efforts, the identification of worst-case exposure scenarios, or the selection 
of potential risk reduction measures. For example,  Webster et al. [206] concluded that the 
influence of spatial variability on chemical fate model outcomes is small compared to 
that of interchemical variability. Indeed, in Chapter 4 we found that spatial differences in 
aquatic risk estimations are mainly driven by variability in emission estimations, linked 
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to API-specific consumption data and sewage treatment removal efficiencies. In Chapter 
3, a decision support tool for physicians was described that can aid in the choice between 
two comparable pharmaceutical prescriptions, based on their relative environmental 
impact. A case study with ciprofloxacin and levofloxacin showed that the choice for one 
or the other varies spatially throughout Europe. An analysis of the relative influence of 
spatially variable parameters on this ‘best choice’ showed that local surface water volume 
mainly determined the choice of one or the other for comparisons based on aquatic 
risks; local population density mainly determined the choice for one or the other for 
comparisons based on human health risks.
8.1.1 Uncertainty
Different frameworks and typologies have been proposed to coherently deal with the 
concept of uncertainty in model-based risk assessment [44, 426-428]. Here, we use the definition 
of uncertainty provided by Walker et al. [44], and their corresponding typology, to structure 
the discussion and evaluation of uncertainty in the context of the risk assessment of APIs. 
Broadly defined by Walker et al. [44] as “any departure from the unachievable ideal of 
complete determinism”, they identified different types of uncertainty, namely context 
uncertainty, model uncertainty, and parameter uncertainty. In lower tier risk assessment 
studies, identification of these uncertainties is necessary to facilitate a conservative worst-
case approach. In higher tier risk assessment studies, uncertainties are quantitatively 
or at least qualitatively assessed in order to enable a more realistic probabilistic risk 
assessment [48]. The three types of uncertainty are discussed in Sections 8.1.1.1 – 8.1.1.3, 
illustrated with the topics that were presented in this thesis and summarised in Table 8.1. 
8.1.1.1 Context uncertainty
When the context of the assessment and the decision support are unclear, uncertainties 
can be introduced. This context uncertainty relates to the framing of the problem, i.e., 
the problem definition, and to the boundaries of the assessment, i.e., what part of the 
real world is captured. While the possibilities for a quantitative assessment of this type 
of uncertainty are often limited, it is essential to describe the boundaries of the model as 
accurately and completely as possible. It enables an informed evaluation of the results and 
prevents erroneous or misled conclusions and recommendations. The model framework 
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presented in Chapters 2 – 4 provides a means to prioritise pharmaceuticals throughout 
Europe based on their relative impact on the aquatic environment and human health. 
However, sources of pharmaceutical emissions other than human consumption fall 
outside the boundaries of the model framework, e.g., pharmaceutical production 
facilities [429]. Moreover, pharmaceuticals used in livestock are not considered, although 
such use can lead to serious environmental effects, e.g., in dung beetles exposed to the 
antiparasitic drug ivermectin [430]. The incorporation of veterinary pharmaceuticals in 
the framework proposed would require additional information on amounts used and 
emission locations [109, 140, 152]. Furthermore, it would require the inclusion of additional 
pathways into the environment, e.g., the disposal of manure from cattle and wastewater 
from fish farms [147]. With respect to the characterisation of effects, the methodologies 
presented in this thesis are limited to those on humans and the aquatic environment, 
but effects on non-aquatic species are not considered. In fact, pharmaceutical residues 
in sewage sludge might be taken up by soil dwelling organisms [431], potentially causing 
effects in these organisms or other organisms feeding on them [432]. Finally, the model 
framework does not include indirect effects, e.g., the development of antibiotic resistant 
pathogens and subsequent human exposure to them [47], nor does it include synergistic or 
antagonistic effects due to exposure to pharmaceutical mixtures [160, 161], or effects related 
to pharmaceutical transformation products and metabolites [433].
Conclusions and recommendations based on the prioritisation results should consider 
these boundary conditions, i.e., that the results relate to the direct effects of APIs on 
humans and the aquatic environment, due to their specific human use. It is important to 
realise that lack of knowledge due to ignorance may lead to a false sense of completeness 
of the assessment [e.g., 434]. An example related to the issue of pharmaceuticals in the 
environment, is the dramatic decline of vulture populations in the Indian subcontinent 
due to diclofenac poisoning [28]. The unforeseen route of exposure through which vultures 
were poisoned, i.e., feeding on dead cattle containing diclofenac residues that were left 
out on the fields, had not been captured in any risk assessment study simply because 
nobody ever considered it. 
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8.1.1.2 Model uncertainty
While context uncertainty relates to the model’s boundaries, model uncertainty arises 
from a lack of sufficient understanding of the system within those boundaries. As such, 
it reflects our limited knowledge of the real world, and how to best represent it in a 
model. Model uncertainty represents uncertainty about the relationships between input 
parameters and variables, among variables, and between variables and output parameters 
[44]. Model uncertainty might potentially be assessed quantitatively through validation, 
although this is sometimes unfeasible in predictive assessments, e.g., for new chemicals. 
Therefore, assumptions about the system modelled should be explicitly communicated to 
enable a qualitative assessment of model uncertainty. 
When multiple model formulations are known to be plausible representations of the 
system modelled, a comparison of results can give insight in the magnitude of model 
uncertainty. For example, in the probabilistic human effect assessment presented in 
Chapter 7, two dose-response models were identified for the derivation of a Point of 
Departure, i.e., an exponential and a Hill model. Both were considered to describe dose-
response data with continuous responses adequately and equally well. The influence of 
model uncertainty was relatively small in this specific situation, since the human exposure 
limits obtained from calculations with both dose-response models were within a factor 
1.1-1.3 for the APIs studied.
8.1.1.3 Parameter uncertainty
Parameter uncertainty stems from our lack of knowledge about the model’s true parameter 
values. With the exception of universal constants and physical constants that are very well 
determined, parameter uncertainty influences all model parameters. It is a consequence 
of the limited data on which parameterisation is based and the variation observed within 
these data. This variation can be due to measurement error, e.g., in the measurement of 
physicochemical properties such as the octanol-water partitioning coefficient [435], or inter-
test differences, e.g., variability in results for the same chemical on the same species in the 
context of ecotoxicity testing [422]. In this thesis, the influence of parameter uncertainty 
was qualitatively assessed in Chapters 2 and 3, via a classification of the data underlying 
the parameters. Additionally, parameter uncertainty was quantified in Chapter 4 (on the 
selection of priority APIs), Chapter 6 (on the setting of human exposure limits), and 
Chapter 7 (on the aquatic risk of realistic chemical mixtures). 
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Parameter uncertainty is often quantitatively assessed via Monte Carlo simulations in 
which all input parameters are assigned distributions reflecting the limited knowledge of 
their true values [e.g., 45]. An extensive amount of model iterations is then performed (e.g. 
10,000), each time with a new set of parameter values drawn from these distributions. 
The variation in the outcomes of these model runs represents the influence of parameter 
uncertainty. When uncertainty in an input parameter is quantified with an uncertainty 
distribution, the parameters of this distribution are often derived from limited data. 
Consequently, these distribution parameters are themselves subject to uncertainty. 
This type of parameter uncertainty, so-called secondary parameter uncertainty, can be 
quantified with sampling distributions [45]. Secondary parameter uncertainty was assessed 
within this thesis, in the parameters of the distributions for toxicokinetics and –dynamics 
constructed in Chapter 6, and in the parameters of the species sensitivity distributions 
constructed in Chapter 7. 
8.1.2 Variability
Parameters that intrinsically have one true value that is unknown due to limited 
knowledge can be distinguished from parameters that are intrinsically variable, e.g., over 
time, space, between individuals, between species, or between chemicals, but that are 
represented in the model by a single value. Sources of variability that have been included 
quantitatively in this thesis, are presented in Table 8.1.
8.1.2.1 Spatial variability
Spatial variability relates to parameters that vary between locations. This variability 
might be described at different levels of aggregation, i.e., at different spatial resolutions. 
Depending on the aim and nature of the assessment, the relevant spatial resolution 
can range from a small local scale, e.g., within one contaminated site to identify 
specific locations of soils to be remediated [436], to a large global scale, e.g., variability 
between ecoregions in the assessment of worldwide biodiversity loss [e.g., 437, 438]. In this 
thesis, spatial variability was considered in Chapters 2 – 5. In the model framework 
presented in Chapters 2 – 4, it related to differences between 100 * 100 km2 grids 
throughout Europe for which calculations were made with the multimedia fate model 
SimpleBox [e.g., 86]. This spatial resolution was based on the level of spatial detail of the 
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available environmental characteristics data [201]. It must be noted, however, that spatial 
variation in water and soil concentrations increases when predictions are made for 
smaller grids [208]. In Chapter 5, concentration estimations were made at a higher spatial 
resolution of 5 * 5 Arc minutes (approximately 6 km * 9 km), with the geographic based 
water resources model GWAVA [251], to be able to make more spatially explicit specific 
statements about concentrations in European rivers. At this spatial resolution, advection 
processes become more relevant for the fate of chemicals. Since chemical differences in 
advection are relatively small, the influence of interchemical variability (Section 8.1.2.5) 
decreases at a higher spatial resolution. Furthermore, the spatial variability considered 
in this thesis relates to variability in the exposure and fate of pharmaceuticals, but 
spatial variability in effects is not considered. In reality, certain surface waters might 
be considered more vulnerable than others, for example due to their function as nature 
protection area or drinking water source [439].
8.1.2.2 Temporal variability
In this thesis, variability over time is only considered to a limited extent. Indeed, 
in a situation of steady state, a general assumption underlying the multimedia fate 
calculations as performed in Chapters 2 – 4, temporally variable parameters are averaged 
and variability over time is considered irrelevant. This is a reasonable assumption for 
specific assessments aimed for example at prioritisation of APIs under chronic exposure 
conditions and at constant emissions. In Chapter 5 of this thesis, temporal variability 
was included through the incorporation of information on monthly water flow rates 
between the years 1970 to 2000. This enabled the formulation of median and low-flow 
scenarios, respectively, resulting in most likely and worst-case concentration profiles of a 
number of cytostatic pharmaceuticals in European waterways. While temporal variability 
in hydrological and meteorological characteristics were included in Chapter 5, chemical-
specific parameters and processes were not considered temporally variable, mainly due 
to lack of data. Temporal variability in emissions might for example relate to diurnal 
or seasonal dependency of consumption of specific APIs [440], or seasonal variation in 
stormwater overflow events [441]. Additionally, degradation processes like biodegradation 
and photolysis might vary over time due to seasonal variation in temperature and light 
intensity, respectively [442]. 
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8.1.2.3 Interspecies variability
Interspecies variability relates to the intrinsic differences between species. This source 
of variability was included in Chapter 7 of this thesis, in which species sensitivity 
distributions (SSDs) were constructed. Within the context of the human effect assessment 
conducted in Chapter 6, interspecies variability was included in the extrapolation from 
(median) test animal to (median) human. However, here this variability acted as a source 
of uncertainty, because for a specific API, the difference between the typical (= median) 
test animal and the typical human intrinsically has one true value. This value is unknown 
and is estimated from the interspecies variability for a range of compounds in a range 
of species. Section 8.1.3 further reflects on the potential role of variability as a source of 
uncertainty.
8.1.2.4 Interindividual variability
A relevant source of variability in human health risk assessment is interindividual 
variability, as it aims to estimate the fraction of the population at risk. In Chapter 6, 
interindividual variability was included through the construction of distributions 
describing the variation in toxicokinetics present within two human subpopulations, 
i.e., the adult subpopulation and the subpopulation of young children. Similarly, in 
Chapters 2 and 3, the inter-subpopulation variability in exposure to APIs was compared 
for four subpopulations, i.e., infants, children, adults, and elderly people. Mainly because 
of limited data availability, variability within these latter four subpopulations was not 
included. Instead, country-specific average consumption rates and behavioural patterns 
were applied per subpopulation. Variability in exposure related parameters has been 
considered before in adult subpopulations, both in the modelling of human environmental 
exposure [50] and occupational exposure [301]. However, data are currently insufficient to 
allow for such calculations in other (spatially explicit) subpopulations.
8.1.2.5 Interchemical variability
Interchemical variability relates to the intrinsic differences between chemicals in their 
characteristics. In Chapters 2 – 4, interchemical variability is reflected in the spatially 
explicit prioritisation of APIs. Here, the interplay between spatially varying and 
interchemically varying parameters resulted in different aquatic and human health risks 
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for each of the APIs assessed throughout Europe. In Chapter 6, interchemical variability 
distributions were constructed to describe the differences between chemicals in the extent 
of their human toxicodynamics (and the interindividual variability therein). Similarly, 
database-derived distributions were constructed in Chapter 7 for the interchemical 
variability in average aquatic toxicity and variation in sensitivity between aquatic species. 
Finally, variability in certain chemical properties or activities, e.g., sorption to soils, 
basal toxicity, (bio)degradation, might be quantitatively related to variability in specific 
physico-chemical or structure-related properties. Such quantitative structure-activity or 
structure-property relationships (QSARs or QSPRs) can then be used to predict unknown 
chemical characteristics, as was done in Chapters 2 – 4 for the sorption and accumulation 
potentials of certain pharmaceuticals. 
8.1.3 The interface between parameter uncertainty and variability
Importantly, intrinsically variable parameters can function as a source of parameter 
uncertainty, depending on the perspective of the assessment. An example from this thesis 
relates to the human health risk assessment performed in Chapter 6. In this assessment, 
presented from a regulatory perspective, the aim was to derive an exposure limit that 
protects a certain percentage of the human population, e.g., 99%. The assessment was 
aimed at the total human population, and the available data on interindividual variability 
in sensitivity were thus aggregated accordingly. However, this source of variability 
becomes a source of uncertainty for specific individuals within the population who 
wonder whether they are part of the unlucky 1% for which the exposure limit is not 
protective enough.
Thus, variable parameters can function as a source of uncertainty when they are at 
a different level of aggregation compared with the assessment’s actual subject of interest 
(Fig. 8.1). This subject of interest can relate to any of the dimensions of variability 
discussed in the previous sections, e.g., individuals or species, but also regions, countries 
or continents, or even days, months, seasons, or years. When no or little specific data are 
available on the subject of interest, its properties are often inferred from information at 
a higher level of aggregation. Consequently, this can lead to extrapolation uncertainty. 
Several examples of this can be found throughout this thesis (Table 8.1). In Chapter 7, little 
toxicity data were available for some of the APIs in the mixture assessed. Therefore, the 
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distribution of toxicity for a larger population of chemicals was constructed, and the APIs 
in the mixture were assumed to be part of it. Then, selection of the correct toxicity value 
from that distribution resulted in uncertainty. Another example is described in Chapter 
2, in which aquatic and human health risks were calculated for a set of antibiotics and 
anticancer drugs throughout Europe, based on per capita consumption for the individual 
EU Member States. For some of the anticancer drugs, consumption data were lacking 
for some EU Member States, and the actual consumption in these countries was inferred 
from that in the other countries. Thus, spatial variability in per capita consumption 
increases the uncertainty in the extrapolation towards other EU Member States. 
In addition to extrapolation uncertainty, intrinsically variable parameters can also 
simply function as a source of sampling uncertainty (i.e., how to estimate a population 
parameter using a limited sample). The subject of interest is characterised with an 
aggregate value based on information from a lower level of aggregation. In Chapter 
6, data on adverse effects in individual rats were used to derive an effect value for the 
median rat. Consequently, the estimated median effect value is uncertain due to the 
combination of a limited sample size and the interindividual variability present within 
that population of rats. In the same chapter, toxicodynamics data on chemicals sharing 
the same Adverse Outcome Pathway (AOP) were averaged to derive an AOP-specific 
value for (interindividual variability in) toxicodynamics. Differences between chemicals 
sharing the same AOP then resulted in sampling uncertainty in the characterisation of 
that specific AOP.
These types of uncertainty can be reduced either via the generation of more data on the 
subject of interest, so that less inferences have to be made from sources of variability at other 
levels of aggregation, or via a better (qualitative) description of the subject of interest. In 
the latter case, quantitative properties of the subject of interest can be inferred from a more 
specifically defined and thus less variable range of other subjects. In other words, decreasing 
the distance (e.g., spatial, temporal, taxonomical, genetic) between these subjects reduces 
the uncertainty. It is important, however, to ensure that this narrowed definition remains 
valid for the properties of interest, i.e., that the inference is based on representative 
subjects. Furthermore, data availability will generally decrease with increasing specificity, 
and secondary (sampling) uncertainty will thus be larger. This became apparent in 
Chapter 7, in which interchemical variability distributions were constructed, based on 
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a large inventory of a wide range of 
chemicals. These distributions were 
used to infer the toxicity of a mixture 
containing data-poor chemicals. The 
interchemical variability present 
in the distribution, and thus the 
extrapolation uncertainty, was 
smaller when a more specific subset 
of the inventory was used for its 
characterisation. At the same time, 
however, sampling uncertainty was 
larger in these distributions, because 
less chemicals were available for the 
characterisation of their parameters. 
In conclusion, a balance has to be 
found between specificity and data availability, to optimally reduce extrapolation and 
sampling uncertainty. Finally, the aquatic risk assessment study described in Chapter 7 
showed that optimal use of all available data can substantially reduce the uncertainty 
in the results of the assessment. Through the use of Bayesian hierarchical modelling, 
information at different levels of aggregation can be used to decrease rather than increase 
uncertainty, especially when little data are available on the subject of interest.
8.2 CONCLUSIONS AND RECOMMENDATIONS
The novel methodologies and tools developed within this thesis provide a means to 
perform informed probabilistic human and aquatic risk assessments. The spatially 
explicit fate and exposure tools, as described in Chapters 2-5, can be combined with 
probabilistic methodologies for effect and hazard assessment, as described in Chapters 6 
and 7. Additionally, the probabilistic framework from Chapter 4 enables the identification 
of the most important sources of uncertainty and spatial variability in the potentially 
affected fractions of species (PAFs) throughout Europe. The uncertainty in species 
sensitivity distributions (Chapter 8), introduces most uncertainty in these PAFs, while 
FIGURE 8.1
Sources of variability functioning as source 
of uncertainty in risk assessment. Colours 
represent different types of variability. 
171
General discussion
8
consumption volumes and the presence of certain sewage treatment techniques explain 
most of the spatial variability in PAF values found throughout Europe. Similarly, the 
probabilistic framework from Chapter 7 enables the identification of the most important 
sources of uncertainty and interindividual variability in the human dose distributions 
from which human exposure limits can be derived. For ciprofloxacin and methotrexate, 
the two drugs included in the case study in Chapter 7, most uncertainty is introduced 
during the extrapolation steps covering sub-chronic/sub-acute to chronic toxicity, and 
covering interspecies differences in toxicity. 
The human health risk assessment performed in this thesis showed that the risks due 
to environmental exposure can be considered negligible, at least for the set antibiotics 
and anticancer drugs assessed. Indeed, probabilistically derived human exposure limits 
for ciprofloxacin and methotrexate (Chapter 6) are 6-7 orders of magnitude larger than 
the highest worst-case exposure estimations derived for environmental grids in Europe 
(Chapter 2). Similar conclusions on human health risks due to environmental exposure 
to human pharmaceuticals have been drawn by others [e.g., 29, 67, 68]. It must be noted, 
however, that the human exposure limits probabilistically derived for ciprofloxacin are 
based on its chondrotoxicity, and that stricter deterministic exposure limits have been 
derived based on its microbiological toxicity, i.e., its effect on the human intestinal flora 
[32, 310]. Nevertheless, these conservative deterministic exposure limits are still 3-5 orders of 
magnitude larger than the highest worst-case exposure estimated. Nevertheless, as already 
mentioned in Section 8.1.1.1, the human health risk assessment performed in this thesis 
was limited to direct effects after human use, due to exposure to the parent compound. It is 
recommended that future research on human health risks due to environmental exposure 
to antibiotics includes the assessment of indirect effects, i.e., the development of antibiotic 
resistant pathogens and subsequent environmental transport and human exposure, not 
only resulting from human but also from non-human antibiotics use, e.g., veterinary and 
aquaculture use. Moreover, future human health risk assessment methodologies should 
be developed that include the identification, fate and effect of human metabolites as well 
as transformation products that might arise during wastewater treatment and drinking 
water purification.
Contrary to human health risks, potential freshwater ecosystem risks due to exposure 
to antibiotics and anticancer drugs cannot be considered negligible. In certain densely 
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populated regions in Europe, up to 3% of the aquatic species are potentially affected by 
one or more human antibiotics present in the surface waters, based on EC50 values derived 
from short-term toxicity tests (Chapter 4). Detrimental chronic and subtle effects have 
been shown to occur in the environment for other human pharmaceuticals, e.g., (semi-)
synthetic oestrogens affecting reproductive organs in male fish [65], the anti-anxiety drug 
oxazepam influencing fish behaviour [443], and the anti-depressant fluoxetine decreasing 
territorial aggression in coral reef fish [444]. Consequently, it is recommended that existing 
pharmaceuticals, so-called legacy APIs, are subjected to a spatially explicit screening of 
their potential environmental risks. The large amount of legacy APIs (more than 4,000 
currently in use [35]) necessitates an approach that requires relatively little data, balancing 
complexity and capacity, and that includes a thorough uncertainty analysis. When 
aquatic risks are considered undesirable, end-of pipe solutions might seem to be most 
logical at first glance, because of the societal benefits of pharmaceuticals. However, this 
would generally imply upgrading sewage treatment plants (STPs), the expected costs of 
which are extremely high. For example, the upgrade of all STPs in the United Kingdom in 
order to reach proposed European environmental quality standards for (semi-)synthetic 
hormones costs an estimated £13 to £15 billion pounds [445]. Thus, other measures should 
be explored relating to the start rather than the end of the pipe, e.g. the inclusion of 
environmental considerations in prescription practice as proposed and described in 
Chapter 3. Other initiatives relate to the development process of new pharmaceuticals. So-
called benign-by-design or re-design principles can be applied to make pharmaceuticals 
more susceptible to environmental (bio)degradation while retaining their therapeutic 
potency [446]. Also, pharmacological properties measured during the development of new 
pharmaceuticals might be used to make an early assessment of their environmental fate 
possible [447, 448]. Indeed, it is recognised that knowledge in the field of human pharmacology 
can be of importance for environmental risk assessment of pharmaceuticals, for example 
through the evaluation of the potential existence of human drug targets in non-human 
species [381].
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SUMMARY 
Chemical risk assessment follows the four steps of hazard identification, fate and exposure 
assessment, effect assessment, and risk characterisation. During hazard identification, the 
intrinsic toxicity of the chemical of concern is assessed. The fate and exposure assessment 
step involves either the estimation of the concentration in the medium of contact (e.g., 
aquatic risk assessment), or of the intake dose (e.g., human risk assessment). During 
effect assessment the relationship between exposure and effect, i.e. the dose-response 
relationship, is established. Finally, the estimated or measured exposure is compared 
with this dose-response relationship in order to characterise the risk. This thesis shows 
how these four steps can be quantified in a probabilistic risk assessment of human 
pharmaceuticals, both for the aquatic environment and for human health. 
The importance of using a location-specific approach in aquatic and human health 
risk assessment of active pharmaceutical ingredients (APIs), is emphasised in Chapter 2, 
in which a screening tool for spatially explicit prioritisation of APIs in 100 km * 100 km 
grids throughout Europe is described and applied to a set of 11 antibiotics and 7 anticancer 
drugs. It is shown that APIs are prioritised differently throughout Europe, depending 
on local environmental characteristics and emission patterns. Moreover, prioritisation 
of APIs based on their risks for the aquatic environment might differ from prioritisation 
based on their human health risks, even at the same location. From the set of antibiotics 
and anticancer drugs, levofloxacin, doxycycline and ciprofloxacin show the highest risk 
quotients for the aquatic environment. These relatively high risk quotients are found in 
Northern Italy (Milan region; particularly levofloxacin) and other densely populated 
areas in Europe (e.g., London, Krakow and the Ruhr area). With respect to human health, 
infants in eastern Spain that consume locally produced food and conventionally treated 
drinking water are predicted to run the highest risks. 
The same screening tool can be used as a basis to provide physicians with the 
opportunity to include environmental considerations in their choice of prescription. 
This is shown in Chapter 3, in which a case study with two alternative pharmaceutical 
prescriptions, i.e., ciprofloxacin and levofloxacin, is performed. At three locations 
throughout Europe, the environmental impacts of a prescription of ciprofloxacin and 
a prescription of levofloxacin are compared. The results show that preference for either 
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ciprofloxacin or levofloxacin, based on their relative environmental impacts, depends 
on the location of prescription considered. The relative impacts of ciprofloxacin and 
levofloxacin on human health are largely determined by the local handling of secondary 
sludge, agricultural disposal practices, the extent of secondary sewage treatment, and 
local food consumption patterns. The relative impacts of ciprofloxacin and levofloxacin 
on the aquatic environment are mostly explained by the presence or absence of specific 
sewage treatment techniques, since effluents from sewage treatment plants (STPs) are the 
relevant emission pathway for the aquatic environment. 
While Chapters 2 and 3 emphasise the importance of using a spatially explicit 
approach in the environmental prioritisation of APIs, the influence of parameter 
uncertainty on this prioritisation is not considered in these chapters. Since a spatially 
explicit approach is relatively data intensive, it is subject to parameter uncertainty 
due to limited data. In Chapter 4, the question is answered to what extent a spatially 
explicit approach for the environmental prioritisation of APIs remains worthwhile when 
accounting for uncertainty in parameter settings. In a case study with nine antibiotics, 
uncertainty distributions of the PAF (Potentially Affected Fraction) of aquatic species 
are calculated throughout Europe and used for the selection of priority APIs. Two APIs 
have median PAF values that exceed a threshold PAF of 1% in at least one environmental 
grid in Europe, i.e., oxytetracycline and erythromycin. At a tenfold lower threshold PAF 
(i.e., 0.1%), two additional APIs would be selected, i.e., cefuroxime and ciprofloxacin. 
However, in 94% of the environmental grids in Europe, no APIs exceed either of the 
thresholds. This illustrates the relevance of following a spatially explicit approach in the 
prioritisation of APIs. The added value of a spatially explicit approach remains when 
accounting for uncertainty in parameter settings, i.e., if the 95th percentile of the PAF 
instead of its median value is compared with the threshold. In 96% of the environmental 
grids, the use of a spatially explicit approach still enables a reduction of the selection of 
priority APIs of at least 50%, compared with a Europe-wide approach. 
In the prioritisation tool described in Chapters 2-4, spatial variability in API 
concentrations and risks is represented in 100 km * 100 km environmental grids 
throughout Europe. In Chapter 5, a geographic based water resources model is used to 
predict concentrations of four cytostatic pharmaceuticals (i.e., 5-fluorouracil, capecitabine, 
cyclophosphamide, and carboplatin), in sewage treatment plant (STP) effluents and 
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rivers throughout Europe. Partly because of the considerable variation of popularity of 
individual cytostatic pharmaceuticals across Europe, substantial spatial variability exists 
in their water concentrations. Because of the relatively high spatial resolution, statements 
can be made about concentrations at specific locations in European rivers. For example, 
a 90th percentile (worst case) prediction indicates that more than 99% of Europe’s rivers 
(by length) would have concentrations below 1 ng/L for the cytostatic pharmaceuticals 
assessed, with the exception of capecitabine. Predicted concentrations in STP effluent are 
in line with measurements in the literature, and many non-detects could be explained by 
insufficient limits of detection.
The steps of hazard characterisation and effect are probabilistically assessed in 
Chapter 6 (for human health) and Chapter 7 (for the aquatic environment). In Chapter 
6, a framework is presented for the probabilistic derivation of human exposure limits for 
chemicals with a toxicological threshold. Such exposure limits are traditionally derived 
using default (i.e., deterministic) assessment factors (AFs) that should account for 
variations in exposure duration, species sensitivity and individual sensitivity. However, 
these default AFs are generic conservative values with a weak empirical basis, that cover 
a wide spectrum of chemicals and toxic mechanisms. Via the separate propagation of 
sources of interindividual variability and uncertainty throughout the derivation process, 
the probabilistic framework can be used to quantify the population fraction exceeding a 
pre-selected critical effect level with an estimate of the associated uncertainty. This enables 
policy makers to set separate standards for the fraction of the population to be protected 
and the confidence level of the assessment. The approach is demonstrated for two 
pharmaceuticals, i.e. the antibiotic ciprofloxacin and the anticancer drug methotrexate. 
For both substances, the probabilistic human exposure limit is mainly influenced by 
uncertainty originating from the point of departure (PoD), extrapolation from sub-acute 
to chronic toxicity, and interspecies extrapolation. However, when assessing the tails of 
the two-dimensional human dose distributions, i.e. the section relevant for the derivation 
of human exposure limits, interindividual variability in toxicodynamics also becomes 
important. 
In Chapter 7, a hierarchical Bayesian approach for aquatic effect assessment of 
chemical mixtures is presented. This approach aims to make optimal use of the toxicity 
information available in a large chemical inventory, in order to reduce the uncertainty 
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involved in the assessment. The credibility intervals on the estimated potentially affected 
fraction of species after exposure to a mixture of chemicals at environmentally relevant 
surface water concentrations can be extremely wide if a classical approach is followed, 
i.e., an approach in which each chemical in the mixture is considered in isolation. 
However, the use of knowledge on the toxicity of chemicals other than those assessed 
leads to a more realistic estimation of the potentially affected fraction. This is shown 
in a case study with a mixture of 13 pharmaceuticals, at surface water concentrations 
estimated in Chapter 2. A classical approach results in a median potentially affected 
fraction of 0.04-0.16 due to exposure to this mixture. The range in median values is a 
result of different mechanisms of aggregation that can be assumed relevant. The use of a 
hierarchical approach, however, reduces this median potentially affected fraction to 0.01-
0.02. Additionally, the uncertainty around this median potentially affected fraction of 
species (characterised with its 95th percentile credibility interval) decreases from ~0.01-
0.94 based on the classical approach to ~0.002-0.10 based on a hierarchical approach.
Finally, Chapter 8 discusses the roles of different types of uncertainty and variability 
within the context of the risk assessment of pharmaceuticals. It reflects upon this in the 
light of the work presented in the prior chapters of the thesis. Moreover, it discusses 
the notion that intrinsically variable parameters can function as a source of parameter 
uncertainty, depending on the perspective of the assessment. When no or little specific 
data are available on the subject of interest, its properties are often inferred from 
information at a higher level of aggregation. Consequently, this can lead to extrapolation 
uncertainty. Similarly, intrinsically variable parameters can also function as source of 
sampling uncertainty when the subject of interest is characterised with an aggregate 
value, using information from a lower level of aggregation. Chapter 8 ends with the 
main conclusions and recommendations of the thesis. It is concluded that human health 
risks due to environmental exposure are negligible, at least for the set of antibiotics 
and anticancer drugs assessed in the thesis, but that aquatic risks cannot be excluded 
as easily. Further development of methodologies for (probabilistic) risk assessment 
of pharmaceuticals should focus on the inclusion of sources of use other than human 
consumption, and should include the assessment of indirect effects, i.e., the development 
of antibiotic resistant pathogens and subsequent transport and human exposure, and 
transformation products that might arise during tertiary sewage treatment and drinking 
water purification.
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De risicobeoordeling van chemische stoffen volgt de vier stappen van gevaarsidentificatie, 
blootstellingsanalyse, effectanalyse, en risicokarakterisatie. In de eerste stap, de 
gevaarsidentificatie, wordt de intrinsieke toxiciteit van de chemische stof bepaald. Een 
blootstellingsanalyse behelst ofwel de schatting van de concentratie in het relevante 
blootstellingsmedium (bijv., aquatische risicoanalyse), ofwel de dagelijkse inname (bijv., 
humane risicoanalyse). Tijdens de effectanalyse wordt de relatie tussen blootstelling 
en effect vastgelegd, de dosis-respons relatie. Tot slot wordt de geschatte of gemeten 
blootstelling vergeleken met deze dosis-respons relatie om het risico te karakteriseren. 
Dit proefschrift laat zien hoe deze vier stappen kunnen worden gekwantificeerd in een 
probabilistische risicoanalyse van geneesmiddelen, zowel voor het aquatische milieu als 
voor de humane gezondheid. 
In Hoofdstuk 2 wordt het belang benadrukt van een locatie-specifieke benadering 
voor aquatische en humane risicoanalyses van geneesmiddelen. Het beschrijft een 
methode om geneesmiddelen ruimtelijk expliciet te  prioriteren in 100 km * 100 km 
grids in Europa. De methode is toegepast op een verzameling van 11 antibiotica en 7 
anti-kanker medicijnen. De resultaten laten zien dat geneesmiddelen verschillend 
worden geprioriteerd door Europa, en dat deze prioritering afhangt van lokale 
milieuomstandigheden en emissiepatronen. Bovendien kan de prioritering op basis 
van aquatische risico’s verschillen van de prioritering op basis van humane risico’s, zelfs 
wanneer deze voor dezelfde locatie zijn bepaald. Van de set van antibiotica en anti-kanker 
medicijnen veroorzaken levofloxacin, doxycycline en ciprofloxacin de hoogste aquatische 
risico’s. Deze risico’s veroorzaken ze vooral in Noord-Italië (de regio van Milaan; vooral 
levofloxacin) en andere dichtbevolkte gebieden in Europa zoals Londen, Krakau en het 
Ruhrgebied. Met betrekking tot de humane gezondheid lopen zuigelingen in Oost-Spanje 
de hoogste risico’s, vooral als zij lokaal geproduceerd voedsel en drinkwater gezuiverd via 
conventionele technieken consumeren.
Dezelfde prioriteringsmethode kan worden gebruikt om artsen de mogelijkheid te 
bieden de impact op het milieu mee te laten wegen in het voorschrijven van medicijnen. 
Hoofdstuk 3 beschrijft dit aan de hand van een case study met twee vergelijkbare 
geneesmiddelen, te weten ciprofloxacin en levofloxacin. Een vergelijking van een 
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voorschrift van elk op drie locaties in Europa, laat zien dat de voorkeur voor ciprofloxacin 
of levofloxacin, gebaseerd op hun relatieve impact op het milieu, verschilt van locatie tot 
locatie. De relatieve impacts van ciprofloxacin en levofloxacin op de humane gezondheid 
worden vooral bepaald door de mate waarin secundaire afvalwaterzuiveringstechnieken 
worden toegepast, de mate waarin het slib van deze afvalwaterzuiveringsinstallaties op 
landbouwgrond wordt uitgereden, en verschillen in lokale voedselconsumptie patronen. 
De relatieve aquatische impacts van ciprofloxacin en levofloxacin kunnen vooral worden 
verklaard door de aan- of afwezigheid van specifieke afvalwaterzuiveringstechnieken, 
doordat het effluent van zuiveringsinstallaties de belangrijkste emissiebron vormt voor 
het aquatische milieu.
Hoewel Hoofstuk 2 en Hoofdstuk 3 het belang benadrukken van een ruimtelijk 
expliciete benadering voor de prioritering van geneesmiddelen, wordt de invloed van 
parameter onzekerheid hierop niet meegenomen. Aangezien behoorlijk veel data nodig 
zijn voor een ruimtelijk expliciete benadering, kan parameter onzekerheid wel degelijk 
een belangrijke rol spelen. In Hoofstuk 4 wordt de vraag beantwoordt in welke mate een 
ruimtelijk expliciete benadering voor de prioritering van geneesmiddelen nog de moeite 
waard blijft wanneer rekening gehouden wordt met onzekerheid in parameterinstellingen. 
In een case studie met negen antibiotica zijn onzekerheidsverdelingen van de PAF 
(Potentially Affected Fraction) van aquatische soorten berekend in heel Europa. Deze 
zijn gebruikt om deze negen antibiotica te prioriteren. Twee geneesmiddelen, namelijk 
oxytetracycline en erythromycine, hebben mediane PAF waarden die een drempelwaarde 
van 1% overschrijden in ten minste één ruimtelijk grid in Europa. Bij een tien keer lagere 
drempelwaarde (d.w.z., 0.1%), zouden twee extra geneesmiddelen worden geselecteerd, 
namelijk cefuroxime en ciprofloxacin. Echter, in 94% van de ruimtelijke grids in Europa 
worden beide drempelwaarden door geen van de antibiotica overschreden. Dit illustreert 
het belang van een ruimtelijk expliciete aanpak in de prioritering van geneesmiddelen. 
Deze toegevoegde waarde blijft overeind wanneer parameter onzekerheid wordt 
meegenomen, dat wil zeggen, als de 95e percentiel van de PAF in plaats van de mediane 
waarde wordt vergeleken met de drempelwaarde. In 96% van de ruimtelijke grids levert het 
gebruik van een ruimtelijk expliciet aanpak een vermindering op in het aantal prioriteits-
geneesmiddelen van ten minste 50% ten opzichte van een Europa brede aanpak.
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Ruimtelijke variabiliteit wordt in de prioriteringsmethode van Hoofdstukken 2-4 
weergegeven als de variatie in concentraties en risico’s tussen 100 km * 100 km grids 
in Europa. In Hoofdstuk 5 wordt een geografisch model gebruikt om concentraties te 
voorspellen van vier cytostatica, te weten 5-fluorouracil, capecitabine, cyclophosphamide, 
en carboplatin, in het effluent van Europese afvalwaterzuiveringsinstallaties en in 
het water van Europese rivieren. De ruimtelijke variabiliteit in deze concentraties 
is behoorlijk, gedeeltelijk door de aanzienlijke variatie in gebruikspatronen van 
de individuele cytostatica. Dankzij de relatief hoge ruimtelijke resolutie, kunnen 
uitspraken worden gedaan over concentraties op specifieke locaties in Europese rivieren. 
Bijvoorbeeld, in het slechtste geval zullen in nog geen 1% van de lengte van de Europese 
riveren de concentraties van de vier cytostatica boven 1 ng/L uitkomen, met uitzondering 
van capecitabine. Metingen gerapporteerd in openbare literatuur zijn vergelijkbaar 
met de voorspelde concentraties in het effluent, en veel non-detects kunnen worden 
toegeschreven aan te hoge detectielimieten van desbetreffende studies.
Een probabilistische effectanalyse is uitgevoerd in Hoofdstuk 6 (voor de humane 
gezondheid) en Hoofdstuk 7 (voor het aquatische milieu). In Hoofdstuk 6 wordt 
een framework gepresenteerd voor de probabilistische afleiding van humane 
blootstellingsnormen voor chemische stoffen met een toxicologische drempelwaarde. 
Zulke blootstellingsnormen worden traditioneel afgeleid met behulp van standaard 
(deterministische) extrapolatiefactoren die verondersteld worden de variatie in 
blootstellingsduur en de variatie in gevoeligheid tussen diersoorten en tussen 
individuen te ondervangen. Deze standaard extrapolatiefactoren zijn echter generieke en 
conservatieve waarden met weinig empirische onderbouwing, die bovendien een breed 
spectrum aan chemische stoffen en toxische werkingsmechanismen moeten beslaan. 
Het probabilistische framework maakt het mogelijk om de fractie van de bevolking te 
kwantificeren die een vooraf vastgesteld kritisch effectniveau overschrijdt, inclusief een 
schatting van de daarbij horende onzekerheid. Dit geeft beleidsmakers de mogelijkheid om 
afzonderlijk normen vast te stellen voor de fractie van de bevolking die beschermd dient 
te worden, en de mate van zekerheid die daarbij vereist is. Het framework is toegepast op 
twee geneesmiddelen, te weten ciprofloxacin en methotrexaat. Voor beide stoffen wordt de 
probabilistische blootstellingsnorm vooral beïnvloed door onzekerheid in het startpunt 
van de normafleiding, de extrapolatie van subacute naar subchronische toxiciteit, en de 
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extrapolatie voor interspecies verschillen. Echter, in de staarten van de humane dosis 
verdelingen, het deel dat relevant is voor de afleiding van blootstellingsnormen, speelt 
interindividuele variabiliteit in toxicodynamiek ook een belangrijke rol.
In Hoofdstuk 7 wordt een hiërarchische Bayesiaanse benadering gepresenteerd voor 
de aquatische effectanalyse van chemische mengsels. Deze benadering heeft als doel om 
optimaal gebruik te maken van toxiciteitsinformatie die beschikbaar is in een uitgebreide 
database van chemische stoffen, zodat onzekerheid in de analyse zoveel mogelijk beperkt 
kan worden. Na blootstelling aan voor het milieu relevante oppervlaktewater concentraties, 
kan het geloofwaardigheidsinterval rondom de PAF van aquatische soorten extreem 
breed zijn wanneer een klassieke benadering wordt gevolgd, dat wil zeggen wanneer elke 
stof in het mengsel op zichzelf wordt beschouwd. Echter, het gebruik van kennis over de 
toxiciteit van andere chemische stoffen dan die in het mengsel kan zorgen voor een meer 
realistische schatting van de PAF. Dit wordt laten zien in een case studie met een mengsel 
van 13 geneesmiddelen, bij oppervlaktewater concentraties geschat in Hoofdstuk 2. De 
klassieke benadering leidt tot een mediane PAF van 0.04-0.16. De spreiding in mediane 
waarden is het resultaat van verschillende mogelijke manieren om individuele stoffen in 
het mengsel te aggregeren tot één PAF waarde. Wanneer een hiërarchische benadering 
wordt toegepast, neemt de mediane PAF af tot 0.01-0.02. De onzekerheid rondom deze 
mediane PAF (gekarakteriseerd met diens 95-percentiel geloofwaardigheidsinterval) 
neemt bovendien aanzienlijk af van ~0.01-0.94 (klassieke benadering) naar ~0.002-0.10 
(hiërarchische benadering).
Tot slot bespreekt Hoofdstuk 8 de rol van verschillende types van onzekerheid en 
variabiliteit, binnen de context van de risicoanalyse van geneesmiddelen. Het hoofdstuk 
reflecteert hierop met behulp van het werk gepresenteerd in de voorafgaande hoofdstukken 
van het proefschrift. Bovendien bespreekt het de notie dat intrinsiek variabele parameters 
als bron van parameter onzekerheid kunnen fungeren, afhankelijk van het perspectief 
van de analyse. Immers, als geen of weinig gegevens beschikbaar zijn voor het onderwerp 
van de analyse, worden diens eigenschappen vaak afgeleid uit gegevens van een hoger 
aggregatieniveau. Dit kan dientengevolge leiden tot extrapolatie onzekerheid. Op een 
vergelijkbare manier kunnen intrinsiek variabele parameters ook als bron van steekproef 
onzekerheid functioneren, wanneer het onderwerp van de analyse gekarakteriseerd wordt 
met behulp van gegevens van een lager aggregatieniveau. Hoofdstuk 8 eindigt met de 
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belangrijkste conclusies en aanbevelingen van het proefschrift. Er wordt geconcludeerd 
dat humane gezondheidsrisico’s als gevolg van milieublootstelling verwaarloosbaar 
zijn, ten minste voor de set van antibiotica en anti-kanker geneesmiddelen die in het 
proefschrift onderzocht zijn. Echter, aquatische risico’s kunnen niet zo gemakkelijk 
worden uitgesloten. Toekomstig onderzoek zou zich moeten richten op de verdere 
ontwikkeling van methoden voor (probabilistische) risicoanalyse van geneesmiddelen, 
waarbij de focus zou moeten liggen op niet-humane bronnen van geneesmiddelen, de 
analyse van indirecte effecten, zoals de ontwikkeling van voor antibiotica resistente 
pathogenen en daarop volgend transport en humane blootstelling, en het ontstaan van 
bijproducten tijdens geavanceerde afvalwaterzuivering en drinkwaterzuivering.
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